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Gap junction intercellular channels allow the exchange of ions and small 
molecules between neighbouring cells. Our laboratory showed previously 
that tumour suppressor protein and cell polarity regulator hDlg (human 
homologue of Drosophila Discs Large) binds to the wide-spread gap junction 
protein Connexin 43 (Cx43) in human papillomavirus (HPV) - positive cervical 
tumour cells. Cx43 relocated together with hDlg to the cytoplasm of these 
cells, and hDlg knockdown resulted in some Cx43 reappearing on the plasma 
membrane. This led to our hypothesis that hDlg could control Cx43 
trafficking. High-risk HPV oncoprotein E6 via its PDZ-binding domain targets 
hDlg for proteasome degradation. Previously, co-immunoprecipitation 
indicated Cx43 binds to hDlg in vitro in cervical tumour cell lines and 
proximity ligation assays indicated their interaction in vivo in cervical 
epithelial tissue from high-grade cervical lesions. Moreover, our protein-
protein interaction data indicated that HPV E6 oncoprotein took part in the 
hDlg/Cx43 interaction. Cx43 and hDlg were observed on the plasma 
membrane in non-transformed cervical tumour cells (W12G, low level of 
HPVE6) but appeared in the cytoplasm in fully transformed cervical tumour 
cells W12GPXY (high level of HPVE6). C33a cells (HPV-negative cervical 
tumour cells with membranous Cx43) transfected with mutated HPVE6 (loss 
of ability to bind to hDlg) showed membranous Cx43 while re-location of 
Cx43 to the cytoplasm was observed in C33a cells transfected with wild-type 
HPVE6. This indicates that HPVE6 negatively regulates the trafficking of 
Cx43 through interaction with hDlg. It may be that the ability of hDlg to 
suppress cell growth relies on correct GJIC communication, and HPVE6 
interference with Cx43/hDlg functionality may provide a growth advantage 
to cells, which would increase viral production.  
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To determine if the Cx43/hDlg interaction requires HPVE6, Cx43/hDlg 
interaction was investigated in HPV-negative cervical cancer cell lines (C33a 
and C33aE6 (C33a cells stably expressing HPV16E6). Co-immunoprecipitation 
indicates Cx43 binds hDlg in these cells. Immunofluorescence confocal 
microscopy shows the co-localisation of Cx43/hDlg on the plasma membrane 
in C33a cells and in the cytoplasm in C33aE6 cells. To determine if the 
Cx43/hDlg interaction is dependent on the cancer environment, similar 
experiments were carried out in non-tumour epithelial cell lines that do not 
express E6 (HEK293, HaCaT, NIKS) and NIKS16 cells (NIKS cells stably 
transfected with HPV16 genomes). Co-immunoprecipitation shows that Cx43 
forms a complex with hDlg in HEK293, HaCaT, NIKS cells and the presence of 
HPVE6 at low levels in NIKS16 cells do not affect their interaction. Co-
localisation of Cx43 and hDlg was observed on the plasma membrane in 
these cells. This indicates the Cx43-hDlg interaction is neither HPV-E6-
dependent nor cancer-cell-specific.  
The role of hDlg in controlling the trafficking of Cx43 has been investigated 
by siRNA depletion of hDlg in HaCaT, HEK293, NIKS and NIKS16 cells. siRNA 
depletion of hDlg in these cells led to a reduction in levels and cytoplasmic 
location of Cx43. HaCaT cells with stable depletion of hDlg (HaCaT shDlg) 
also displayed a similar pattern of Cx43 rearrangement. 
Endolysosomal/lysosomal inhibition by ammonium chloride (NH4Cl) and 
chloroquine (CQ) led to increased levels of Cx43 in HaCaT and HEK293 cells 
and HaCaT cells with siRNA depletion of hDlg. These data indicate the role 
of hDlg in maintaining a cytoplasmic pool of Cx43 and suggest that hDlg may 
play roles in the delivery of Cx43 to the membrane.  
To investigate if changes in cell signalling can alter the Cx43/hDlg complex 
formation, a scrape wound healing model was used since the wound healing 
process shares many similarities with tumour progression. The changes in 
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subcellular location and expression levels of the two proteins during scrape 
wound closure were investigated. The wound closure rates in the non-
tumour epithelial cells were also been checked. At the start of wound 
closure in HaCaT keratinocytes, Cx43 and hDlg colocalised on the plasma 
membrane but both proteins moved into the cytoplasm 4-16 hours post-
wound. After 24 hours, most of the proteins regained a membrane location. 
A similar phenomenon was also observed in NIKS cells during wound healing. 
There were significant reductions in Cx43 and hDlg levels during the early 
stages of wound closure and changes in Cx43 phosphorylation were also 
observed during the wound closure process. 
hDlg is one of the regulators of cell polarity, which is important in cell 
migration especially in direct migration. In wound closure experiments, hDlg 
depletion led to cell death and a significantly delayed wound closure rate in 
HaCaT and NIKS16 cells. The cell monolayer was not repaired after 24 hours 
(less than 50% closure). Sudden loss of hDlg by siRNA might lead to loss of 
regulation of cell polarity and affect the wound healing process. Surprisingly, 
in HaCaT shDlg cells (HaCaT cells stably depleted of hDlg), wound closure 
was completed at 16h post-wound (faster than control HaCaT cells with 70% 
closure at 24h) and no cell death was observed. hScrib, a tumour suppressor 
protein, is involved in the regulation of cell polarity (Dow et al., 2003). 
Faster wound closure might be due to the role of hScrib in HaCaT shDlg cells 
to complement the stable loss of hDlg, while the sudden loss of hDlg through 
siRNA treatment might lead to lower tolerance of cell stresses such as 
wound healing.  
Interestingly, the presence of the HPV16 genome drives faster closure of the 
wound in NIKS16 cells compared to NIKS cells. Wound closure was complete 
at 16h post-wound in NIKS16 cells while after 24h post-wound a small gap 
remained in NIKS cell monolayers. This might be due to the effect of beta-
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catenin. Beta-catenin transits to the nucleus and induces gene expression of 
proteins involved in cell migration, which enhance wound healing. HPVE6 
causes beta-catenin to accumulate in the nucleus. However, none of the 
cervical cancer cell lines (C33a, C33aE6 and HeLa43) were able to close the 
scrape wound properly (closure of 17%, 33% and 28% respectively). This 
might be due to a combination of the effect of membranous Cx43 and HPVE6 
on the regulation of nuclear beta-catenin. Nuclear transmission of beta-
catenin could be prevented by interaction with membranous Cx43, which 
could explain the loss of membranous Cx43 at the early stage of wound 
repair. C33a cells (membranous Cx43, no HPVE6) close the wound at the 
slowest rate (17%) while C33aE6 (cytoplasmic Cx43, HPVE6) and HeLa43 
(membranous Cx43, HPVE6) show faster wound closure (33% and 28%). 
However, whilst no evidence is presented, it is known that HPVE6 induces 
accumulation of nuclear beta-catenin via its PDZ-binding domain and thus is 
a good candidate for future studies.  
Lastly, through Cx43 C-terminal mutagenesis and co-immunoprecipitation 
experiments, the Cx43-hDlg binding region has been limited to amino acids 
348-382 of the Cx43 C-terminus. Six different serine residues were chosen 
for the mutation to alanine to mimic un-phosphorylated serine. Four of 
these were MAPK kinase phosphorylation sites, one was an Akt and one a 
PKC phosphorylation site. However, these Cx43 C-terminal nonphospho-
mutants could still interact with hDlg, suggesting that phosphorylation does 
not affect Cx43 binding to hDlg. 
In conclusion, hDlg binds to regions of amino acids 348 -382 of the Cx43 CT. 
This Cx43-hDlg interaction is not cancer cell-specific and not HPVE6-
dependent. The data in this thesis add to accumulating evidence of a role 
for hDlg in maintaining a cytoplasmic pool of Cx43 and delivery of Cx43 to 
the plasma membrane.  
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1 Chapter 1 Introduction  
1.1 Connexin 43 (Cx43) 
1.1.1 Gap junctions, connexons and connexins  
Cell-cell communication is a key event to maintain the homeostasis of 
tissue/organs in living creatures. Through this communication, cells can 
alter the concentration of different materials within cells to adjust to 
the changes of different environments. By making the correct response 
to alterations of the environment, cells send/receive signals to/from 
neighbouring cells to maintain the integrity of tissues. Gap junction 
intercellular channel communication (GJIC) is one of the key 
communication types, which allows direct connection between the 
cytoplasm of adjacent cells. The observation of gap junctions can be 
traced back to the year 1958 when Sjostrand and co-workers (Sjostrand 
et al., 1958) observed specific regions between plasma membranes of 
neighbouring cardiac muscle cells using electron microscopy (EM). Later 
the tight apposition (nexus) that they described was also observed in 
smooth and striated muscle cells (Karrer, 1960, Dewey and Barr, 1962). 
These nexus sites were then found to contain hexagonal array structures 
with defined ―gaps‖ of 2 nm between apposed cell membranes in mouse 
heart cells (Revel and Karnovsky, 1967). In a key experiment, yellow dye 
M4RS (molecular weight approximately 500 Da) was able to spread from 
one cytoplasm to another cytoplasm via gap junctions of synapses but 
did not enter the cytoplasm from the extracellular space. This increased 
the understanding of gap junctions in allowing the direct interaction 
between cells (Payton et al., 1969). Gap junctions of hepatocyte from 
mice were isolated and characterised by X-ray diffraction assay 
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(Goodenough and Stoeckenius, 1972). Two years later, bulk isolation of 
gap junctions from the same mouse tissue led to the isolation of 
structural protein subunits of gap junctions, which were named 
―connexons‖(Goodenough, 1974). GJIC provides direct interaction 
between opposing cells by allowing the exchange of small molecules (<1 
kDa), including metabolites and second messengers (Alexander and 
Goldberg, 2003b). Gap junctions are thought to be involved in many 
cellular activities such as proliferation, differentiation and apoptosis 
(Vinken et al., 2006). For example, GJIC inhibitors 18a-glycyrrhetinic 
acid (AGA) and octanol (OcOH) blocked GJIC and induced the reduction 
of cell proliferation and initiation of cell apoptosis in human 
endometrial stromal cells (Yu et al., 2014). GJIC is found in all 
multicellular animals and the majority of vertebrate cell types (Saez et 
al., 2003).  
Gap junctions on the plasma membrane can be regulated in several ways: 
1) regulation of connexin gene transcription; 2) regulation of connexin 
protein synthesis; 3) the building of subunits of gap junctions; 4) 
regulation in the delivery of gap junction proteins to the plasma 
membrane; 5) regulation of gap junction protein recycling from the 
plasma membrane; 6) regulation in the degradation of gap junction 
proteins; 7) functional regulation of opening and closing of gap junction 
intracellular channels. These regulation events could be summarised as 
regulation in the life cycle of gap junction proteins that affect the 
function of gap junctions and gating of gap junctions. Due to GJIC 
functions at the plasma membrane, any factors that affect the 
formation of gap junctions at the cell membrane will affect their 
function (this will be reviewed in detail in 1.3). In terms of gating of gap 
junctions, any factors that affect the opening/closing of gap junctions 
will be counted such as phosphorylation of connexins or changes in 
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response to calcium concentration (Nielsen et al., 2012a). For example, 
phosphorylation at serine368 at Cx43 C-terminus led to a decrease in 
gap junctional communication (Lampe et al., 2000), while increasing 
calcium concentrations led to a block in dye transfer between HeLa cells 
stably transfected Cx43 and expressing functional gap junctions (Lurtz 
and Louis, 2007).  
Gap junction intracellular channels are structurally formed of two 
connexons (also called hemichannels) with head-to-head docked 
formation (Figure 1.1 A). Each connexon is formed of six connexins, 
which could be the same connexins (homologous connexon) or 
combinations of different connexins (heterologous connexon) (Figure 1.1 
B). Each connexin contains two extracellular loops (E1 and E2), which 
are the most conserved domains among connexins. Three cysteine 
residues in the E1 and E2 domains form disulphide bonds that are 
contained by all connexins able to form functional GJs. Hydrogen bonds 
at the docking interface act like ―glue‖ to help the docking of two 
connexons and form functional GJs between neighbouring cells (Bai et 





Figure 1.1: A schematic diagram of a gap junction intracellular channel (GJIC) between 
neighbouring cells.  
(A) Gap junction intercellular channels (GJIC), formed by two docked connexons, allow the 
exchanges of ions and small molecules that are less than 1kDa. (B) Each connexon is formed 
by six connexins, either the same connexin (homologous connexon) or combinations of 
different connexins (heterologous connexon). (C) Each connexin contains an N-terminus, four 
trans-membrane domains which are linked with two extracellular loops (EL) and one 
intracellular loop (IL) and a C-terminal tail which normally contains protein-protein interaction 
sites or post-translation modification sites such as phosphorylation. The figure is taken from 




The gap junction proteins, connexins, traverse the cell membrane four 
times with amino and carboxyl termini staying in the cytoplasmic 
intracellular environment. A schematic diagram of a general connexin is 
shown in Figure 1.1. This generates the following structure: four trans-
membrane domains (TM) that contain helices anchored into the lipid 
bilayer of the plasma membrane; two extracellular loops that allow the 
connexons of neighbouring cells to couple; one cytoplasmic loop; and an 
N- and C-terminal region located on the cytoplasmic membrane face 
(Figure 1.1 C).  The amino acid sequence of the extracellular loops and 
trans-membrane domains are highly conserved between different 
connexins. Therefore, the connexins are different from each other, 
mainly in the amino acid differences in the intracellular loop and the 
variable length of the carboxyl-terminal tail (Evans and Martin, 2002). 
Research has been done to investigate the function of different domains 
in the connexins. The amino terminus acts as a calmodulin-binding 
domain that may affect the oligomerisation (Ahmad et al., 2001, Torok 
et al., 1997). This region also plays an important role in membrane 
insertion and trafficking. Site-specific mutation at position 12 led to an 
accumulation of the protein in the cytoplasm, and it was mainly located 
in the Golgi apparatus (Martin et al., 2000).  
All the trans-membrane domains act as membrane anchors. Deletion of 
TM1 blocked overall membrane insertion (Martin et al., 2000). Mutation 
of Cx32 TM1 (I28L) resulted in Cx26-like trafficking and post-translation 
insertion properties. This suggested the TM1 plays key roles in regulating 
trafficking pathways of individual connexins (Martin et al., 2001). The 
TM3 is thought to contribute to the formation of the channel wall 
(Skerrett et al., 2002). The extracellular loops, as mentioned above, 
function in the docking of connexons between neighbouring cells. 
Genetic mutations leading to disordered function and trafficking 
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emphasised the importance of these loops in docking (Marziano, 2003, 
Bakirtzis et al., 2003). It has been reported that the C-terminal tail of 
connexins interacts with the intracellular loop like a ―ball and chain‖ 
model, which monitors the chemical gating of the channel 
(Stergiopoulos et al., 1999). Cx32 with truncation of the carboxyl tail 
showed little effect on the assembly of gap junctions (Yum et al., 2002). 
Cx26 with the addition of the C-terminus of Cx43 maintained the original 
trafficking pathway, which indicted the carboxyl tail was not involved in 
the trafficking of connexins (George et al., 1999). However, in most 
connexins (apart from Cx26), C-terminal tails contain multiple post-
translation modification sites. For example, the C-terminal tail of Cx43 
contains 33 phosphorylation sites phosphorylated by more than one 
protein kinases (Chen et al., 2013a). Its C-terminus also contains many 
protein-protein interaction regions allowing it to interact with other 
associated proteins such as microtubules and ZO-1 (Giepmans et al., 
2001b, Toyofuku et al., 1998). 
Since the first gap junction protein was cloned and sequenced from rat 
heart in 1986, there are now 21 connexin genes identified in the human 
genome and 20 in the mouse genome. Connexins can be divided into five 
subgroups (α, β, γ, δ, or ε) based on their sequence similarities and the 
length of their cytoplasmic loop. Their names depend on their predicted 
molecular weight (e.g. Cx43 is about 43 kDa in size) (Beyer et al., 1987, 
Nielsen et al., 2012b). This project focuses on Cx43 because it is the 
most widespread connexin, and its long C-terminus contains many 
phosphorylation sites and protein-protein interaction domains.  
As the first gap junction protein being cloned and sequenced, Cx43 is 
well-studied compared to other connexins. Cx43, with the molecular 
weight of 43 kDa, is the major building unit of gap junctions that can be 
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found in many mammalian cell types, and especially epithelial cells 
(Laird, 2010). These post-translation modification sites on the Cx43 CT 
makes it different from most other connexins (Leithe et al., 2017a). The 
carboxyl-terminal domain of Cx43 is 17 kDa and reported to contain 
many sites phosphorylated on serine or tyrosine residues by different 
kinases (Lampe and Lau, 2004). This CT domain is also reported to be 
associated with the stabilisation of Cx43 anchoring in plasma membranes. 
Investigation of Cx43 CT truncated mutants indicates the important role 
of 235 – 242 amino acid (aa) of Cx43 CT in GJ formation in the plasma 
membrane; the amino acid region of 271 – 302 in the CT of Cx43 is 
associated with controlling the size of GJ plaques; 325-342 aa region 
plays an important role in the control of internalisation of GJ plaques 
(Wayakanon et al., 2012). There are in total 66 S/T/Y sites in Cx43, and 
32 of them are in the CT domain (Chen et al., 2013b). Monomeric Cx43 
molecules are found in phosphorylated form, which indicates that Cx43 
receives phosphorylation before insertion into the plasma membrane 
(Musil and Goodenough, 1993). Phosphorylation of Cx43 influences many 
aspects of gap junctions: gap junctions formed by Cx43 with mutations 
after 239aa are still functional but inhibited in the opening of the 
hemichannel, which indicates that phosphorylation sites in this region 
are important for opening the channel (Johnstone et al., 2012). 
Connexins phosphorylated by PKC and MAPK maintain hemichannels in a 
closed state. PKC directed phosphorylation of S368 in Cx43 reduces the 
opening of hemichannels. Therefore, the opening/closing state of 
hemichannels is controlled by the balance of phosphorylation/ de-
phosphorylation at the C terminus of Cx43 (Contreras et al., 2002, De 
Vuyst et al., 2007). Phosphorylation of S364 by PKA and S325/S328/S330 
by CK1 is thought to increase the assembly and stability of gap junctions. 
Generally, Cx43 is positively phosphorylated by CK1 (and PKA) while PKC, 
MAPK, v-SRC and CDC2 reduce gap junction activity. De-phosphorylation 
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of Cx43 at S365 may result in intracellular redistribution and removal 




Figure 1.2: A schematic diagram of the C-terminus of Cx43 with phosphorylation sites 
indicated. 
Cx43 CT contains many phosphorylation sites phosphorylated by many kinases such as PKA, 
PKC, and MAPK. Phosphorylation at tyrosine residues is coloured in brown, and 
phosphorylation at serine residues is coloured in blue. The phosphorylation sites and kinases 




1.1.2 Connexin protein-protein interactions 
In the beginning, connexins were thought only as the building blocks of gap 
junctions, but more and more evidence has been found that connexins are 
able to interact with other proteins and regulate cell functions or cell 
activities. Such interactions can regulate connexins at different levels, 
including biosynthesis, trafficking, and degradation of connexins and the 
formation of GJIC. As mentioned above, sequences of connexins are 
conserved from the N-terminus to the fourth trans-membrane region, but 
there is variation in C-terminal tails. Peptides correlated to the N-terminus 
(residues 1-21) and C-terminus (residues 216-230) of Cx32 have been found 
to bind to fluorescently-tagged Calmodulin (a Ca2+ -binding protein) in a Ca2+ 
-dependent manner. The third amino acid at the N-terminal of Cx32 (Trp3) 
is critical in this interaction (Torok et al., 1997). However, the Calmodulin-
binding motif has been identified differently in Cx43, which is located at the 
intracellular loop (residues 136-158) in a Ca2+ -dependent manner (Zhou et 
al., 2007). Cx43, the most widespread connexin, contains SH2, SH3 and PDZ 
binding domains at its C-terminus facilitating the interactions between Cx43 
and its binding partners. A diagram with potential binding partners of Cx43 
CT and some binding domains is shown in Figure 2. It has been shown that 
many proteins can interact with the C-terminal tail of Cx43 and other 
connexins. These include tight-junction proteins, cytoskeletal proteins and 
some protein kinases. The examples have been listed below.   
Zonula occludens-1 (ZO-1), the first identified tight junction protein 
(Stevenson et al., 1986), belongs to the membrane-associated guanylate 
kinase (MAGUK) family that contains Postsynaptic density/Discs large/ZO-1 
(PDZ) domains and has a role in maintaining epithelial cell polarity (Van 
Itallie and Anderson, 2014). ZO-1, with its second PDZ domain, has been 
found to directly interact with Cx46, Cx50 and Cx43 (Giepmans and 
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Moolenaar, 1998, Toyofuku et al., 1998, Nicholson, 2003). The extreme C-
terminus (amino acids DLEI) of Cx43 was identified as the binding sites for 
ZO-1 PDZ2 domain (Giepmans and Moolenaar, 1998). Phosphorylation of 
Cx43 at Ser373 negatively affects the Cx43-ZO-1 interaction. A mimetic 
peptide representing the last 12 amino acids of the Cx43 C-terminal tail 
with the phosphorylated mimic substitution at Ser373 site displays a 7-fold 
lower affinity of binding to the second PDZ domain of ZO-1 compared with 
wild-type peptide (Chen et al., 2008). Elimination of the Cx43-ZO-1 
interaction by Akt-dependent phosphorylation at Ser373 in the C-terminus of 
Cx43 led to enlarged gap junction size (Dunn and Lampe, 2014). This rapid 
increase in GJ communication may potentially let cell signalling molecules 
enter the cells and initiate the activation and migration of keratinocytes in 
response to a wound or ischemic injury (Dunn and Lampe, 2014). HeLa cells 
stably transfected with Cx43-GFP expressing abnormal large size and this 
could be normalised by transfection of native Cx43. This was due to Cx43-
GFP block the Cx43-ZO-1 interaction since peptide inhibition of Cx43-ZO-1 
interaction led to enlarged gap junction (Hunter et al., 2005). This enlarged 
gap junction was due to the incorporation of non-junctional connexons to 
gap junctions (Hunter et al., 2005). This enlarged size of gap junctions may 
decrease the non-junctional pool of Cx43 on the plasma membrane since 
they incorporation into gap junctions and may also allow internalisation of 
annular junctions more efficiently (Solan and Lampe, 2014). Phosphorylation 
at S368 has been observed increasing with the blocking of Cx43-ZO-1, 
followed by internalisation of Cx43 (Palatinus et al., 2011).    
Cx43 has been reported to interact with cytoskeleton proteins. The Cx43 CT 
binds to tubulin directly through its juxtamembrane region with 35 amino 
acids (residues 228-263). This tubulin-binding motif is not found in other 
connexins, therefore it is Cx43-specific (Giepmans et al., 2001a). A mimetic 
peptide correlated to residues 234-259 at Cx43 CT has been shown to 
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interact with tubulin, and it could compete with Cx43 CT to limit tubulin-
binding. This Cx43-tubulin interaction is prevented by Src kinase-mediated 
phosphorylation on Cx43 CT Y247 (Saidi Brikci-Nigassa et al., 2012) Cx43 CT 
binds to both alpha-tubulin and beta-tubulin equally (Giepmans et al., 
2001b). Cx43 can bind to ZO-1 (which can bind to actin), tubulin and drebrin 
(an actin-binding protein) with different non-overlapping binding domains 
located at its C-terminus to form a supramolecular complex, which indicates 
the important role of this protein complex in the regulation of cytoskeleton 
rearrangement and further regulating cell migration (Ambrosi et al., 2016).   
Cx43 CT binds to 14-3-3 theta and zeta at the 14-3-3-binding motif (370-376), 
which requires Akt induced phosphorylation of Cx43 CT-S373 (Park et al., 
2006, Park et al., 2009). The interaction between Cx43 and 14-3-3 theta was 
associated with the internalisation of gap junctions (Smyth et al., 2014). 
There are seven isoforms of 14-3-3 protein (beta, epsilon, gamma, eta, 
tau/theta, zeta and sigma), involved in many biological processes such as 
cell proliferation and cell migration (Moreira et al., 2008). Overexpression 
of 14-3-3 tau was observed in breast cancer, through activation of Rho 
GTPase and ROCK2. This led to increased cell migration and invasion of 
breast cancer cells, and reduced adhesion within each other (Xiao et al., 
2014). An increasing level of 14-3-3 zeta was observed in chronic wounds 
and mice with deficiency of 14-3-3 zeta exhibited faster wound healing 
associated with increasing signalling downstream of ROCK (Kular et al., 
2015).      
There are a number of other proteins which bind to Cx43 CT. Caveolin-1 
directly binds to Cx43 CT via its caveolin-scaffolding domain (residues 82-
101) and the C-terminal domain (135-178) (Schubert et al., 2002). Cx43 was 
targeted to lipid rafts where it interacted with caveolin-1 (Schubert et al., 
2002).  The specific binding region of caveolin-1 on Cx43 CT remains unclear. 
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CIP75 (Cx43-interacting protein of 75kDa) binds to Cx43 CT with its C-
terminal UBA (ubiquitin-associated) domain. The Cx43-CIP75 interaction 
region is between amino acids 264 and 302 within Cx43 CT. Its role was 
suggested to be involved in the turnover of Cx43 since overexpression of 
CIP75 increased the degradation of Cx43, possibly through the proteasome 
(Li et al., 2008). NEDD4 (neural precursor cell-expressed developmentally 
downregulated gene 4) binds to the PY motif (XPPXY, where P is proline, X is 
any amino acid, and Y is tyrosine) on the Cx43 CT, specifically at 283-286. 
The role of NEDD4 was also thought to be involved in the degradation of 
Cx43 since downregulation of NEDD4 led to an increasing number of gap 
junction plaques on the plasma membrane (Spagnol et al., 2016). Drebrin, 
an actin-binding protein, directly binds to three regions of Cx43 CT, residues 
264-275 being critical for this interaction. Src phosphorylation at Y265 
negatively regulated Cx43-drebrin interaction (Ambrosi et al., 2016). 
Specifically, another MAGUK family protein hDlg is found to bind to the C-
terminal of Cx43 via its N-terminal and C-terminal. However, the last four 
amino acids of Cx43 CT (required to bind ZO-1) were not required for hDlg 




Figure 1.3: A schematic diagram of the Cx43 C-terminal tail from amino acids 234 to 
382 with some potential binding partners and binding domains. 
Cx43 interacts with many other proteins through its binding domain located at its C-terminus. 
Different colours indicate different binding partners, and the location of the interaction region 




1.1.3 The life cycle of Cx43 
Fully functional GJIC requires the correct levels of properly folded 
connexins (the building blocks of gap junctions) to be structured in gap 
junction plaques on the cell membrane. In this case, tissues regulate the 
number of connexins forming the gap junctions on the plasma membrane by 
regulating the expression of connexins, trafficking, recycling and 
degradation of connexins. Like many secreted proteins, connexins are 
transcribed to mRNA in the nucleus and translated into protein in the 
ribosome, followed by post-translation modification in the endoplasmic 
reticulum (ER) and Golgi complex and then are delivered to the plasma 
membrane.  
The gene, named GJA1, that encodes Cx43, contains two exons and one 
intron located in the 5‘untranslated region (5‘-UTR) (Sullivan et al., 1993). 
Genes encoding different connexins are located in different chromosomes. 
For example, GJA1 (encoding Cx43) was mapped to human chromosome 6, 
while GJB1 (encoding Cx32) was located on the X chromosome (Fishman et 
al., 1991). The expression of different connexins is cell-/tissue-specific. For 
example, in the basal cell layer of human epidermis, the expression of Cx26 
is predominant, while Cx43 is found only in small amounts. But in the 
spinous cell layer and granular cell layer of human epidermis, the expression 
of Cx43 is predominant (Oyamada et al., 2005). DNA methylation might be 
one of the modulators of transcription that cause variation in connexin 
expression. Methylation was found in the Cx32 promoter in rat liver 
epithelial cells that expressed Cx43 but not Cx32, whereas in rat 
hepatocytes, it was the promoter of Cx43, not Cx32, which was methylated 
leading to the totally opposite expression of these two connexins (Piechocki 
et al., 1999).  
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Gap junction connexins have been reported to have a short half-life of 1.5 – 
5 hours. This short lifespan allows the GJIC formed by connexins to respond 
to alteration of the surrounding environment rapidly via either up-regulated 
or down-regulated gap junction coupling (Laird, 2006). For example, in the 
myometrium, the total number of gap junctions dramatically increases just 
before labour onset and following labour, reduces back to a steady state of 
GJIC levels in the uterus (Hendrix et al., 1992, Risek and Gilula, 1996). 
Connexins are believed to insert into the ER (endoplasmic reticulum) co-
translationally. In vitro experiments have shown that both Cx26 and Cx32 
can co-translationally insert ER membranes. Cx26 but not Cx32 can also 
insert ER membranes post-translationally (Zhang et al., 1996). Connexins 
folding into mature states and the formation of disulfide bonds between 
cysteine residues at extracellular loops occurs in the ER (John and Revel, 
1991, Rahman and Evans, 1991).  
Connexins are transported from the ER to the Golgi complex, where the 
oligomerization occurs. Monomers formed of Cx43 or Cx46 are found in the 
Golgi apparatus while oligomerizations of these two connexins were found in 
the trans-Golgi network (Musil and Goodenough, 1993, Koval et al., 1997). 
Fractionation studies have shown connexons consisting of Cx26 and Cx32 
were found in the Golgi apparatus in the guinea-pig liver (Diez et al., 1999). 
In general, connexins exist as monomer forms in the ER and become 
oligomerized in the trans-Golgi network. However, oligomerization of 
connexins could be induced by a high level of connexins in the ER (VanSlyke 
et al., 2009) because in baby-hamster kidney (BHK) cells, gap junction-like 
structures consisting of Cx32 were observed in the ER (Kumar et al., 1995). 
The chaperone ER-localized, 29-kDa thioredoxin-family protein (ERp29) has 
been suggested to stabilize monomeric Cx43 in the ER and enable the 
oligomerization occurring in the Golgi apparatus (Das et al., 2009).    
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After being properly folded and oligomerized in the trans-Golgi network, 
connexins in the form of connexons are transported to the cell surface. 
Microtubules are thought to be involved in this trafficking of connexins. 
Microtubules, act as a high-way in the cytoplasm connecting the Golgi and 
membrane-anchored proteins (e.g. Adherens junction proteins). Connexons 
leaving the Golgi in vesicles can traffic to the membrane along the 
microtubules (Shaw et al., 2007). In cells treated with Brefeldin A (a drug 
that disrupts the Golgi compartment), the majority of Cx32 and Cx43 was 
trapped and unable to traffic to the cell membrane and gap junction 
communication was largely inhibited while Cx26 was minimally affected 
(George et al., 1999, E. et al., 2001). This indicates that Cx26 can traffic to 
the membrane independent of Golgi trafficking. In the cells treated with 
nocodazole (a drug that disrupts microtubules), assembly of Cx26 gap 
junctions was abolished while there was little effect on Cx43 gap junction 
assembly (George et al., 1999, E. et al., 2001). This indicates that Cx43 can 
traffic to the membrane by alternative pathways to microtubules. Non-
sarcomeric actin has been thought to be involved in the delivery of Cx43, in 
addition to microtubules, via regulating vesicular transport. The 
dependence of GJ formation and maintenance has been identified to involve 
actin (Theiss, 2002, Qu et al., 2009, Thomas et al., 2001). Apart from direct 
binding to actin, Cx43 can interact with actin indirectly via binding to ZO-1 
and drebrin (both can interact with actin) (Ambrosi et al., 2016). Live cell 
imaging with different colour labels distinguishing older and younger protein 
molecules of Cx43 indicated that newly synthesis Cx43 trafficked in vesicles 
with the size between 10 – 150 nm to the plasma membrane at the edge of 
gap junction plaques while older Cx43 located at the centre of the plaques 
(Gaietta et al., 2002).   
Older Cx43 connexons have been shown to be removed from the centre of 
the gap junction plaques (Gaietta et al., 2002). Co-culture of NRK cells 
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expressing GFP –labelled Cx43 and cells with endogenous expression of Cx43 
resulted in fluorescently tagged Cx43 being internalised into the non-
fluorescent cells (Naus et al., 1993). Combined with the observation of 
double-membrane annular gap junctions internalised in cells (Gaietta et al., 
2002), this suggests that older Cx43 from the centre of gap junction plaques 
as annular gap junctions (connexosomes) can be internalised into one of the 
neighbouring cells. Annular gap junctions removed from the centre of gap 
junction plaques can sometimes be recycled to the membrane regenerating 
the gap junction instead of newly synthesised connexins. This can occur 
after mitosis is completed in cell lines such as SW-13 adrenocortical tumour 
cells and normal rat kidney (NRK) cells (Boassa et al., 2010, Vanderpuye et 
al., 2016). The internalisation of Cx43 occurs after ubiquitination prior to 
lysosomal or proteasomal degradation. These events can be triggered by 
post-translation modification, such as phosphorylation. Phosphorylation at 
Ser373 in the Cx43 CT led to the binding of 14-3-3 theta and subsequently 
phosphorylation at Ser368 that resulted in gap junction ubiquitination, 
internalisation and degradation in the event of acute cardiac ischemia 
(Smyth et al., 2014).   
Cx43 can be degraded through the proteasome and lysosome but mainly the 
latter. Degradation of Cx43 was delayed in the presence of proteasome 
inhibitor, and Cx43 was also found to be a substrate for ubiquitin, which is 
normally a target to the proteasome. But mono-ubiquitination was found for 
Cx43, which is thought to act as a trigger for internalisation while proteins 
with poly-ubiquitination are normally the target to the proteasome. 
Accumulated evidence has revealed that the degradation of Cxs is mostly via 
the lysosomes. For instance, immunofluorescence assay indicates that 
intracellular Cx43 is located in the lysosome and lysosome inhibitor-treated 




Figure 1.4: The life cycle of connexins.  
Properly folded connexins are delivered to the Golgi apparatus through the trans-Golgi 
network (TGN). Improper folded connexin may be targeted for endoplasmic-reticulum-
associated protein degradation (ERAD).  Connexins, in the form of connexons, are delivered 
to the cell surface in vesicles. Microtubules facilitate this process.  New gap junction channels 
are delivered to the margins of gap junction plaques while older channels are found in the 
centre of the plaques. Older channels are internalized as annual junctions (connexosomes). 
Connexins may also be internalized through classical endocytic pathways.  Internalized 




1.1.4 Connexins and disease 
Gap junction intercellular channels, as a bridge connecting cells to 
neighbouring cells allowing the exchange of small molecules or signals 
between cells and their surrounding environment, act as a maintainer of 
homeostasis that ensures that cellular physiological activities occur properly. 
As building blocks of gap junctions, connexins behaving abnormally will 
affect the function of gap junctions. Fourteen inherited human diseases 
have been linked to connexin mutations. These include myelin-related 
diseases, deafness and skin diseases, cataracts and oculodentodigital 
dysplasia (ODDD) (Table 1)(Kelly et al., 2014). X-linked Charcot-Marie-Tooth 
disease (CMTX), a genetic neuropathy in the peripheral nerves resulting in 
muscle weakness, especially in the limbs (Wang and Yin, 2016), was the first 
identified connexin-linked human disease for which seven different 
mutations were found in the Cx32 gene in patients from eight CMTX families 
(Bergoffen et al., 1993). There have been over 400 mutations found in the 
gene GJB1 (encoding Cx32) in CMTX patients, most of which lead to the 
unsuccessful formation of gap junctions, or gap junctions with abnormal 
properties (Kleopa et al., 2012).  Transgenic mice with point-mutation in 
the Cx32 gene resulted in loss-of-function of Cx32 in Schwann cells and 
oligodendrocytes (Sargiannidou et al., 2009). In addition, mice with 
knockout Cx32 showed more susceptibility to chemically induced liver 
carcinogenesis (Temme et al., 1997).  
More than 220 different Cx26 mutations have been linked to non-syndromic 
hearing loss (Hilgert et al., 2009). In the inner ear, gap junctions 
predominantly formed by Cx26 are thought to be critical in recycling 
potassium to maintain the high endolymphatic potassium concentration (Xu 
and Nicholson, 2013). Apart from Cx26 mutations, many hearing loss cases 
are also associated with mutations in the Cx30 gene (Common et al., 2005). 
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Apart from Cx26 and Cx30 mutations, the linkage has also been reported 
between mutations in another three connexins (Cx30.3, Cx31, and Cx43) and 
hearing loss (Xu and Nicholson, 2013, Hong et al., 2010, Scott and Kelsell, 
2011).   
In humans, Cx43 is the predominant connexin expressed in the epidermis. 
Cx43 is mainly confined to the basal epithelial layers, whereas other 
connexins like Cx26 and Cx30 are expressed in the spinous layer (Martin et 
al., 2014). Mutations occurring in the genes encoding these connexins can 
cause various skin diseases including Erythrokeratoderma Variabilis (EKV), 
which is associated with short-lasting red patches and thickened skin 
(hyperkeratosis); and Bart-Pumphrey syndrome, which is characterized by 
white discolouration of the nails and knuckle pads on the knuckles of the 
fingers and toes (Kelly et al., 2014). EKV was linked to the mutations in the 
genes encoding Cx31 and Cx30.3 (Richard et al., 1998, Richard, 2003). Gene 
mutations of Cx46 and Cx50 have been linked to cataracts (Pal et al., 2000). 
The first Cx43 gene mutations were associated with the inherited disease, 
Oculodentodigital Dysplasia (ODDD), which leads to congenital craniofacial 
deformities (Paznekas et al., 2003). Over 73 mutations of Cx43 have been 
found associated with ODDD (Laird, 2014). As a widespread connexin that is 
expressed in most cell types in humans, Cx43 is critical. This is supported 
with experimental data where homozygous Cx43-knockout mice (-/-) died 
shortly after birth due to failure of gas exchange in the lung while in 
heterozygous Cx43-knockout mice (+/-), the majority of cells were coupled 
and membrane Cx43 were observed. Importantly, the morphology of the 
heart appeared normal in heterozygous mice while in homozygous mice 




Gap junctions are abundant in the normal cervix but dramatically decreased 
in severe dysplasia and deficient in cervical carcinomas (McNutt and 
Weinstein, 1969b, McNutt et al., 1971). Immunohistochemistry on cervical 
biopsies showed strong expressing of Cx43 in the normal epithelium but a 
dramatic reduction in Cx43 in dysplasia regions (King et al., 2000, Aasen et 
al., 2005). GJIC was lost, and Cx43 relocated from the membrane into the 
cytoplasm, in HPV-positive cervical cells (Aasen et al., 2003a). Co-
localisation of Cx43 and hDlg were observed on the plasma membrane of 
W12G cells (immortal but non-transformed cervical epithelial cells)  but 
moved into the cytoplasm of W12GPXY cells (fully transformed cervical 
epithelial cells derived from W12G cells) and co-immunoprecipitation 
indicated the direct interaction between Cx43 and hDlg in cervical epithelial 
cells W12 and W12GPXY cells (Macdonald et al., 2012b). Later HPVE6 was 
indicated involved in this Cx43/hDlg interaction since co-
immunoprecipitation of Cx43/hDlg, hDlg/E6 and E6/Cx43 was observed in 
cervical tumour cells W12GPXY. Transfection of HPVE6 in C33a cells (HPV-
negative cervical tumour cells) led to the relocation of Cx43/hDlg from the 
plasma membrane (in C33a cells) into the cytoplasm (in C33aE6 cells). This 
relocation of Cx43 could be due to interaction between HPVE6 and hDlg 
since transfection of mutated HPVE6 (loss ability to bind hDlg) in C33a cells 
did not lead to the cytoplasmic location of Cx43 and hDlg. This Cx43/hDlg 
interaction was also observed in cervical tumour cells in vivo (Sun et al., 




Table 1: List of 14 inherited diseases associated with human connexin gene mutations.  
Taken from (Kelly et al., 2014). 
Inherited disease Connexin gene (protein) 
Syndromic and non-syndromic hearing 
loss 
 
Most common GJB2 (Cx26) GJB6 (Cx30) 
Less common GJA1 (Cx43), 
pGJA1(pCx43)/GJB3 
(Cx31)/GJB4 (Cx30.3) 
Auditory-linked neuropathies GJB1 (Cx32)/GJB3 
(Cx30.2/Cx29) 
  
Myelin-related disease  
X-linked Charcot-Marie-Tooth disease GJB1 (Cx32) 




Cataracts GJA3 (Cx46)/GJA8 (Cx50) 
  
Skin diseases  
Bart-Pumphrey syndrome GJB2 (Cx26)/GJB6 (Cx30) 
Clouston syndrome GJB6 (Cx30) 
Erythrokeratoderma Variabilis (EKV) GJB3 (Cx31)/GJB4 
(Cx30.3)/GJB6 (Cx30) 
Hystrix-like icthyosis with deafness GJB2 (Cx26) 
Keratitis ichthyosis deafness syndrome GJB2 (Cx26)/GJB6 (Cx30) 
Vohwinkel syndrome GJB2 (Cx26)/GJB6 (Cx30) 
  
Cardiovascular diseases  
Atrial fibrillation GJA5 (Cx40)/GJA1 (Cx43) 




1.1.5 Connexins and cancer  
Apart from the many diseases mentioned above, connexins are also thought 
to be linked to tumour progression since gap junctions are involved in 
controlling cell growth (growth factors passing through gap junctions or 
independent from the formation of gap junctions) (Moorby and Patel, 2001) 
and cells becoming lack of growth control, which is one of the main 
characteristics in cancer. In 1966, Loewenstein and colleges observed that 
electrical communication in healthy rat liver cells was lost in liver cancer 
cells. Cancer formation induced the reduction of communication in cells 
around and between cancer cells (Loewenstein and Kanno, 1966). Similar 
phenomena of the loss of intercellular communication in rat liver cancer 
cells, rat and hamster thyroid cancer cells were also observed (Loewenstein 
and Kanno, 1967, Jamakosmanovic and Loewenstein, 1968), which indicated 
that the loss of cellular communication is one of the identifying 
characteristics in cancer cells. Later in 1969, deficiencies in gap junction 
ultrastructure (nexuses intracellular junction) were demonstrated in human 
invasive cervical squamous cell carcinoma (SCC) (McNutt and Weinstein, 
1969a).    
Metabolic cooperation, a transferring of metabolites (hypoxanthine in their 
experiment) to adjacent cells, was found to be mediated by cell-cell 
contacts (H et al., 1969) that were identified with electron microscopy as 
gap junctions (Gilula et al., 1972). Metabolic cooperation between HPRT+ 
(hypoxanthine phosphoribosyltransferase) and HPRT- cells rescued HPRT- 
cells from dying in HAT medium, which provided a way of measuring 
metabolic cooperation by measuring the release of radioactivity during co-
culture of labelled HPRT- cells and unlabelled HPRT+ cells in HAT medium. 
Metabolic cooperation was dysregulated between mouse embryonal 
carcinoma (EC) cells (resemble multipotential embryonic cells lacking of 
39 
 
HPRT) and human teratocarcinoma-derived cell lines (Nicolas et al., 1978). 
Tumour promoters (chemical agents with weakly carcinogenic or non-
carcinogenic activity themselves that require other agents to initiate 
tumours), especially 12-O-tetradecanoyl-phorbol-13-acetate (TPA), blocked 
such metabolic cooperation in Chinese hamster cells (Yotti et al., 1979), in 
cocultured epidermal and 3T3 cells (Murray and Fitzgerald, 1979) and gap 
junctions in mouse epidermal cells (Kalimi and Sirsat, 1984). Apart from 
tumour promoters, tumour-associated viruses such as the avian sarcoma 
virus negatively affected gap junction intracellular channel permeability 
(Atkinson et al., 1981).  This further supports the hypothesis that loss or 
alteration in gap junctions is a hallmark of cancer.  
On the one hand, the loss of gap junctions in cancer cells could be due to 
the abnormal expression of gap junction proteins. For example, Cx43 levels 
were reduced in cervical dysplastic cells and colorectal carcinomas 
compared to normal epithelial cells (TJ et al., 2000, Sirnes et al., 2015). In 
human bladder cancer cells, Cx26 expression was reduced by upregulation 
of KDM5B (a demethylase at H3K4) (Li et al., 2013). However, up-regulated 
expression of connexins has also been observed in some cancer cells such as 
Cx26 in pancreatic carcinomas and colorectal cancer (Kyo et al., 2008, 
Ezumi et al., 2008). On the other hand, the loss of GJIC in cancer cells could 
be also due to the alteration of the subcellular location of gap junction 
proteins. For example, in cancer cells connexins located in the cytoplasm 
instead of on the plasma membrane. Alterations in subcellular location of 
connexins from the plasma membrane into the cytoplasm have been 
demonstrated in many cancers (for example, Cx26 in colorectal cancer cells 
and pancreas carcinoma (Kyo et al., 2008, Ezumi et al., 2008), Cx32 in liver 
cancers (Krutovskikh et al., 1994), and Cx43 in cervical cancer cells (Aasen 
et al., 2003b). 
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Since the loss of gap junction intracellular channels has been observed in 
many cancers, it is interesting to investigate whether the restoration of gap 
junctions could reverse or delay the carcinoma process in these cells. In 
transformed mouse embryo cells, transfection of an expression plasmid 
containing the Cx43 coding region led to the restoration of gap junctions 
and inhibited the growth of the transformed cells (Mehta et al., 1991). 
Expression of a gene encoding Cx43 in rat glioma cells enhanced gap 
junction intracellular channels and slowed their growth in vitro and in vivo 
(Zhu et al., 1991, Naus et al., 1992). It was hypothesised that this was 
accomplished possibly by the interaction between Cx43 and CCN3, which 
belongs to a family of Cyr61/connective tissue growth factors overexpressed 
in nephroblastomas (Fu et al., 2004). Small interfering RNA (siRNA) 
knockdown of Cx43 in breast cancer cells led to faster growth and increasing 
migration ability of the cells (Shao et al., 2005). Mouse models have shown 
that downregulation of Cx43 caused by deletion of one allele of the Cx43 
gene resulted in increased susceptibility to urethane-induced lung tumours 
(Avanzo et al., 2004). Cx32-deficient mice showed high susceptibility to 
spontaneous and chemically-induced lung tumours (Temme et al., 1997), 
and the increasing prevalence of radiation-induced lung tumours in Cx32-
knockout mice was associated with the increased activation of mitogen-
activated protein kinase (MAPK) (King and Lampe, 2004). Taken together, 
these data demonstrate that some, but not all connexins, could act as 
tumour suppressors in some cancers.  
The ability of connexins as tumour suppressors can vary among different 
tissue types and different stages of cancer and different connexin isoforms 
(Aasen et al., 2016). However, dye transfer has been observed between 
metastatic melanoma cells and bovine aortic endothelial cells that were 
prevented by gap junction communication blockers. The expression of Cx43 
was found in metastatic melanoma cells (el-Sabban and Pauli, 1991). Since 
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then, increasing evidence has demonstrated the relationship between 
connexin expression and cancer cell migration into the blood vessels, and 
metastases of cancer cells, which indicates the role of connexins in helping 
cancer cell invasion and metastasis that is one of the hallmarks of cancer 
(Kotini and Mayor, 2015). Cx26 may enhance the metastasis of human 
melanoma cells by facilitating their communication with surrounding cells 
(Saito-Katsuragi et al., 2007). Increased levels of Cx43 and Cx26 and 
membrane location of both proteins were found in lymph node metastatic 
breast cancer cells (Kanczuga-Koda et al., 2006). Alternatively, the 
expression of Cx26 was significant linked with lymphatic vessel invasion in 
tumour samples from patients with breast cancer (Naoi et al., 2007). 
Expression of Cx43 in GJIC-deficient breast tumour cells (HBL100) showed 
the membrane location and connection between tumour cells and 
endothelial cells and an increase in diapedesis, a process involved in 
metastasis (Pollmann et al., 2005). Increasing expression of Cx43 was 
observed in the cell contact area between mouse breast tumour cells and 
pulmonary microvascular endothelial cells in vitro and in vivo (Elzarrad et 
al., 2008). Overexpression of Cx43 in mouse breast tumour cells led to their 
increasing attachment to lung endothelium, which required the involvement 
of functional gap junctions (Elzarrad et al., 2008). Injection of mouse breast 
tumour cells with a knockout of Cx43 (4T-1KNCx43) led to decreasing 
formation of microtumour, less extravasation and invasion in the brain of 
zebrafish compared to control (4T-1) (Stoletov et al., 2013). Injection with 
4T-1KNCx43 led to decreased brain colonization and less co-option with 
brain vasculature in chicken compared to control (4T-1) (Stoletov et al., 
2013). The metastatic gene Twist induced tumour cell extravasation and 
metastasis in the brain by inducing the expression of Cx43 (Stoletov et al., 
2013). cGAMP transfer utilizing Cx43 gap junctions was thought to involve in 
brain metastasis (Chen et al., 2016). In 2017, after reviewing related studies 
using human tissue samples, Phillips observed the loss of GJIC in breast 
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cancer due to the cytoplasmic relocation of Cx43 but the increased 
expression and membrane localization of Cx43 in breast cancer metastasis, 
which indicates different roles of Cx43 in different stages of breast cancer 
(Phillips et al., 2017). Also, connexin expression could increase the 
resistance of cancer cells to chemotherapy and radiotherapy (Munoz et al., 
2014, Artesi et al., 2015). The expression of Cx30 in human glioblastoma 
cells reduced their growth and decreased radiation-induced DNA damage 
and cell death (Artesi et al., 2015). Cx43 expression was observed in 
glioblastoma cells that showed the resistance to Temozolomide (TMZ), a 
frontline chemotherapeutic agent that induces cell apoptosis of 
Glioblastoma Multiforme (GBM) (Munoz et al., 2014). siRNA knockdown of 
Cx43 in GBM cells led to more cell death under the treatment with TMZ 
(Munoz et al., 2014). Tumour microtubes (extend ultra-long membrane or 
membrane connections in astrocytoma) mediated by Cx43 in brain tumour 
cells was demonstrated to be involved in tumour cell invasion and resistance 
to radiotherapy (Osswald et al., 2015). Furthermore, some connexins (e.g. 
Cx43) can act as oncogenes by establishing metastasis of cancer cells, but 




1.1.6 Connexin and wound healing 
Skin is the first barrier for human to prevent the invasion of bacteria and 
virus. Any damage to the skin will lead to wound healing as a result of lesion 
closure (Gantwerker and Hom, 2011). Wound healing is a complex, dynamic 
process that generally can be divided into four phases: Haemostasis, 
inflammation, proliferation and maturation/remodelling (Gantwerker and 
Hom, 2011). Haemostasis is a necessary step to stop bleeding immediately 
after onset of the lesion. This achieved by aggregation of platelet as a result 
of the formation of a fibrin clot (Shaw and Martin, 2009). The involvement 
of leukocytes and cytokines is essential in the inflammation step to prevent 
skin from infections from bacteria (Eming et al., 2007). Then newly formed 
cells are needed to fill the lesion and restore the wound, which involves 
many cellular processes such as cell proliferation and cell migration 
(Gonzalez et al., 2016). These are the sorts of processes that often involve 
connexins.  
Growth factors synthesized by fibroblasts were stimulated by keratinocytes 
and can induce the proliferation of keratinocytes. Moreover, keratinocytes 
can modulate the differentiation of fibroblasts (Werner et al., 2007). Skin 
keratinocytes and fibroblasts express different types of connexins but the 
predominant connexin expressed is Cx43, which is normally expressed in the 
suprabasal layers. In a human cutaneous wound healing model generated 
from biopsies taken from patients and cultured in laboratory condition, first 
alterations were observed at 6h post-wounding when Cx43 was down-
regulated at the wound edge and the protein level was continually reduced 
until Cx43 was virtually non-detectable within the first 1-2 days after 
wounding (Brandner et al., 2004). These events are regulated through a 
―kinase program‖, where specific Cx43 CT-phosphorylation events 
(especially phosphorylated at S368) occur in a time-dependent manner 
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during wound closure (Figure 1.5) (Solan and Lampe, 2016). Solan and co-
workers (Solan and Lampe, 2016) found that in response to wound, Cx43 was 
first phosphorylated at S373 by Akt at 5-30min, which enlarges GJ size and 
blocks Cx43-ZO-1 interaction (Dunn and Lampe, 2014); followed by PKC that 
phosphorylated at S368 at 15-60min that induced the ubiquitination and 
internalization of Cx43 (Richards et al., 2004).  
Although Cx43 is dramatically reduced in actively migrating leading edge 
keratinocytes, it has been found at relatively high levels a few cell rows 
back from the wound edge where there are actively proliferating cells. 
Interestingly, in wound edge keratinocytes Cx43 is reduced as early as 5h 
post-wound and nearly undetectable by 24h while Cx26 and Cx30 which are 
normally expressed at low levels were found to be greatly increased in cells 
at the edge of wounds (Brandner et al., 2004). This indicates that gap 
junction communication might be still required for keratinocyte migration 
but the loss of Cx43 is a key event (Coutinho et al., 2003). However, in most 
non-healing wounds, instead of decreasing but abnormal increasing in level 
for Cx43 in the wound margin (Sutcliffe et al., 2015). Peptides targeting 
Cx43 has been researched and utilized to improve healing the wound 
(Montgomery et al., 2018a).  
Factors that affect the normal wound healing process such as infection or 
hypoxia might lead to chronic wounds (Gantwerker and Hom, 2011). Body 
state of humans such as age and diabetes will also affect the wound healing 
process and cause chronic wound (Gantwerker and Hom, 2011). Patients 
suffered from chronic wounds become more prevalent due to more people 
with older ages and increasing incidence of diabetes. Chronic wounds 
severely affect the quality of life (Goodridge et al., 2005). Abnormal 
expressions of Cx43 were observed at the wound edge of keratinocytes in a 
human chronic wound, which was thought to be the response for a slow 
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healing in diabetes patients (Brandner et al., 2004). However, antisense of 
Cx43 reduced the level of Cx43 and increased the healing rate (Qiu et al., 
2003). The effect of Cx43 antisense oligodeoxynucleotide (Cx43asODN) on 
acute wound healing has been reviewed in Becker 2012 (Becker et al., 2012). 
The main findings are: 1. Increasing levels of Cx43 normally occurs in the 
blood vessels around wound sites, and this upregulation is reduced by 
Cx43asODN, which reduces the leakiness of blood vessels; 2. Rapidly 
reduced levels of Cx43 by Cx43asODN at the wound edge in keratinocytes 
and fibroblasts leads to increased proliferation and migration rate of 
keratinocytes and fibroblasts. This results in faster wound closure resulting 
in faster reepithelialisation and smaller scars. There are a few antisense or 
Cx43 mimetic peptides that have been investigated for their therapeutic 
potential for the treatment of chronic wound and some of them have been 
developed as drugs and tested in clinical trial for example Nexagon 
(Lorraine et al., 2015). A peptide mimetic of Cx43 the C-terminal (alpha CT1) 
has shown a significant effect in increasing healing in chronic wounds and is 
now in Phase III clinical trials (Montgomery et al., 2018b). Mimetic peptide 
Gap27 inhibited Cx43-GJIC and increased the cell migration rate of both 
keratinocytes and fibroblasts to the wound area (Wright et al., 2009). 
Chronic wounds might be treated with keratin-based treatment and after 
treatment, 64% (29 out of 45) of chronic wounds from patients were healed 
completely and over 50% reduction in wound size was observed in 8 samples 
(Batzer et al., 2016). Keratins are typical intermediate filament proteins 
that compose the cytoskeleton in epithelial cells. Their major function is 
maintaining the integrity of cells in response to mechanical stress such as 
wound healing (Moll et al., 2008). The role of keratins in epithelial cell 
migration has been review (Yoon et al, 2019) and might depend on 
interaction with actin (Kölsch et al., 2009). Keratins 6 (K6) and 16 (K16) 
were observed to increase at the wound edge within 6h after injury of 
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human epidermis (Paladini et al., 1996). Activated keratinocytes exhibit 
upregulated K6/16 at the onset of migration to the wound region and the 
expression of K6 and K16 persists until complete closure of the wound 
(DePianto and Coulombe, 2004). Delayed wound healing was observed in 
mice with knockout of keratin 6a (Wojcik et al., 2000). There is no evidence 
showing that Cx43 interacts with keratins, but they might interact through 
intermediate proteins such as beta-catenin since keratin 19 interacts with 
beta-catenin and enhances nuclear translocation of beta-catenin in breast 





Figure 1.5: The expression of Cx43 during the wound healing process.   
In unwounded skin, Cx43 expression (labelled in green) is mainly in the differentiated 
suprabasal layers. In wounded skin, the expression of Cx43 reduced at the very near the 
wound and redistributed into lower layers in the cells behind the wound. phosphorylated Cx43 
at S368 (labelled in orange) is found in basal keratinocytes. The figure is taken from (Solan 





1.2.1 MAGUK proteins 
Proteins belonging to the membrane-associated guanylate kinases (MAGUKs) 
family serve as scaffold proteins. They are enriched at cell-cell junctions 
and play important roles in many cellular processes including maintaining 
cell polarity (Ye et al., 2018). All MAGUK proteins have a distinctive domain 
structure: one or more PDZ domains, an SH3 domain and a guanylate kinase 
(GK) region. In addition to these core domains, some MAGUKs contain other 
motifs such as homologous to CaM kinase domain and the HOOK domain 
(Dimitratos et al., 1999).  These protein-protein domains make MAGUK 
proteins recruit many other proteins such as cytoskeleton protein and 
signalling molecules to form a large complex, which can speed up signal 
transmission within some cellular processes (Dimitratos et al., 1999). 
MAGUKs can cluster these proteins recruited in the large complex at the 
plasma membrane. For example, PSD-95 protein binds directly to subunits of 
the K+ channel and anchors it at the plasma membrane (Kim et al., 1995). 
MAGUKs can be divided into several subfamilies depended on their 
difference of domain structure: Discs large (DLGs), zonula occludens (ZOs), 
palmitoylated membrane proteins (MPPs), caspase recruitment domain 
family (CARMA), calcium/calmodulin-dependent protein kinase (CASK), 
calcium channel beta subunit (CACNB) and inverted repeated membrane-
associated guanylate kinase (MAGI) (Figure 4) (de Mendoza et al., 2010). The 
product of Drosophila tumour suppressor gene Discs-large (dlg) was the first 
identified MAGUK proteins, which is located at septate junctions. Neoplastic 
overgrowth with loss of apical-basal polarity was observed in the imaginal 
discs of flies carrying a loss-function mutation in the DLG gene (Woods and 
Bryant, 1993, Woods et al., 1996a). The Dlg subfamily contains SAP97 
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(DLG1), PSD93 (DLG2), SAP102 (DLG3) and PSD95 (DLG4). All share similar 
domain structures with three PDZ domains, an SH3 domain and a GK domain 
(Figure 3)(Nithianantharajah et al., 2012). These proteins are essential in 
the regulation of glutamate receptors in synapses (Elias and Nicoll, 2007).  
Zonula occludens made up the second MAGUK subfamily, containing ZO-1, 
ZO-2 and ZO-3. All of them contain three PDZ domains, an SH3 domain and a 
GK domain (Figure 4). They constitute the tight junctions and act as a linker 
between tight junction proteins and the cytoskeleton built with actin 
(González-Mariscal et al., 2000). CASK proteins contain one PDZ domain, an 
SH3 domain, a GK domain and two L27 domains (target Lin-2 and Lin-7 
proteins) (Figure 4). CASK is concentrated in synapses and modulates the 
trafficking of synaptic vesicles and is involved in synaptic signalling 
transmission (Butz et al., 1998, Sheng et al., 1998). MPPs are p55-like 
proteins containing a single PDZ domain, an SH3 domain, and a GK domain 
(Figure 4). They are essential in the maintenance of the apical junction 
complex and involved in neuronal migration (Dudok et al., 2013). MAGIs 
contain several PDZ domains and an inverted GUK domain (instead of being 
located at the C-terminal of protein, it is located at the N-terminal) with no 
SH3 domain. Additionally, it contains two WW domains (Figure 4). MAGIs, 
enriched in the brain, modulate the trafficking of AMPA receptors in 
synapses and act as tumour suppressor maintaining the integrity of non-
neuronal cells (Danielson et al., 2012, Nagashima et al., 2015).   
Despite the variety of protein-protein domains in the proteins belonging to 
the different subfamily of MAGUKs, all MAGUKs share a distinct structure 
(except for MAGI) with one or more PDZ domains, an SH3 domain, and a GK 
domain (Figure 3). PDZ domains, originally named as GLGF (relatively 
conserved sequence of Gly-Leu-Gly-Phe) or DHR motifs (Discs-large 
homologous region), now are named after the name of the protein in which 
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they were originally identified: post-synaptic density protein with molecular 
weight 95kDa (PSD-95), Drosophila tumour suppressor (Dlg) and tight 
junction protein Zonula occluden-1 (ZO-1) (Ponting et al., 1997) and they 
are the best-characterized binding domain in all the MAGUK proteins. PDZ 
domains are found in many proteins other than MAGUKs from many species 
such as mammal, fish, flies, and even in bacteria (Ponting et al., 1997). PDZ 
domains are normally 80-90 amino acid regions with GLGF motifs that 
forming a ‗pocket‘ for binding activity (Subbaiah et al., 2011). Data from X-
ray crystallography and from specificity binding assays utilizing oriented 
peptide library techniques indicated that PDZ domains can bind to specific 
motifs with S/TXV at the C-terminal, and to other PDZ domains (Doyle et al., 
1996, Cabral et al., 1996, Songyang, 1997). Src homology 3 (SH3) domains, 
containing approximately 60 amino acids with a proline-rich sequence, are 
involved in regulation of many cellular pathways such as cell migration and 
cytoskeletal modification (Kurochkina and Guha, 2012).  
The GUK domain evolved from an ancient enzyme guanylate kinase, which 
catalyses the conversion of ATP-dependent GMP to GDP. However, the 
catalytic activity of GUK in MAGUKs has been lost and has evolved to 
support specific protein-protein interactions (Olsen and Bredt, 2003, Zhu et 
al., 2011). The crystal structure of SH3-GUK revealed that these two 
domains can form an integrated unit and respond to specific phosphorylated 
protein binding (McGee et al., 2001, Zhu et al., 2011). Besides the core 
domains of PDZ, SH3 and GUK, MAGUKs may also contain other domains such 
as a HOOK domain, a CaM kinase domain and a Lin-7-binding domain 





Figure 1.6: The structure of proteins of the MAGUK families.  
Each protein belongs to membrane-associated guanylate kinase (MAGUK) contains the PDZ 
domains and GK domains. They also contain other functional domains such as the L27 





hDlg (human homologue of the Drosophila discs large protein) belongs to the 
MAGUK (membrane-associated guanylate kinase) family (Subbaiah et al., 
2011). It contains several protein-interaction domains that can form protein 
scaffolds that assemble for signal transduction networks. Similar in structure 
to the tight junction protein ZO-1, hDlg contains an SH3 domain, a HOOK 
domain, a GUK domain, three PDZ domains and also an N-terminal protein-
interaction domain (Matsumine et al., 1996a). Flies with a mutation in the 
SH3 domain lost septate junctions and there was over proliferation in the 
imaginal discs. This suggested that the SH3 domain in hDlg is crucial for the 
control of normal cell proliferation (Woods et al., 1996a). Flies with 
mutated Dlg such that the GUK domain was lost led to overgrowth of 
imaginal discs that were unable to differentiate to adult cuticle without 
affecting epithelial structures (Woods et al., 1996a). In transgenic flies 
expressing altered Dlg with loss of one or more functional domains, showed 
that the HOOK domain is important for membrane targeting because HOOK-
mutated proteins stayed in the nucleus (Hough et al., 1997). The second 
PDZ domain is required for septate junction location, without which, the 
proteins become localised through the entire membrane (Hough et al., 
1997).  
Similar to Dlg in Drosophila, its human homologue (hDlg) is found broadly 
expressed in epithelial tissues and plays role in maintaining cell polarity and 
controlling cell proliferation (Bilder, 2004). Mutation of Drosophila Dlg leads 
to disorganized epithelial structure, therefore perturbation of intercellular 
junctions and loss of cell polarity (Roberts et al., 2012b). The actin and 
tubulin cytoskeleton were both distributed throughout the cell by loss of Dlg 
protein (Woods et al., 1996b). Overexpression of hDlg in mouse fibroblast 
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3T3 cells led to suppressed cell proliferation by blocking cell cycle 
progression from G0/G1 to S phase (Ishidate et al., 2000).  
Loss of cellular polarity, as one of the hallmarks of cancer, leads to 
disruption of cell structure and increasing invasion ability to surrounding 
tissues (Hanahan and Weinberg, 2011). hDlg, as a regulator of cell polarity, 
is believed to be involved in the process of tumorigenesis (Humbert et al., 
2008). Loss of membrane hDlg has been reported during cancer development 
such as cervical cancer, colon cancer and endometrial cancer (Watson, 2002, 
Gardiol et al., 2006, Sugihara et al., 2016). Patients with endometrial 
cancer with loss of expression of hDlg showed poor overall survival than 
those with membrane-expression of hDlg (Sugihara et al., 2016). 
Endometrial cancer cells KLE with stable depletion of hDlg showed increased 
ability in both migration and invasion than control KLE cells (Sugihara et al., 
2016). Cancer-causing human papillomavirus (HPV) oncoprotein E6 has a 
PDZ-binding motif (X-T/S-x-L/V) at its C-terminal, through which, HPVE6 
can bind a large number of proteins containing PDZ domain such as hDlg 
(Thomas et al., 2008).  
The second PDZ domain of hDlg is the target for HPVE6 and HPV18E6 bound 
to hDlg about 5-times stronger than HPV16-bound (Liu et al., 2007). Through 
this interaction, HPVE6 targets hDlg for proteasome-mediated degradation 
(Gardiol et al., 1999, Pim et al., 2000). In addition to HPVE6, other viral 
oncoproteins can also bind to hDlg. For example, adenovirus type 9 
oncoprotein encoded by E4 region ORF1 binds to the second PDZ domain of 
hDlg (Lee et al., 1997). In human T-cell leukaemia virus type 1 (HTLV-1)-
infected T-cells, oncoprotein Tax, utilizing its C-terminus, binds to hDlg and 
prevents hDlg-APC binding (Suzuki et al., 1999). Somatic point mutations 
were observed in the gene encoding the second PDZ domain of hDlg in 
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mammary ductal carcinoma (Fuja et al., 2004), which is the binding domain 
for APC (Matsumine, Ogai et al. 1996).  
hDlg, as a PDZ-domain containing protein, interacts with many other 
proteins that contain the PDZ-binding domain. For instance, hDlg can bind 
to a PDZ-binding motif located at the C-terminal of APC (adenomatous 
polyposis coli), another tumour suppressor protein involved in the Wnt 
signalling pathway (Goode and Perrimon, 1997, Matsumine et al., 1996a). 
The APC-hDlg interaction is important in the negative regulation of the cell 
cycle (Ishidate et al., 2000). hDlg with its second PDZ domain binds to PTEN, 
a tumour suppressor phosphatase, at its C terminus that contains a PDZ-
binding motif, which stabilizes PTEN (Valiente et al., 2005). hDlg (SAP97) 
binds to PBM of aquaporin-2 (AQP2) with its second PDZ domain. This 
interaction regulates PKA-mediated phosphorylation at Ser256 of AQP2 in 
response to arginine-vasopressin (AVP), which induces the AQP2 
translocation from storage vesicles to the membrane in kidney-derived LLC-
PK1 cells (Nooh et al., 2019).  
Loss of Dlg led to the disruption of the network of actin and tubulin (Woods 
et al., 1996b). hDlg (SAP97) colocalised with F-actin at the plasma 
membrane in CACO-2 cells (a colon epithelial cell line), which is 
redistributed to the cytoplasm under the reduction in levels and cytoplasmic 
relocated F-actin caused by drug treatment (Reuver and Garner, 1998). E-
cadherin mediated the localisation of hDlg at cell-cell adhesion sites 
attached to the cortical cytoskeleton (Reuver and Garner, 1998). Although 
hDlg is unable to bind to E-cadherin and beta-catenin directly, hDlg seems 
to form a supermolecular complex since E-cadherin interacts with alpha- 
and beta-catenin and APC, beta-catenin bound to actin (Reuver and Garner, 
1998, Subbaiah et al., 2012, Matsumine et al., 1996b). Overexpression of 
beta-catenin led to an increase in proteasome-degradation of hDlg, while 
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siRNA depletion of beta-catenin enhances the stability of hDlg (Subbaiah et 
al., 2012). Protein 4.1R, a family of cytoskeletal proteins, is reported to 
bind to the HOOK domain of hDlg, which is important for hDlg membrane 
targeting (Hanada et al., 2003, Hough et al., 1997). There is another domain, 
named as L27 (lin-2 Lin-7) domain, located at the N-terminus of hDlg, which 
mediates the membrane targeting of hDlg in epithelial cells (Wu et al., 1998, 
Doerks et al., 2000, Lee et al., 2002).  
hDlg has been reported to interact with gap junction proteins. hDlg 
interacts with Cx32 Ct with its GUK domain (Stauch et al., 2012), and was 
originally identified as a binding partner for Cx43 in a tandem mass 
spectrometry analysis of normal rat kidney cell lysates (Singh and Lampe, 
2009). Previously we demonstrated the interaction between Cx43 and hDlg 
in HPV-positive cervical tumour cells. Due to the fact that HPVE6 binds to 
hDlg, we proposed that the trafficking of Cx43 to the plasma membrane is 




Figure 1.7: The structure of hDlg and its binding partners. 
hDlg (indicated in red) contains three PDZ domains, one SH3 domain and one Guanylate 
kinase (GUK) homology domain, which allows it to bind to other proteins. HPVE6 binds to the 
second PDZ domain of hDlg. APC also binds to the same PDZ domain as HPVE6. Protein 4.1 




1.3 HPV16 E6 
1.3.1 HPV 
Papillomaviruses (PVs) together with polyomaviruses were thought 
previously to belong to the Papoviridae family but later were identified as 
individual taxonomic families (papillomaviridae and polyomaviridae) in the 
7th report of the International Committee on Taxonomy of Viruses (ICTV) 
(Fauquet and Mayo, 2001). The family of papillomaviridae was officially 
nominated in the 8th report of the ICTV and the PV research community in 
2005 (Fauquet et al., 2005). The more research carried on them, the more 
PV subtypes have been widely identified throughout the animal kingdom 
such as in birds, mammals and humans. There are over 240 subtypes of 
papillomavirus classified in 37 genera and the number keeps increasing (Van 
Doorslaer, 2013). The classification of the papillomaviridae family is defined 
based on the homology of the L1 nucleotide sequence (Bernard et al., 2010). 
The L1 gene is the most conserved gene within all the PVs genomes, 
therefore it is used to identify novel PV types and construct the 
phylogenetic trees (de Villiers et al., 2004) (Figure 1.8). In this classification, 
the PV types, subtypes and variants are dependent on the dissimilarity in 
the L1 gene region such that dissimilarity over 10% is identified as a new PV 
type; the dissimilarity between 2 – 10% is identified as a new subtype and 
when it less than 2% is thought to be a variant (de Villiers et al., 2004). In 
this classification, different genera are named utilizing Greek letters. After 
all the Greek alphabet was used, the prefix ―dyo‖ was employed and to 
restart the Greek alphabet, but omitting Alpha, Beta and Gamma letters 
due to these PV genera contain the most medically significant HPVs (Bernard 
et al., 2010). For nomenclature, the abbreviation of the host as initial letter 
followed by PV (refer to papillomavirus) and the number for the reference 
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sequence published. For example, HPV stands for the papillomavirus from 
the host of human or Homo sapiens (Bernard et al., 2010).  
The taxonomy history of HPV dates back to the 1970s when isolating 
papillomavirus from human tissue started. With the development of 
isolating technology and cell biology, more and more HPV types were found 
(de Villiers, 2013). Currently, there are now 226 HPV types established in 
PaVE (https://pave.niaid.nih.gov/) where the highest number is HPV225 due 
to the withdrawn of four previous categorised HPV types (HPV46, HPV55, 
HPV64 and HPV79) in PaVE. These four HPV types were withdrawn because 
they are thought to be a subtype of other HPV types. For example, the 
genome of HPV55 shares 95% homology to that of HPV44 (between 2 – 10%), 
therefore HPV55 is thought to be a subtype of HPV44 (de Villiers et al., 
2004). Phylogenetically, HPV can be divided into five evolutionary genera: 
alpha, beta, gamma, mu and nu. There are 14 groups of HPV in the alpha-
papillomavirus, 5 groups of HPV in the beta-papillomavirus and 17 groups of 
HPV in the gamma-papillomavirus while just one group of HPV in either mu- 
and nu-papillomavirus (Figure 1.9) (de Villiers, 2013).  
Apart from this classification, HPV, based on the tissues where it comes 
from, can be divided into cutaneous or mucosal-infective (de Villiers, 2013). 
According to whether they cause cancer or not, HPVs can also be divided 
into low-risk types and high-risk types. Where high-risk HPV such as HPV16 
and HPV18 are the cause for cervical cancers and low-risk HPV such as HPV6 
and HPV11 causes genital warts (Burd, 2003). HPV type 16 and 18 are 
responsible for 70% of all cervical cancers. In particular, HPV 16 causes 
around 55% of all HPV infections of women depending on geographical 




Figure 1.8: The phylogenetic tree of the papillomavirus.  
The phylogenetic tree is generated based on the sequence of the L1 gene of 
papillomaviruses, obtained from 241 papillomaviruses on the PaVE website. The tree is 
coloured based on the presence/absence of the E5, E6 and E7 proteins. The red clades 
indicate the lack of E6, and the green indicate the lack of E7. The purple clades indicate these 





Figure 1.9: The classification of HPVs.  
The phylogenetic tree is generated based on the L1 ORF sequences of 170 HPV types. HPV 
can be divided into five evolutionary genera: alpha (red), beta (blue), gamma (green), mu 




1.3.2 HPV and cancer 
The DNA of HPV was firstly isolated from common warts of human skin 
(Gissmann and Hausen, 1976, Gissmann et al., 1977). The isolation of HPV16 
and HPV18 from cervical cancer biopsy samples supports the hypothesis of 
German researcher Harold Zur Hausen that HPV is strongly associated with 
cervical cancer (zur Hausen et al., 1976, Durst et al., 1983, Boshart et al., 
1984). This discovery led to him receiving the Nobel Prize in Physiology or 
Medicine in 2008. With deeper research, HPV is also been demonstrated in 
association with other cancers such as anal cancer, penile cancer and head 
and neck cancer (HNC) (Burd and Dean, 2016). 
Cervical cancer is ranked as the fourth leading cause of cancer death in 
women with an estimated 570,000 cases and 311,000 deaths in 2018 
worldwide, which occupied 6.6% in the incidence and 7.5% in the mortality 
in 10 most common cancer in women in 2018 (Bray et al., 2018). It is the 
most frequent cancer in 28 countries mainly in the south and west of Africa 
and the leading cancer cause of death in 42 countries mainly in Africa (Bray 
et al., 2018). In the UK, it is estimated that there are 3430 women 
diagnosed with cervical cancer and 1033 die from it each year and 79% of 
invasive cervical cancers are contributed to HPV16/18. It is the second most 
common diagnosed cancer among women in the UK with the age ranged 
from 15 to 44. In China, every year it is estimated that there are 106430 
women diagnosed with cervical cancer and 47739 died from it and 69.1% of 
invasive cervical cancers are contributed to HPV16/18. It is the 3rd most 
frequent cancer in women in China with the age ranged from 15 – 44 (HPV 
information centre, https://www.hpvcentre.net/datastatistics.php). 
Although most HPV infections will be cleared by the immune system, the 
antibodies produced by natural infections are normally not enough for 
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protection against reinfections (Schwarz et al., 2010). Therefore, vaccines 
are required to ensure high and sustained antibody levels to provide 
protection from HPV infections. Currently, three HPV vaccines are licensed: 
Cervarix® , a bivalent HPV vaccine targeting HPV16 and HPV18, which are 
responsible for most cervical cancer cases; Gardasil® , a quadrivalent 
vaccine targeting HPV16 and HPV18 and additionally HPV6, HPV11; and 
Gardasil 9, a nonavalent vaccine targeting HPV31, HPV33, HPV45, HPV52, 
and HPV58 in addition to those targeted by the Gardasil quadrivalent 
vaccine (Wang et al., 2020). These vaccines have been utilized and 
significantly reduces cervical HPV infections (Harper and DeMars, 2017) and 
cervical diseases (Palmer et al., 2019).  
Normally, high-risk HPVs infections will be eventually cleared by the 
immune system over a period of time. However, about 10-15% of infected 
women failed to mount a successful immune response and the persistent 
viral infection will lead to the development of cervical cancer (Stanley, 
2010). Cancer progression is not the ideal outcome for the virus because the 
carcinoma progression abrogates the viral replication cycle in the infected 
cells and no virions are produced (Graham, 2017). The cervical disease can 
be divided into a three-stage system (cervical intraepithelial neoplasia (CIN)) 
or a two-stage system (squamous intraepithelial lesion (SIL)) with the 
increased expression of oncoprotein HPV E6 and E7 from CIN1 to CIN3 
(Baldwin et al., 2003, Doorbar et al., 2015).  
Human papillomavirus can only infect epithelial cells and reproduce itself 
through the differentiation of host cells (Figure 10). The initial infection 
starts from an entry of viral particles into cells of the basal layer of the 
epithelium presumably via micro-wounds. Following infection, the viral 
episomal genome is maintained in a low copy number in the basal 
epithelium with a low expression level of early proteins E6, E7, E2 and E1 
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(Doorbar, 2005). For normal epithelial basal cells when they undergo 
proliferation they can undergo migration to the suprabasal layers and 
terminal differentiation (Graham, 2017). With the proliferation of basal 
cells, HPV genomes are also replicated and once these cells begin to 
differentiate, they carry the HPV genomes to the suprabasal layer of the 
epithelium. E1 and E2 bind to the origin of the replication region in the 
Upstream Regulatory Region (URR) in the viral genome (McBride, 2013). 
They replicate the viral genome utilizing the host DNA replication machinery. 
E6 and E7 from high-risk HPVs interact with p53 and pRb respectively so that 
they modulate the cell cycle: abolish the restraints on cell cycle progression, 
degrade p53 so that abnormally dividing cells do not die and retard terminal 
differentiation (Pol and Klingelhutz, 2013, Roman and Munger, 2013). L1 and 
L2 are structural proteins that form the viral capsid. They are synthesised in 
the uppermost epithelial layers that support the assembly of viral particles 
(Graham, 2017). Expression of these HPV antigens is delayed until they 
reach the surface of the epithelium so that the immune system is unable to 




Figure 1.10: The life cycle of HPV depends on the differentiation of epithelial. 
HPV infects the basal layer cells of the epithelium. With the division and differentiation of 
infected basal layer cells, viral genomes are segregated into daughter cells and carried into 
upper differentiated layers. The viral expression during the differentiation of keratinocyte is 





1.3.3 HPV genome 
HPV is a circular double-stranded DNA virus with a genome length of around 
8000bp. The genome of HPV can be divided into three parts: 1) the early (E) 
region encoding viral proteins (E1, E2, E4, E5, E6 and E7) that regulate the 
cellular function in infected cells, within which high-risk HPV E6 and E7 are 
defined as oncoproteins (Roman and Munger, 2013, Pol and Klingelhutz, 
2013). 2) The late (L) region that encodes late proteins (L1 and L2) which 
are the structural proteins responsible for the formation of the virus capsid 
(Buck and Trus, 2012). 3) The LCR (long control region), also called the 
upstream regulatory region (URR) that is located between L1 and E6 
(Van Doorslaer et al., 2017)(Figure 11 ). The LCR contains no open reading 
frames (ORF) but the transcription start site of E6 promoter (P97) in HPV16, 
transcriptional enhancers or activators, silencers or repressors and other cis-





Figure 1.11: A schematic diagram of HPV16 genome. 
HPV16 encodes six early proteins (E1, E2, E4, E5, E6 and E7) and two late proteins (L1 and 
L2). Promoters are indicated with P (e.g. P97). HPV16 also contains a long control region 




1.3.4 HPVE6  
E6 and E7 proteins from high-risk HPVs (such as HPV16/18) act as 
oncoproteins and are important for the stimulation of cell growth and cell 
transformation. Utilizing this property, HPVE6 and E7 can immortalize 
several human cell types (Münger and Howley, 2002). Low levels of E6 and 
E7 is observed in CIN I (mild dysplasia) and CIN II (moderate dysplasia) 
lesions in which the viral genomes replicate episomally, but in CIN III (severe 
dysplasia, carcinoma in situ) where the viral genome is often intergraded 
into the host genome, the high levels of E6 and E7 are observed. In a word, 
during the carcinoma progression, the high-risk HPV genome integrates into 
the host genome leading to the overexpression of viral oncoprotein E6 and 
E7 (Narisawa-Saito and Kiyono, 2007).  
HPV16 E6 is a basic nuclear protein with a molecular weight of 18 kDa and 
151 amino acids. It contains four Cys-X-X-Cys motifs forming two zinc finger 
domains that directly bind to zinc and a PDZ-binding domain at its very end 
of the C-terminus (Thomas et al., 2008, Kanda et al., 1991). A schematic 
representation of high-risk HPV E6 and its binding proteins is shown in Figure 
12. Although E6 is a small protein, as one of the HPV oncoproteins, it has 
effects on many cellular progress that are involved in the HPV viral life 
cycle, inhibition of immune-response, immortalization and transformation of 
cells, inhibition of cell apoptosis and differentiation and further leading to 
cancer (Narisawa-Saito and Kiyono, 2007). For oncogenic function of E6, the 
first insight is its interaction with p53. p53 is a well-known tumour 
suppressor protein that regulates the expression of proteins involved in the 
control of the cell cycle or the apoptosis process when the cell is facing 
cellular stress or DNA damage. In response to DNA damage, p53 is activated 
and arrests the cell cycle at G1 by inducing the expression of p21WAF1 
(senescent cell-derived inhibitor) and at G2/M, as well as leading to 
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apoptosis (Ozaki and Nakagawara, 2011). In cervical cancer and head-and-
neck cancers caused by high-risk HPV, degradation of p53 by viral 
oncoprotein E6 is observed (Pol and Klingelhutz, 2013). E6 binds to ubiquitin 
ligase E6AP at a short leucine (L)-rich sequence LxxLL through its zinc-
binding domains. The E6/E6AP complex then results in recruitment and 
ubiquitination and subsequent degradation of p53 (Martinez-Zapien et al., 
2016). Appropriate nuclear distribution of p53 is important for the 
expression of proteins regulated by p53. Therefore, abnormal cytoplasmic 
location leads to loss-of-function of p53 (Ozaki and Nakagawara, 2011). In 
cervical cell lines, blocking the E6-induced degradation of p53 led to an 
increasing level of p53 but the p53 was located in the perinuclear area and 
not in the correct nuclear location (Mantovani and Banks, 1999). Only high-
risk HPVE6 can induce the ubiquitin degradation of p53, low-risk HPV E6 is 
able to bind to p53 with relatively low affinity but unable to induce the 
degradation of p53. Only high-risk HPV E6 binds to the core domain of p53, 
while both high-risk and low-risk HPV E6 bind to the C-terminal domain of 
p53 (Pietsch and Murphy, 2014).  
HPVE6 is important for immortalizing several human cell types. However, 
the immortalization ability is not p53-dependent. HPV16 E6 mutants that 
were unable to induce the degradation of p53 retained the ability to 
immortalize human mammary epithelial cells (Liu et al., 1999). One of the 
important onco-functions is that E6, only from high-risk HPV but not low-risk 
HPV, contains a PDZ (PSD-95/Dlg/ZO-1) binding domain allowing its 
association with the proteins of the PDZ-containing family such as hDlg, 
Scrib, MAGI (Ganti et al., 2015). Through this PDZ-binding domain, HPVE6 
targets many PDZ-containing proteins for proteasome-mediated degradation, 
the majority of which are related to the regulation of cell polarity 
(Nagasaka et al., 2013a). The PDZ-binding motif (PBM) (sequence x-S/T-x-
V/I/L) of HPV16 E6 is located at the extreme end of the C-terminus. This 
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interaction between HPVE6 and PDZ-containing proteins is important in the 
viral life cycle and is thought to stabilize HPVE6 protein in a PBM-dependent 
manner during the early stage of the viral life cycle (Nagasaka et al., 2013b). 
The importance of this interaction is confirmed by transgenic mice 
experiments where mutated HPV16 E6 lacking the PDZ-binding motif 
retained the ability to inactivate p53 but failed to display epithelial 
hyperplasia which is normally seen in wild-type E6 transgenic mice (Nguyen 
et al., 2003). 
Another important role of HPV E6 is its contribution to cellular 
transformation, of which telomerase is involved. Human telomerase is a 
ribonucleoprotein enzyme that is composed of at least two parts: a 
template RNA component hTR (human telomerase RNA) and a catalytic 
subunit hTERT (the telomerase reverse transcriptase). As a cellular reverse 
transcriptase, it synthesises and elongates the telomeric DNA (Pendino et al., 
2006). Telomerase is normally expressed in germ-line cells and its absence 
in somatic cells results in telomere shortening and somatic cell ageing. 
However, in many cancer cells, the activity of telomerase is reconstituted 
(Pendino et al., 2006). hTERT gene transfected into normal human somatic 
cells led to the reconstitution of the telomerase activity, elongated 
telomere and extended life span of cells (Bodnar, 1998). HPVE6 activates 
the activity of telomerase in human keratinocytes (Klingelhutz et al., 1996). 
This activation of telomerase is achieved by HPV E6 induced expression of 
hTERT, in which Myc and Sp-1 are thought to be involved (Oh et al., 2001). 
In the presence of HPVE6, Myc binds to the promoter of hTERT and replaces 
the repressors USF1 and USF2, as a result of increasing levels of hTERT and 
furthermore the activation of telomerase (McMurray and McCance, 2003, 
Veldman et al., 2003). NFX1-91, a novel repressor of the hTERT promoter, is 
degraded in the presence of E6/E6-AP so that Myc is able to bind the 
promoter of hTERT and further increase the telomerase activity (Gewin, 
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2004). Besides these interactions, HPVE6 has many other binding partners 
that are involved in many cellular pathways such as CBP/p300 involved in 
down-regulation of p53 activity; and Bak involved in the apoptosis process 
(Narisawa-Saito and Kiyono, 2007).   
Specifically, for this project, HPV16 E6, via its PDZ-binding domain, targets 
hDlg (human discs large protein; a protein containing PDZ domains (Subbaiah 
et al., 2011) for proteasome degradation. The forms of hDlg in the nucleus 
and cytoplasm are mainly targeted while membrane-bound forms are 
unaffected (Ganti et al., 2015). hDlg is a tumour suppressor. For example, it 
could prevent the transformation of primary baby rat kidney (BRK) cells 
induced by HPV E7/ras (Massimi et al., 2004). This ability of hDlg to suppress 
cell growth could be overcome by HPVE6 that targets hDlg and for 
degradation (Massimi et al., 2004). In terms of Cx43, a building block of gap 
junctions, was observed to a dramatic reduction in level in dysplasia regions 
of cervical biopsies while it strongly expressed in the normal epithelium 
(King et al., 2000, Aasen et al., 2005). Overexpression of Cx43 in HeLa cells 
(HPV-positive cervical cancer cells) led to decreased saturation density and 
reduced cell growth rate (Aasen et al., 2003a, J.King et al., 2000). It may 
be that the ability of hDlg to suppress cell growth relies on correct GJIC 
communication, and HPVE6 interference with Cx43/hDlg functionality may 
give a growth advantage to increase keratinocyte proliferation. This could 
lead to increased viral replication that might result in cellular 





Figure 1.12: A schematic diagram of the structure of HPVE6 and its binding partners. 
HPVE6 contains two zinc fingers and the regions interacted with cellular proteins targeted by 
other viral oncoproteins. There is a PDZ binding motif located at the C-terminus of HPVE6 
that allows its binding to PDZ-containing proteins such as hDlg and hScrib. The figure is taken 





1.4 Hypothesis and aims 
The hypothesis that this study addresses is that hDlg controls the 
trafficking of gap junction protein Cx43 and maintains its cellular levels.  
Aim 1: To investigate the interaction of Cx43/hDlg in normal epithelial cells. 
a. To identify the subcellular location of Cx43 and hDlg in normal 
epithelial cells. 
b. To investigate the alteration in protein level and subcellular location of 
Cx43 in normal epithelial cells with the siRNA knockdown of hDlg. 
c. To investigate Cx43 trafficking by examining the effect of lysosomal 
inhibition in the protein level of Cx43 in HaCaT cells.  
Aim 2: To investigate the alteration of Cx43 during the wound closure 
process in HPVE6 positive and negative cells. 
a. To identify the subcellular location of Cx43 and hDlg in HaCaT and 
NIKS cells. 
b. To identify the alteration in protein levels of Cx43/hDlg in normal 
epithelial cells during wound closure.  
c. To investigate the wound healing speed in normal epithelial cells with 
or without siRNA knockdown of hDlg.  
d. To investigate the behaviour of HPV-positive cells during the wound 
healing process.  
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Aim 3: To investigate the region of the Cx43 CT that interacts with hDlg and 
whether selected phosphorylation site point mutations on Cx43 CT affect its 
interaction with hDlg.   
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2 Chapter 2 Materials and methods 
2.1 Materials 
2.1.1 Cell culture reagents 
Dulbecco‘s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), L-
glutamine, penicillin and streptomycin (P/S) and trypsin were purchased 
from GibcoTM by life Technologies, Renfrew, UK. Keratinocyte basal medium 
(KGM) was purchased from Lonza, Slough, UK.  
 
2.1.2 Common chemicals and buffer 
All chemicals were purchased from Sigma Chemical Co., Irvine, UK except 
the following: 
Protease inhibitor cocktail tablets and phosphatase inhibitor cocktail tablets 
were purchased from Roche, Welwyn Garden city, UK. 
High-performance chemiluminescence film was purchased from GE 
Healthcare, Hatfield, UK. 
Trizol reagent was purchased from Ambion, Renfrew, UK. 






Table 2.1: Buffers  
solution comment 
Coomassie stain solution 0.02% (w/v) Coomassie Brilliant Blue TM, 
50% (v/v) methanol, 7% (v/v) acetic acid 
Destain solution 5% (v/v) methanol, 10% (v/v) acetic acid 
PBS  170mM NaCl, 3.4mM KCl, 10mM Na2HPO4, 
1.8mM KH2PO4, pH7.2 
PBS-Tween PBS containing 0.1% (v/v) Tween 20 
0.5% NP40 lysis buffer 50mM Tris-HCl pH 8.0, 150mM NaCl, 0.5% 
(v/v) NP40 (TGPAL CA-630), protease and 
phosphatase inhibitor cocktail (one tablet 
of each inhibitor in 10 ml NP40 lysis buffer) 
MES SDS running buffer (20X) Invitrogen, Renfrew, UK, ref no B0002 
 
2.1.3 Antibodies 
The antibodies used in western blotting and immunofluorescence 




Table 2.2: List of antibodies, source and dilution. 
Antibody Species Dilution Source Reference 
Number 
Cx43 Rabbit 1:2000 (WB) Sigma C6219 












hDlg Mouse 1:1000 (WB) 
1:200 (IF) 
Santa Cruz  Sc-9961 
HPV18E6 Mouse 1:500 (WB) Santa Cruz  Sc-365089 
GAPDH Mouse  1:1000 (WB)   
Anti-mouse 
IgG HRP 





























2.1.4 Bacteria culture  
The BL21 E. coli strain (gift from Dr. Li Ping, Centre for virus research, 
Glasgow) was used for plasmid transformation and GST-protein purification. 
L-broth (10g NaCl, 16g Bactopeptone, 5g yeast extract in 1 litre H2O, pH 7.5) 
was used to grow bacteria. Agar plates made of 1.5% (w/v) agar in L-Broth 
was used to grow bacteria. When necessary, 100 µg/ml ampicillin or 0.5 M 
IPTG (SIGMA, Irvine, UK, ref no 16758) were added to the bacteria culture.  
 
2.1.5 Cell lines 
C33a: HPV negative but p53 mutated cervical carcinoma cell line (Crook T, 
1991). 
C33aE6: C33a cells with stable transfection of a plasmid expressing HPV16E6 
(Sun et al., 2015) 
HeLa43: HeLa cells (transformed cervical epithelial adenocarcinoma cell 
line) with stable expression of Cx43 (Johnstone et al., 2010)  
HaCaT: HPV negative spontaneously immortalized aneuploid human 
keratinocytes cell line (Boukamp et al., 1988).  
HEK293: human embryonic kidney 293 cell line (ATCC, 
https://www.lgcstandards-atcc.org/products/all/crl-
1573.aspx?geo_country=gb) 
NIKS: spontaneously immortalized human keratinocyte cell line (Allen-
Hoffmann et al., 2000)  
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NIKS16: NIKS cells stable transfected with the HPV16 genome (Isaacson 
Wechsler et al., 2012)  
J2-3T3 cells (3T3 cells): Fibroblast J clone cell line from random-bred swiss 
mouse. 






2.2.1 Small scale preparation of plasmid DNA (mini preps) 
The small-scale extraction of plasmid DNA prepared from bacterial culture 
was carried out using the QIAprep® spin miniprep kit (Qiagen, Manchester, 
UK, cat no 27104) following the manufacturer‘s instruction. Briefly, a single 
colony of transformed bacteria was selected and dipped into 5 ml of L-broth 
containing 100µg/ml ampicillin shaking incubation overnight at 37°C. 
Overnight-incubated bacterial solution was then pelleted at 14000 rpm for 4 
minutes at room temperature. The supernatant was discarded, and the 
pellet was re-suspended in 250µl buffer P1 (containing 100µg/ml RNase A) 
followed with gentle mixing with 250µl buffer P2 (lysis buffer). After 5 
minutes of incubation at room temperature, 350µl buffer N3 (neutralization 
solution) was added to the lysate. Cell debris was removed by certification 
at 14000 rpm for 10 minutes at room temperature. The supernatant 
containing the plasmid DNA was transferred to a QIAprep spin column and 
centrifuged at 14000 rpm for 1 minute at room temperature. After two 
washes with wash buffer, the column was further centrifuged for 1 minute 
at 14000 rpm at room temperature to ensure no residual wash buffer was 
left. Buffer EB (elute buffer) was added to the column, incubated at room 
temperature for 1 minute and followed with 1-minute centrifugation at 
14000 rpm at room temperature. After concentration was measured by 




2.2.2 Large scale preparation of plasmid DNA (midi-preps) 
Larger amounts of plasmid DNA were obtained from bacterial culture using 
the QIAGEN plasmid midiprep kit (Qiagen, Manchester, UK, cat no. 12943) 
following the manufacture‘s instruction.  
 
2.2.3 PCR mediated site-directed mutagenesis and 
recombinant DNA 
The GST-tagged human Cx43 plasmid pGEX2T-Cx43 was used as the template 
to carry out PCR-mediated site-directed mutagenesis. The primers were 
designed to allow mutation of Ser residues to Alanine (Table 2.3). The PCR 
reactions were carried out according to the manufacturer‘s protocol. The 
PCR product was treated with a cloning enhancer (Takara Clontech, Saint-
Germain-en-Laye, France) and the plasmids were cloned using the 
mutagenesis protocol with the In-Fusion kit (Takara Clontech, Saint-
Germain-en-Laye, France).  
Reactions were transformed into E. coli Stellar Competent Cells and 
transformants selected on L-agar plates containing 100 µg/ml ampicillin 
(Sigma, Irvine, UK). Plasmid DNA was prepared (Qiagen QIAprep Spin 
Midiprep Kit) and the clones and mutations were verified by DNA sequencing 
(Eurofins, Livingston, UK). Mutant plasmids created were transformed into E. 




Table 2.3: List of primers designed for Cx43 CT phosphorylation site mutations 
mutation Primers (5‘ – 3‘) 
S255A Fw: TGGTGCGCTGGCCCCTGCCAAAGACTGTGGGTCTC 
Rv: AGGGGCCAGCGCACCACTGGTCGCATGGTAAGGGTCG 
S262A Fw: TGCCAAAGACTGTGGGGCCCAAAAATATGCTTATTTCAATGGC 
Rv: TTGGGCCCCACAGTCTTTGGCAGGGCTCAGCGCACCACTG 





S373A Fw: AGCAGTCGTGCCGCCAGCAGACCTCGGCCTGATGACCTGGAGATC 
 Rv: TGCTGGCGGCACGACTGCTGGCTCTGCTTGAAGGTCGCTGG 









2.2.4  RNA extraction  
RNA was extracted using Trizol according to the manufacturer‘s instructions 
(Invitrogen, Renfrew, UK).  Briefly, cells were washed with ice-cold PBS two 
times. 500µl Trizol (Ambion, Renfrew, UK, ref no 15596026) was added into each 
well of a 6-well culture plate and cells were scraped using a cell scraper and 
transferred into 1.5ml screw-capped Eppendorf tubes. 100µl chloroform (CHCl3) 
was added into each sample followed by shaking by inversion for 20 seconds. The 
mixed solution was incubated at room temperature for 3 minutes followed by 
centrifugation at 10,000g for 15 minutes at 4°C. The aqueous phase was taken 
and transferred into a new tube and mixed with 250µl isopropanol. After 10 
minutes of incubation at room temperature, the mixed solution was centrifuged 
at 10,000g for 10 minutes at room temperature to precipitate the RNA. The 
supernatant was removed, and the small blueish pellet was washed with 500µl 
70% ethanol. Ethanol was removed by centrifugation at 10,000g for 10 minutes 
at 4°C. Further centrifugation for 1 minute was required to remove residual 
ethanol. RNA was re-suspended in RNAse-free water. RNA concentration was 
measured by a Nano-Drop 2000 Spectrophotometer (a machine used to quantify 
and assess the purity of DNA, RNA and proteins; ThermoFisher Scientific, 
Renfrew, UK) and stored at -20°C.  
 
2.2.5 cDNA synthesis 
cDNA was generated using the Maxima First Strand cDNA Synthesis kit according 
to the manufacturer‘s instructions (ThermoFisher Scientific, Renfrew, UK). 
Briefly, for each reaction, 500 ng RNA templates were mixed with 0.5µl DNase 
buffer, 0.5µl DNase and ddH2O to make the total volume of 5µl. After incubation 
in a water bath at 37°C for 2 minutes, the reaction solution was mixed with 2µl 
Reaction mix, 1µl Maxima enzyme mix and 2µl ddH2O to make a total volume of 
10µl. After incubation at room temperature for 10 minutes, the reaction was 
incubated at 50°C for 30 minutes and subsequently incubated at 85°C for 15 







The qRT-PCR reactions were carried out using a TakyonTM qPCR kits (Eurogentec, 
Seraing, Belgium, cat no. UF-RPMT-B0701) according to the manufacturer‘s 
instructions. Briefly for each reaction, 1µl cDNA was mixed with 10µl 2X Master 
Mix, forward and reverse primers (final concentration for GAPDH was 300nM, for 
HPV16E6 was 900nM), probes (final concentrations for both were 100nM) and 
nuclease-free water to make a final volume of 20µl. The reaction was performed 
on an ABI Biosystems 7500 machine. Analysis was carried out using the 7500 v2.3 
ThermoFisher software (ThermoFisher Scientific, Renfrew, UK) and the Ct value 
relative to GAPDH as the reference target gene was quantified.  
Table 2.4: List of primers and probes used in RT-PCR 
 GAPDH HPV16E6 
Forward 5‘ -GAAGGTGAAGGTCGGAGT -3‘ 5‘ –CAATGTTTCAGGACCCACAG -
3‘ 
Reverse 5‘ –GAAGATGGTGATGGGATTTC -3‘ 5‘ –
CTGTTGCTTGCAGTACACACATTC 
-3‘ 






2.2.7 Cell culture 
HEK293, HaCaT and C33a cells were cultured in Dulbecco‘s modified Eagle‘s 
medium (DMEM) (Gibco, Renfrew, UK, ref no 31966-021), supplied with 1% (v/v) 
Penicillin Streptomycin (P/S) (Gibco, Renfrew, UK, ref no 15140-122) and 10% 
(v/v) Fetal bovine serum (FBS) (Gibco, Renfrew, UK, ref no 10270-106). C33aE6 
cell was cultured as above but with the addition of 0.5 mg/ml G418 (Gibco, 
Renfrew, UK, ref no 10131-035). 
HaCaT shDlg and HeLa43 were cultured as above but supplemented with 10 
mg/ml puromycin (Gibco, Renfrew, UK, ref no A11138-03) instead of G418.  
3T3 cells were cultured in DMEM supplied with 10% (v/v) Donor Bovine Serum 
(DBS) (Gibco, Renfrew, UK, ref no 16030-074), 1% (v/v) Penicillin/Streptomycin 





(Gibco, Renfrew, UK, ref no 25030-024)). 3T3 cells were treated with 4 µg/ml 
mitomycin C (Sigma, Irvine, UK, cat no M0503-2MG) for 2-5 hours to inhibit cell 
division. After two times wash with PBS, cells were harvested by incubation with 
0.05% trypsin-EDTA (Gibco, Renfrew, UK, ref no 25300-054) until all cells were 
detached. Media containing FBS was added to inactivate trypsin.  
NIKS and NIKS16 cells were cultured in DMEM supplied with 1% (v/v) Penicillin 
Streptomycin, 10% (v/v) FBS, 0.5 µg/ml hydrocortisone (SIGMA, Irvine, UK, ref no 
H0888-1G) and 8.4 ng/ml cholera toxin and 10 ng/ml epidermal growth factor 
(EGF) cocultured with 4µg/ml mitomycin C-treated J2-3T3 cells. NIKS and NIKS16 
cells were also cultured in Keratinocyte Basal Medium (Lonza, Slough, UK, cat no 
cc-3101) supplemented with KGM SingleQuots (Lonza, Slough, UK, cat no cc-
4131). All cells were maintained under humidified conditions in 5% CO2 at 37°C. 
 
2.2.8 Preparation of cell stocks 
After trypsinisation and counting, the confluent cells were resuspended into an 
appropriate growth medium containing 10% DMSO at 1X106 cells/ml. The cells 
suspensions were aliquot into 1 ml/vial and frozen at -80°C overnight before 
transferring into a liquid nitrogen freezer in vapour-phase.  
 
2.2.9 Total cell extract preparation 
Confluent monolayer cells were washed twice with ice-cold PBS and lysed in 
appropriate amounts of LDS sample buffer (Noves, ref no B0007). The cell lysates 
were scraped into Eppendorf tubes and passed through an 18-20-gauge needle 8-
10 times to shear the chromosomal DNA. The cell lysate was centrifuged to 
pellet the cell debris. If cells were lysed in NP40 lysis buffer (0.5% NP-40, 150 
mM NaCl, 50 mM Tris0HCl pH8) containing PhosphoSTOP (Roche, ref no 
04906845001) and complete mini protease inhibitor cocktail (Roche, ref no 
04693159001), similar lysis steps to lysis using LDS sample buffer were followed 
but without the syringe passing step. Protein concentration was determined by 






2.2.10 Bradford assay 
Bradford assay was used to measure the concentration of protein extracts 
according to the manufacturer‘s protocol. Briefly, Bradford reagent (Bio-Rad, 
Perth, UK) was diluted at 1:5 with distilled water. 10 µl protein extract and 1 ml 
diluted reagent were mixed and put into the Nanodrop machine for 
measurement. Diluted reagent was used as blank and different concentration of 
BSA (2mg/ml, 1mg/ml, 0.4mg/ml, 0.2mg/ml and 0.1mg/ml) were used to 
prepare a standard curve.  
 
2.2.11  SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated in pre-made BoltTM 4-12% Bis-Tris plus 12-well gel 
(Invitrogen, Renfrew, UK, ref no NW04122BOX) in 1X MES SDS running buffer 
(Invitrogen, Renfrew, UK, ref no B0002) in a Bolt mini gel tank (Invitrogen, 
Renfrew, UK). 10µl of protein lysate in NP40 lysis buffer (about 10µg) was mixed 
with 4µl LDS sample buffer and 1.6µl reducing reagent. No further treatment 
was used for samples lysed with LDS sample buffer. Protein samples were then 
boiled at 100°C for 5 minutes. All the samples were loaded into the pre-made 
BoltTM 4-12% Bis-Tris plus 12-well gel with 5µl of SeeBlue®Plus prestained 
standard (Invitrogen, Renfrew, UK, cat no LC5925) loading in the first lane. The 
gel was run at 150V until the dye front reached the bottom of the gel.  
 
2.2.12 Western blot 
Separated proteins were transferred to a nitrocellulose membrane using iBlot® 
gel transfer nitrocellulose stacks (Invitrogen, Renfrew, UK, ref no IB301001) in 
an I-blot dry blotting system model P3 (ThermoFisher, Renfrew, UK), following 
the manufacturer‘s instructions. After 7 minutes of electrotransfer, the proteins 
were completely transferred from the gel to the membrane. The transferred 





room temperature for 1 hour followed by overnight incubation with primary 
antibody diluted in blocking solution at 4°C on a rotating shaker. After washing 
with PBS-tween for 5 minutes three times, the membrane was incubated on a 
rotating shaker at room temperature for 1 hour with horseradish peroxidase 
(HRP)-conjugated secondary antibodies (1:1000) diluted in blocking solution. The 
membranes were subsequently washed for 3 times 5 minutes with PBS-Tween 
followed by the development of the signal with enhanced 
chemilumiluminescence (ThermoFisher, Renfrew, UK, ref no 32106) for 1min or 
with ECL plus (ThermoFisher, Renfrew, UK, ref no 32132) for 5 minutes and 
exposed to high-performance chemiluminescence film (GE health, ref no 
28906835).  
Alternatively, after incubation with primary antibody and 3 PBST washes, the 
membranes were incubated with fluorescent IRdye® secondary antibodies 
(detail in table 2.2) diluted in blocking solution for 1hr at RT. The membranes 
were washed with PBS-tween for 10 minutes three times and one final wash with 
PBS (no Tween) for 10 minutes. The membranes were kept in the dark during the 
wash steps due to the light sensitivity of IRdye® secondary antibodies. The 
membranes were subsequently imaged and analysed with the two-colour 
fluorescent western blotting on the Odyssey infrared imaging system (Oddysey® 
CLx scanner, LI-COR® Biosciences, Cambridge, UK) and the image studio® 
software (LI-COR® Biosciences, Cambridge, UK). 
 
2.2.13 Co-immunoprecipitation  
Cells were washed with ice-cold PBS twice followed by scraping into ice-cold 0.5% 
NP40 lysis buffer containing protease and phosphatase inhibitors. After 30min 
incubation on ice, the cell lysate was centrifuged at 12000 g for 5min at 4°C. 
Protein concentrations were determined by Bradford assay. Protein Sepharose 
beads (Sigma, Irvine, UK, ref no P3296-5ml) were washed three times with 500 
µl NP40 lysis buffer by centrifugation at 4°C at full-speed for 30 seconds. 200 ng 
proteins were incubated with rotation with pre-cleared ProteinG Sepharose 
beads at 4°C for 1h. This step is to remove the non-specific binding proteins 





and the volume was made up to 200µl with NP40 lysis buffer and incubated with 
rotation with either antibody (hDlg H-60) or control (Rabbit IgG (Abcam, 
Cambridge, UK, ref no ab37415)) at 4°C for 1h. Then 20µl pre-cleared beads 
were added into each tube and incubated with rotation at 4°C overnight. The 
beads were washed 5 times with ice-cold NP40 lysis buffer by centrifugation at 
4°C at full speed for 30 seconds before the addition of 10µl LDS loading buffer. 
The input was one-tenth of the protein volume used in Co-IP. The beads and 
inputs were heated at 100°C for 5 min and followed by gel electrophoresis and 
western blot analysis.  
 
2.2.14 GST protein purification 
One colony of bacteria BL21 transformed with GST-fusion protein expression 
plasmids was incubated at 37°C in a shaker overnight. Bacteria cultures were 
diluted 1 in 10 and cultured for 2h at 37°C in a shaker until the OD600  reached 
0.4 – 0.6 followed by induction with 1mM IPTG (SIGMA, ref no 16758) for 3h at 
30°C. Cells were pelleted by centrifugation at 5500 g for 5 min at 4°C. The 
supernatant was decanted, and the pellet was re-suspended in 2ml PBS/ 1% 
Triton X-100 containing protease and phosphatase inhibitors and suspensions 
were sonicated for three times 20 seconds on ice.   The cell debris was removed 
by centrifugation at 1200 g at 4°C for 15min. The supernatant was transferred to 
a fresh tube and stored at -20°C. The protein concentration was determined by 
the Bradford assay. 5 µg of bacterial lysate with GST only or GST-Dlg were 
incubated with 20µl of pre-cleared Glutathione Sepharose 4B (GE Healthcare, ref 
no 17075601) at 4°C for 1h on a rotating shaker. Samples were made up to 100µl 
with NP40 lysis buffer. This step was to allow the GST-fused protein to bind to 
the beads. Then the beads were washed twice with 500µl NP40 lysis buffer by 
centrifugation at 4°C at full speed for 30 seconds. This step was to remove the 
unbounded GST-fused proteins. Then the beads were incubated with rotation 
with 50 µg extracts from cells expressing Cx43 C-terminal mutations/deletions at 
4°C overnight (samples were made up to 150µl with NP40 lysis buffer). After 
overnight incubation, the beads were washed with NP40 lysis buffer three times 
followed by resuspending with loading buffer. After boiling at 100°C for 5 






2.2.15 Coomassie staining 
To ensure the success of IPTG induction, the lysed bacterial solution was run on 
an SDS-PAGE gel. The gel was stained in Coomassie blue staining solution for 1 
hour at room temperature with shaking. Then the gel was incubated with destain 
solution with shaking overnight.  
 
2.2.16 Transfection of cells with lipofectamine 3000 
HEK293 cells at a confluence of 80% were used for transfection utilizing the 
lipofectamine® 3000 transfection kit (Invitrogen, ref no L3000-008) according to 
the manufacturer‘s instructions. Briefly, cells were seeded on 12-well plates. 
Lipofectamine 3000 reagent was diluted in Opti-MEM medium (Gibco, ref no 
31985-047) and mixed well. A master mix of DNA was prepared through diluting 
the amount of plasmid into Opti-MEM medium and lipofectamine 3000 reagent 
was then added and mix by inversion. The diluted lipofectamine 3000 reagent 
was mixed with the DNA master mix and incubated at RT for 10 – 15 min. After 
incubation, the required amount of DNA-lipid complexes was added to each well 
(125 µl/well in a 12-well plate and 250 µl/well in a 6-well plate). Then the cells 
were incubated at 37°C for 48h. Co-transfection of a GFP expression plasmid 
was used to determine the efficiency of transfection by visualizing the cell 
population under microscopy and counting the percentage of GFP-positive cells 
(transfection efficiency was around 90%). 
 
2.2.17 siRNA knockdown of hDlg  
Cells were plated in a normal culture medium at 200,000 – 500,000 cells/well in 
a 6-well plate one day before transfection. siRNAs against hDlg 
(5‘GAUGAUGAAUAGUAGUAUUTT3‘, Ambion, cat no 4390824) or control siRNA 
(siGLO, Dharmacon, cat no D-001630-01-05) were transfected using 





manufacturer‘s instructions. The final concentration of siDlg was 0.2µM. Cells 
were harvest for protein extraction or used for further wound healing assay at 
48h post-transfection.  
 
2.2.18 Scratch wound assay 
Cells were seeded in a 6-well or 12-well plate and grown until they reached 100% 
confluence. A 20µl yellow tip was used for creating wounds, which were three 
lines in each well in the 6-well plate for protein extraction or one line in the 12-
well plate for gap closure photography and immunofluorescence microscopy. The 
culture medium was changed after scratching. Protein was extracted from cells 
for Western Blot or fixed for immunofluorescence microscopy at 0h, 4h, 8h, 16h, 
24h post-wound. Un-wounded cell layers were used as a control in all 
experiments and harvested at 0h. The wound closure was measured in terms of 
area employing ImageJ (https://imagej.net/Fiji).  
 
2.2.19 Immunofluorescence staining and confocal 
microscopy  
Cells were seeded on sterile 13 X 13 mm coverslips and grown until they reached 
the required confluence for the designed experiment (90% confluence for the 
location of Cx43; 100% for wound healing). Cells were washed three times with 
PBS and fixed with 100% ice-cold methanol at -20°C for 20min. Then cells were 
permeabilized with acetone for 1min at room temperature followed by three 
washes with PBS, each time for 5 minutes. Coverslips were blocked in 10% (v/v) 
donkey serum (Sigma, ref no D9663-10ml) in PBS for 1h at room temperature, 
followed by 1h incubation with primary antibodies diluted in 5% (v/v) donkey 
serum in PBS at room temperature. After washing with PBS three times, 
coverslips were then incubated with secondary antibody labelled with 
fluorescence (details in table 2.2) diluted 1:1000 in 5% (v/v) donkey serum in 
PBS. After washing three times with PBS and one time with distilled water, 
coverslips were mounted with ProLong® Gold antifade reagent with DAPI 





control was applied in all the experiments. Images were taken using a Zeiss 
LSM880 Meta confocal microscope. Images were analysed using ImageJ 
(https://imagej.net/Fiji). 
2.2.20 Quantification  
All the experiments were repeated three times (N = 3) and analysed using 
ImageJ (https://imagej.net/Fiji).  
Briefly, the intensity of western blot bands was measured by ImageJ with the 
equation: 
the real intensity of bands = band intensity measured – the intensity of the 
background. 
The expression of Cx43 and hDlg was normalised with the expression of GAPDH in 
each cell lines. 
For the wound healing process, bands intensity was measured as above and 
normalised to un-wound for each cell line. The area of a gap was measured by 
ImageJ delineating the edges of the wound. The wound area was normalised to 
that at 0h of each cell line. Significant of data were indicated by student T-test 







3 Chapter 3  
The interaction between Cx43 and hDlg is 
neither HPVE6-dependent nor tumour cell-
specific  
There are a predicted 570,000 new cases of cervical cancer per annum, the 
fourth most frequent cancer in woman worldwide, which accounted for 6.6% of 
all female cancers in 2018 (WHO). Averages of 3200 new cervical cancer cases 
were found every year in the UK between 2014 and 2016. Human papillomavirus 
(HPV) shows a strong connection with cervical cancers especially HPV16 and 18, 
which are responsible for 70% of all cervical cancers (Crosbie et al., 2013).  
HPVE6, one of the oncoproteins synthesized by HPV, is known to be the key driver 
in cervical tumour progression. Together with E6-associated protein (E6-AP), it 
can target and degrade tumour suppress protein p53. Cellular ubiquitin ligase E6-
AP is known to participate in the degradation of the p53 tumour suppressor 
protein by E6 and the crystal structure of the ternary complex has been solved 
(Martinez-Zapien et al., 2016). Besides this p53 degradation activity, HPVE6 is 
known to target the PDZ tumour suppressor protein hDlg for ubiquitin-
proteasome degradation. It is uncertain whether E6-AP is involved in hDlg 
degradation. (Grm and Banks, 2004) used an in vitro E6-AP immunodepletion 
assay to indicate that the degradation of hDlg by HPVE6 is E6-AP-independent. 
However, a different conclusion was made two years later. In vitro binding 
assays indicated the complex formation of hDlg, E6 and E6-AP. The degradation 
ability of E6 to hDlg correlated with its ability to interact with E6-AP. Therefore, 
the authors concluded that E6-AP is involved in the degradation process of hDlg 
by HPVE6 (Matsumoto et al., 2006). Aside from the involvement of E6-AP in the 
degradation of hDlg by HPVE6, hDlg can be degraded via the proteasome both in 
the presence or absence of HPVE6 (Mantovani et al., 2001). 
Cx43, a widespread building block of gap junction intercellular channels (GJIC), 
was observed to be lost from the plasma membrane in HPV-E6-positive cervical 
tumour cells. Experiments carried out by our group firstly found that Cx43 can 
form typical gap junction plaques (accumulation of many gap junctions) in HPV-
positive non-transformed W12G cervical epithelial cells, but Cx43 relocates to 





GJIC (Aasen et al., 2003b). Ectopic expression of HPVE6 in C33a cells (HPV-
negative cervical cancer cells) leads to Cx43 being relocated from the plasma 
membrane into the cytoplasm (Sun et al., 2015). siRNA depletion of HPVE6 in 
HPV16-positive W12GPXY cervical cancer cells leads to restoration of membrane 
Cx43 (Sun et al., 2015). HPVE6-mediated relocation of Cx43 from the plasma 
membrane into the cytoplasm is due to its interaction with hDlg because 
membrane Cx43 is observed in C33a cells transfected with mutated HPV18E6 
that has lost the ability of binding to hDlg, while in C33a wild-type HPV18E6 
Cx43 is in the cytoplasm (Sun et al., 2015). Cx43 colocalised with hDlg on the 
membrane in W12G cells but in the cytoplasm in W12GPXY cells (Macdonald et 
al., 2012b). Pull-down-assays indicate Cx43 interacts with hDlg in both W12G and 
W12GXY cells. More specifically, GST pull-down assay using bacterially produced 
hDlg and W12GPXY cell extracts indicate that Cx43 binds directly to both N- and 
C-terminal of hDlg through its C-terminus (Macdonald et al., 2012b). 
Based on the relationship between Cx43-hDlg and hDlg-HPVE6, it would be 
interesting to investigate whether the interaction between Cx43 and hDlg 







3.1 Cx43/hDlg interaction is not HPVE6-dependent 
Previously Cx43 and hDlg interaction was found both in vitro by pull-down assay 
and in vivo by Proximity Ligation Assay in high-grade cervical lesions (Sun et al., 
2015). However, HPVE6 is expressed in both W12G cells (in the nucleus) and 
W12GPXY cells (in the cytoplasm) (Sun et al., 2015). HPVE6 has a PDZ binding 
domain and binds to the second PDZ domain of hDlg, which might affect the 
interaction between hDlg and other proteins such as Cx43. To investigate 
whether HPVE6 is essential for the Cx43/hDlg interaction, we used C33a (HPV-
negative cervical cancer cells) and C33aE6 cells (C33a cells stably transfected 
with an HPVE6 expression plasmid).  
First, immunofluorescence confocal microscopy was used to investigate the 
subcellular location of Cx43 and hDlg in the presence and absence of HPVE6 in 
C33aE6 and C33a cells. In the absence of HPVE6 in C33a cells, Cx43 was mainly 
found on the plasma membrane, displaying the long and continued line pattern 
of staining that is consistent with the presence of gap junction plaques. Very 
little cytoplasmic Cx43 was observed in C33a cells (Figure 3.1 A). In contrast, in 
C33aE6 cells with the presence of HPVE6, Cx43 accumulated in the cytoplasm 
and particularly in the peri-nuclear area with less staining found on the plasma 
membrane (Figure 3.1 B). This was consistent with our previous observation in 
W12GPXY cells (Sun et al., 2015). A similar staining pattern was observed for 
hDlg in both C33a and C33aE6 cells: in C33a cells, hDlg was mainly observed on 
the plasma membrane and little cytoplasmic hDlg was observed (Figure 3.1 A). 
However, in C33aE6 cells, accumulated hDlg was found in the cytoplasm and less 
membrane staining was observed (Figure 3.1 B). Strong co-staining of Cx43 and 
hDlg was observed in C33a cells on the plasma membrane indicating that hDlg 
co-localised with Cx43 in the gap junction plaques (Figure 3.1 A). Strong co-
staining of Cx43 and hDlg was observed in the cytoplasm in C33aE6 cells (Figure 
3.1 B). This was consistent with the observation that HPVE6 restricted the Cx43 
and hDlg from the plasma membrane into the cytoplasm in W12GPXY cells (Sun 
et al., 2015). HPVE6 relocation of Cx43 from the plasma membrane into the 
cytoplasm was due to its interaction with hDlg (Sun et al., 2015). HPV16 
targeted and degraded hDlg less efficient than HPV18 (Pim et al., 2000). This 






Then qRT-PCR was used to ensure that there was reduced HPVE6 in C33a cells, 
confirming that the Cx43/hDlg interaction in C33a cells is not due to HPVE6. RNA 
was extracted from each cell line using the Trizol/chloroform method, followed 
by qRT-PCR analysis. The expression of HPV16E6 was detected in C33aE6 cells 
but not in C33a cells, while GAPDH was expressed in both cell lines as expected 
(Figure 3.1 C). Thus, it appeared that the interaction between Cx43 and hDlg in 
cervical cancer cells was not due to the effect of HPV16E6. 
Next, Cx43/hDlg interaction was investigated through immunoprecipitation, 
using cell extracts of C33a and C33aE6. Beads incubated with rabbit anti-hDlg 
antibody immunoprecipitated Cx43, which was clearly observed in C33aE6 cells 
expressing HPVE6 (Figure 3.2 line 5) while no bands were detected in beads 
bound with rabbit IgG control (Figure 3.2 line 6). This is consistent with the 
previous observation in co-immunoprecipitation in W12GPXY cell extracts 
(Macdonald et al., 2012b). Importantly, there is a clear observation of 
interaction between Cx43 and hDlg in the absence of HPVE6 in C33a cells, 
compared to rabbit IgG control (Figure 3.2 line 2 and 3). The additional bands in 
the co-immunoprecipitation western blots are the heavy and light chains of the 













Figure 3.1: Cx43 colocalised with hDlg mainly on the plasma membrane in C33a cells but mainly in the cytoplasm in C33aE6 cells. 
Confocal immunofluorescence microscopy showing the location of Cx43 and hDlg in (A) C33a (HPV-negative cervical cancer cells) and (B) C33aE6 (C33a cells 
transfected with HPV16E6). The image shows Cx43 (red) and hDlg (green) colocalised mainly on the plasma membrane in C33a cells but mainly in the cytoplasm in 
C33aE6 cells. Large merged images of typical colocalisation of each cell line are shown on the right-hand side.  Nuclei were stained with DAPI (blue). The scale bar is 
20µm. (C) qRT-PCR analysis ensures the expression of HPV16E6 in C33aE6 but not in C33a cells. RNA extraction of each cell line was done with Trizol/chloroform 







Figure 3.2: Interaction of Cx43 and hDlg in cervical cancer cells.  
Co-immunoprecipitation of endogenous Cx43 from C33a and C33aE6 cervical cancer cells using an anti-hDlg antibody. Rabbit antibody against hDlg (H-60) was used 
in Co-IP. Rabbit IgG was used as a negative control in Co-IP. The blot was probed with an anti-Cx43 antibody and checked by X-ray film. Asterisks indicate antibody 







3.2 Cx43/hDlg interaction is not tumour-cell specific 
Given the evidence that Cx43-hDlg interaction is not HPVE6-dependent, it 
was important to investigate whether the interaction only happens in a 
tumour situation. The results so far about this interaction are either in 
cancer cells (C33a, C33aE6, W12GPXY, and cervical lesion) or W12G 
(HPV16E6-positive cervical epithelial cells). Cancer has some major 
characteristics such as unlimited multiplication, invasion and resisting cell 
death (Hanahan and Weinberg, 2011), which are different from normal cells. 
During carcinoma progression or virus infection, the micro-environment 
within cells is changed. For example, p53 is a well-known tumour suppressor 
protein that can arrest the cell cycle, or induce apoptosis of infected cells. In 
cervical cancer cells, HPVE6 targets p53 for degradation. Cx43 has been 
known to have many functions in many cellular activities, apart from forming 
a gap junction channel, such as involvement in cell migration (Kameritsch et 
al., 2012). hDlg, as a tumour suppressor protein, maintains cell polarity, and 
cytoskeleton structure. It would be interesting to know whether Cx43 and 
hDlg interact in non-tumour cells. If this interaction is tumour cell-specific, it 
could suggest that the cell carcinoma process is strongly connected with 
Cx43/hDlg interaction, and this might provide a biomarker for some cancer 
diagnostic tests. Four non-tumour cell lines were used to investigate this 
interaction: HEK293 (human embryonic kidney cells), HaCaT (human 
keratinocyte cells), NIKS (normal immortalized keratinocyte cells) and NIKS16 
(NIKS cells stably transfected with the HPV16 genome).  
Western blot, using rabbit polyclonal Cx43 antibody and mouse monoclonal 
hDlg antibody, demonstrated that all four cell lines expressed Cx43 and hDlg.  
HEK293 and NIKS cells expressed the highest level of Cx43 compared to 
HaCaT and NIKS16 cells. HaCaT expressed the greatest level of hDlg in all 
these cells. The level of hDlg in HEK293 was slightly higher than that in NIKS 
cells. For NIKS16 cells, more than one band was observed for hDlg, which 
might be partial degradation or isoforms for hDlg (Figure 3.3). The low level 





calcium concentration that trigger cell differentiation and the low levels of 
Cx43 expressed in differentiated keratinocytes.  
Then the subcellular location of Cx43 and hDlg was investigated in HEK293 
and HaCaT cells. Cx43 was located on the plasma membrane between 
neighbouring cells in HEK293 and HaCaT with a staining pattern that was 
consistent with gap junction plaques. Some peri-nuclear location of Cx43 was 
observed in HaCaT cells. hDlg was also located on the plasma membrane in 
both cells with a staining pattern similar to that was observed with Cx43. 
Cx43 co-stained with hDlg on the plasma membrane in both non-tumour cells 
(Figure 3.4). Then interaction between Cx43 and hDlg was investigated using 
cell extracts from HEK293 and HaCaT. Beads bound with rabbit anti-hDlg 
antibody pulled-down Cx43 clearly compared to rabbit IgG control in HEK293 
and HaCaT cells. Light and heavy chains of antibody were detected in the co-
immunoprecipitation experiment (Figure 3.5) as observed before. Even if the 
level of Cx43 in HaCaT is lower than that in HEK293, the pulled-down Cx43 
band in HaCaT cells is stronger than that in HEK293 cells (Figure 3.5 line 1, 2 
and 4, 5). This might due to higher levels of hDlg in HaCaT cells and the use 
of an anti-hDlg antibody in immunoprecipitation experiments. These results 







Figure 3.3: Cx43 and hDlg expression in non-tumour cells (HEK293, HaCaT, NIKS and 
NIKS16). 
Western blot showed the expression of Cx43 and hDlg in cell extracts from non-tumour cell lines 
(HEK293, HaCaT, NIKS and NIKS16). The image of hDlg and GAPDH were obtained from Licor 








Figure 3.4: Cx43 colocalised with hDlg on the plasma membrane in HEK293 and HaCaT cells.  
Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in HEK293 (human embryonic kidney cells) and HaCaT (human keratinocyte cells). 
The image shows Cx43 (red) and hDlg (green) colocalised on the plasma membrane in HEK293 and HaCaT cells. Large merged images of typical colocalisation of 








Figure 3.5: Interaction of Cx43 and hDlg in non-tumour cells (HEK293 and HaCaT).  
Co-immunoprecipitation of endogenous Cx43 from HEK293 and HaCaT cells using an anti-hDlg antibody. Rabbit antibody against hDlg (H-60) was used in Co-IP. 
Rabbit IgG was used as a negative control in Co-IP. The blot was probed with an anti-Cx43 antibody and developed by X-ray film. Asterisks indicate antibody heavy 






Very similar experiments were carried out in NIKS and NIKS16 cells. NIKS (normal 
immortal keratinocytes) is derived from BC-1-Ep normal keratinocytes that were 
isolated from newborn human foreskin (Allen-Hoffmann et al., 2000). NIKS16 are 
NIKS cells that are stably transfected with the episomal HPV16 genome. NIKS and 
NIKS16 cells require co-culture with mitomycin C-treated mouse fibroblasts 3T3 
cells as a feeder layer, which mimics the situation of epithelial cell growth on 
the dermis. There are gaps observed between NIKS/NIKS16 cells and 3T3 cells, 
suggesting that they might not have proper cell to cell communication, including 
gap junctional communication. Comparison between NIKS and NIKS16 can 
provide more information on whether infection with HPV16, as opposed to 
HPV16-associated tumour progression, will affect the Cx43/hDlg interaction.  
NIKS and NIKS16 were co-cultured with 3T3 cells until day 7 before fixation for 
immunofluorescence staining. Cx43 located on the plasma membrane in NIKS 
cells with strong gap junction plaques visible while some cytoplasmic Cx43 was 
also observed (Figure 3.6 A). Similar to NIKS cells, Cx43 was observed in both the 
membrane and cytoplasm in NIKS16 cells (Figure 3.6 B). hDlg was mainly located 
on the plasma membrane in both cell types. Strong co-staining between Cx43 
and hDlg was observed on the cell margin in both NIKS and NIKS16 cells (Figure 
3.6 A & B). Co-immunoprecipitation also showed Cx43 and hDlg could interact in 
both NIKS and NIKS16 cells. Beads incubated with rabbit anti-hDlg antibody 
showed a clear pull-down Cx43 band compared to rabbit IgG control beads 
(Figure 3.6 C & D). These results indicated that the low level of HPVE6 in NIKS16 












Figure 3.6: Cx43 interacted and colocalised with hDlg on the plasma membrane in NIKS and NIKS16 cells. 
Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in (A) NIKS (normal immortalized keratinocyte cells) and (B) NIKS16 (NIKS cells stably 
transfected with HPV16 genome). The image shows Cx43 (red) and hDlg (green) colocalised on the plasma membrane in NIKS and NIKS16 cells. Large merged 
images of typical colocalisation of each cell line are shown on the right-hand side.  Nuclei were stained with DAPI (blue). The scale bar is 20µm. Interaction of Cx43 
and hDlg in (C) NIKS and (D) NIKS16 cells. Co-immunoprecipitation of endogenous Cx43 from NIKS and NIKS16 cells using an anti-hDlg antibody. Rabbit antibody 
against hDlg (H-60) was used in Co-IP. Rabbit IgG was used as a negative control in Co-IP. The blot was probed with an anti-Cx43 antibody and checked by X-ray film. 





3.3 hDlg is a controller of Cx43 
Data above show that Cx43-hDlg interaction is neither HPVE6-dependent nor 
tumour cell-specific. Previous experiments showed that siRNA depletion of 
hDlg in W12GPXY cells leads to a reduction in the levels of Cx43 (Macdonald 
et al., 2012b). Then Sun and co-workers (Sun et al., 2015) found that HPVE6 
was responsible for reducing the level of Cx43 in W12GPXY cells, compared to 
the parental non-tumour W12G cells. Moreover, Cx43 stayed on the plasma 
membrane in C33a cells transfected with an expression construct encoding 
mutated HPV18E6 with the loss of its ability to binding hDlg. This suggested 
that HPVE6 controls the trafficking and reduces the level of Cx43 via binding 
to hDlg. On the other hand, Cx43 can bind hDlg directly, in the absence of 
HPVE6 in in vitro binding assays (Macdonald et al., 2012b). Based on this, it is 
important to investigate the role of hDlg in its regulation of Cx43 in general. 
For this reason, the level of Cx43 was first checked in the four non-tumour 
cell lines, mentioned above, upon the siRNA depletion of hDlg.  
As expected, good depletion of hDlg was observed in HaCaT, NIKS and NIKS16 
cells but there was less of an effect in HEK293 cells compared to mock-
treated cells. A reduction in the levels of Cx43 was observed upon siRNA 
depletion of hDlg in all the non-tumour cells, compared to mock-treated and 
lipofectamine treated control cells (Figure 3.7). Interestingly, in HEK293 cells 
upon siRNA depletion of hDlg, the Cx43 main band is weaker but upper bands 
appear stronger than mock and control bands (Figure 3.7 B). Upper bands 
were also observed in HaCaT siDlg treated cells compared to mock-treated 
cells (Figure 3.7 A). These upper bands might be phosphorylated or 
ubiquitinated forms of Cx43. This could be confirmed in the future with 
antibodies for phosphorylated forms of Cx43. NIKS and NIKS16 cells in these 
experiments (and also for the confocal experiments below) were cultured in 
KGM without co-culture with 3T3 cells. Because western blots display the 
protein level of whole cultured cells, NIKS and NIKS16 were cultured in KGM 
to avoid the effect of 3T3 cells. In NIKS cells, besides the main band of Cx43, 
an upper band (might be a phosphorylation form) was also observed (Figure 
3.7 C) while in NIKS16 cells only the main bands were observed (Figure3.7 D). 





depletion of hDlg, which suggested the role of hDlg in maintaining levels of 
Cx43 in non-tumour cell lines, which is consistent with what was reported for 
HPVE6-positive tumour cells by MacDonald (Macdonald et al., 2012b). 
Next, whether the subcellular location of Cx43 is altered upon the siRNA 
depletion of hDlg was investigated in HaCaT and HEK293 cells. In HaCaT cells, 
Cx43 was located on the plasma membrane with a discontinuous staining 
pattern. hDlg was found at the outer edges of the cell. Some co-localisation 
of Cx43 and hDlg was observed on the plasma membrane (Figure 3.8 A). In 
contrast, in HaCaT cells with siRNA depletion of hDlg, the amount of Cx43 
observed was much less and particularly Cx43 lost its membrane location and 
relocated into the cytoplasm (Figure 3.8 B). The staining of hDlg was hard to 
see, which is consistent with the western blot results (Figure 3.7 A; 3.8 B). 
Similar results were observed in HEK293 cells where Cx43 was located on the 
plasma membrane and hDlg was also located on the plasma membrane 
(Figure 3.8 C). In HEK293 cells with siRNA depletion of hDlg, Cx43 was 
relocated from the plasma membrane into the cytoplasm (Figure 3.8 D). 
Upon siRNA depletion of hDlg, Cx43 was distributed in a more scattered 
fashion in the cytoplasm in HaCaT cells compared to that in HEK293 cells 
(Figure 3.8 B & D). This suggested that hDlg was involved in controlling the 
trafficking or maintaining the membrane location of Cx43. 
HaCaT cells with a stable knockdown of hDlg (named HaCaT shDlg cells) were 
kindly provided by Dr. Lawrence Bank (ICGEB, Trieste, Italy). A reduced level 
of Cx43 and low levels of hDlg were found in HaCaT shDlg cells compared to 
the normal HaCaT cells, similar to what has been observed in HaCaT cells 
with siRNA depletion of hDlg (Figure 3.9 A). Interestingly, the 20kDa Cx43 
isoform was observed in HaCaT shDlg cells but neither in HaCaT cells nor in 
the HaCaT cells upon siRNA depletion of hDlg (Figure 3.9 A). Similar to what 
was shown in Figure 3.8 A, Cx43 displayed a gap junction staining pattern on 
the plasma membrane while hDlg located on the plasma membrane outlining 
the cell in HaCaT cells. Co-staining of Cx43 and hDlg was observed on the 
plasma membrane (Figure 3.9 B). In HaCaT shDlg cells, hDlg was hard to be 
seen as expected. Cx43 was relocated from the plasma membrane into the 





upon siRNA depletion of hDlg. Taken together, these results indicate that 






Figure 3.7: siRNA depletion of hDlg led to a reduction in levels of Cx43 in non-tumour cells: 
(A) HaCaT, (B) HEK293, (C) NIKS, (D) NIKS16. HaCaT (A) and HEK293 (B) cells were treated 
with mock, control siRNA or siRNA for hDlg for 48h before checking with western blotting. NIKS (C) 













Figure 3.8: siRNA depletion of hDlg led to the cytoplasmic location of Cx43 in non-tumour cells (HEK293, HaCaT).  
Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in HaCaT cells with/without siRNA depletion of hDlg (A and B) and in HEK293 cells 
with/without siRNA depletion of hDlg (C and D). These images show Cx43 (red) and hDlg (green) on the plasma membrane in the mock-treated HaCaT and HEK293 
cells (A and C) but Cx43 is in the cytoplasm in HaCaT and HEK293 with siRNA depletion of hDlg (B and D). Large merged images of each cell line are shown on the 












Figure 3.9: Reduced level and cytoplasmic location of Cx43 was observed in HaCaT cells with stable depletion of hDlg (HaCaT shDlg).  
(A) Reduced level of Cx43 was observed in HaCaT shDlg cells compared to HaCaT cells. The 20kDa Cx43 band was observed in HaCaT shDlg cells but not in HaCaT 
cells.  Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in (B) HaCaT cells and (C) HaCaT shDlg. These images show Cx43 (red) and 
hDlg (green) on the plasma membrane in the HaCaT cells (B) but cytoplasmic Cx43 is observed in HaCaT shDlg (C). Large merged images of each cell line are shown 





3.4 Cx43 and lysosome inhibition  
Cx43 is a building block of gap junction channels with a half-life of 1.5 – 5h 
(Laird, 2006). Cx43 can be degraded through proteasome and lysosome but 
mainly the latter. Degradation of Cx43 was delayed in the presence of 
proteasome inhibitor, and Cx43 was also found to be a substrate for ubiquitin, 
which is normally a target to the proteasome. But mono-ubiquitination was 
found for Cx43, which is thought to act as a trigger for internalisation while 
proteins with poly-ubiquitination are the target to the proteasome (Qin et al., 
2003). Accumulated evidence has shown the degradation of Connexins is 
mainly via the lysosomes. For instance, immunofluorescence assay indicates 
that intracellular Cx43 is located in the lysosomes and lysosome inhibitor-
treated breast cancer cells show increasing levels of Cx43 (Qin et al., 2003). 
Upon treatment with the lysosome inhibitor ammonium chloride (NH4Cl), the 
level of both Cx43 and hDlg increased in W12GPXY cervical cancer cells but 
less so in the parental non-tumour W12G cells. NH4Cl also sustained the level 
of Cx43, which was decreased upon siRNA depletion of hDlg in W12GPXY cells 
(Macdonald et al., 2012b). For this reason, whether NH4Cl and another 
endosome/lysosome inhibitor, chloroquine, sustained the level of Cx43 
reduced by siRNA depletion of hDlg was investigated in non-tumour cells. 
HaCaT and HEK293 cells were treated with mock or lysosome inhibitor (NH4Cl 
and chloroquine) for 8h at 37°C before fixation or protein extraction. As 
expected, lysosome inhibitors NH4Cl and chloroquine significantly increased 
the level of Cx43 in HaCaT cells compared to the mock treatment. But less 
effect was observed in the level of hDlg in lysosome-inhibitor-treated HaCaT 
cells (Figure 3.10 A). Two bands of Cx43 were observed in both mock-treated 
and lysosome inhibitor-treated HaCaT cells, which might be phosphorylated 
or ubiquitinated forms of Cx43.  Interestingly, the 20kDa isoform of Cx43 was 
observed in NH4Cl treated HaCaT cells, but not in chloroquine treated cells 
(Figure 3.10 A).  
Then the subcellular location of Cx43 and hDlg in HaCaT cells treated with 
lysosome inhibitors was investigated. With mock-treated HaCaT cells, Cx43 
and hDlg were on the plasma membrane with some colocalisation (Figure 





accumulated in the cytoplasm with very little membrane Cx43 (Figure 3.10 C). 
In chloroquine-treated HaCaT cells, accumulated cytoplasmic Cx43 was 
observed, while some Cx43 stayed on the membrane with larger gap junction 
plaques compared to mock-treated HaCaT (Figure 3.10 D). Both NH4Cl and 
chloroquine seem to have no effects on the location of hDlg that stayed on 
the plasma membrane (Figure 3.10 C and D). The same experiments were 
repeated in HEK293 cells. Similar to the results in HaCaT cells, HEK293 cells 
treated with NH4Cl and chloroquine showed an increasing level of Cx43 and 
no difference in the level of hDlg compared to mock-treated cells. Only one 
band of Cx43 was observed in HEK293 cells whether mock-treated or 
lysosomal inhibitor-treated. The 20kDa Cx43 band was only observed in 
NH4Cl-treated HEK293 cells (Figure3.11 A), which is consistent with the 
observation in NH4Cl-treated HaCaT cells. Accumulated cytoplasmic Cx43 was 
observed in both NH4Cl and chloroquine-treated HEK293 cells while some 
membrane Cx43 was observed. This is a similar observation to that in HaCaT 
cells, where lysosome inhibitors seemed to have no effect on the location of 
hDlg, which stayed on the plasma membrane (Figure 3.11 C and D). These 
results indicated that the major degradation pathway of Cx43 is via the 
lysosome degradation pathway.  
Next, lysosome inhibitors were used to investigate whether the reduced level 
of Cx43 caused by siRNA depletion of hDlg in HaCaT cells could be rescued. 
HaCaT cells underwent siRNA depletion of hDlg for 48h followed by 8h 
treatment with mock treatment or endosome/lysosome inhibitors NH4Cl and 
chloroquine. Both NH4Cl and chloroquine increased the level of Cx43 in 
HaCaT cells with siRNA depletion of hDlg compared to mock-treated cells 
(Figure 3.12).  
The 20kDa Cx43 band was observed in both mock-treated and NH4Cl-treated 
siDlg HaCaT cells but hardly seen in Chloroquine-treated siDlg HaCaT cells. 
However, this 20kDa Cx43 band was not observed in previously siDlg HaCaT 
experiments. In the previous siDlg experiment, HaCaT cell proteins were 
extracted as soon as 48h treatment was completed with siRNA of hDlg. But in 
this experiment, the HaCaT cell grew 8h more before extraction (lysosome 





new synthesis of Cx43 which was unable to traffic to the plasma membrane, 
due to the lack of hDlg, and was delivered to the lysosome for degradation. 
This suggests a role for hDlg in maintaining the stability of Cx43 in 
antagonism to lysosome degradation. 20kDa form of Cx43 was only observed 
in NH4Cl treated but not chloroquine treated cells (HaCaT, HEK293, HaCaT 
siDlg). This indicates that lysosome inhibitor NH4Cl might prevent the 












Figure 3.10: Increasing levels and accumulated cytoplasmic Cx43 was observed in HaCaT cells with lysosome inhibitor treatment.  
(A) Lysosome inhibitor increases the level of Cx43 in HaCaT cells compared to mock-treated cells.  Confocal immunofluorescence microscopy shows the location of 
Cx43 and hDlg in HaCaT cells with (B) mock-treated, (C) NH4Cl treated and (D) chloroquine treated. Cx43 (red) is in the cytoplasm in NH4Cl treated HaCaT cells (C) 
and on both the membrane and cytoplasm in chloroquine treated HaCaT cells (D), hDlg (green) stayed on the plasma membrane with no effect by lysosome inhibitors 













 Figure 3.11: Increasing levels and accumulated cytoplasmic Cx43 was observed in HEK293 cells with treatment of lysosome inhibitor.  
(A) Lysosome inhibitor increases the level of Cx43 in HaCaT cells compared to mock-treated cells.  Confocal immunofluorescence microscopy shows the location of 
Cx43 and hDlg in HEK293 cells with (B) mock-treated, (C) NH4Cl treated and (D) chloroquine treated. Cx43 (red) is in the cytoplasm in NH4Cl treated HEK293 cells (C) 
and on both the membrane and cytoplasm in chloroquine treated HEK293 cells (D), hDlg (green) stayed on the plasma membrane with no effect by lysosome inhibitors 







Figure 3.12: Lysosome inhibitor rescued some level of Cx43 decreased by siRNA depletion of hDlg in HaCaT cells.  




3.5 Discussion  
Gap junction intracellular channels (GJIC) provide direct communication 
between the cytoplasm from neighbouring cells, allowing the exchange of ions, 
small molecules, and some secondary messengers, and maintaining homeostasis. 
Cx43, a widespread building block of gap junctions, has been found associated 
with many disorders like skin diseases, cardiovascular disease, and cancers. A 
reduced level and relocation of Cx43 from the plasma membrane to the 
cytoplasm is observed in vitro and in vivo in cervical cancers. Nearly all cervical 
cancer is HPV-positive and HPVE6 acts as an oncoprotein and has been found to 
be involved in controlling the trafficking of Cx43 by targeting hDlg (Macdonald et 
al., 2012b). 
Data here suggest that Cx43 colocalised with hDlg in the cytoplasm in C33a 
expressing HPV16E6 but mainly on the plasma membrane in C33a (HPV-negative) 
cells. The colocalisation was also observed on the plasma membrane in non-
tumour cells (HEK293, HaCaT, NIKS, and NIKS16). Protein-protein interaction of 
Cx43 and hDlg is found in these non-tumour cells and HPV-negative cervical 
cancer cells (C33a and C33aE6). These data suggest the interaction between 
Cx43 and hDlg is neither HPVE6- dependent nor cancer cell-specific.  
Heavy chain (HC, 55kDa) and light chain (LC, 25kDa) of the antibody were 
observed in the co-immunoprecipitation experiments. This is because the 
traditional secondary antibody, horse radish peroxidase (HRP)-conjugated 
secondary antibody, and Cx43 antibody (Macdonald et al., 2012b), recognises 
denatured HC/LC which are eluted from the beads together with antigen. The 
rabbit polyclonal antibody used in IP and also in Western blot might also be part 
of the reason. In future experiments, specific secondary antibodies (e.g. RP-
conjugated Protein A or Protein G) could be used to remove the background (Lal 
et al., 2005).  
More than one band of hDlg was observed in NIKS16 cells (Figure 3.3). A similar 
pattern of hDlg has been observed in CaSki and HeLa cells (Kranjec and Banks, 
2010). CaSki cells are HPV16-positive while HeLa cells are HPV18-positive. 
HPV18E6 has a greater targeting and degradation efficiency for hDlg rather than 




cells (Figure 3.3) could be a partially degraded form of hDlg due to the low level 
of E6 expressed from the HPV16 genome in NIKS16 cells.  
siRNA depletion of hDlg in HaCaT and HEK293 cells led to a reduction in the 
levels and cytoplasmic location of Cx43. Reduced levels of Cx43 were also 
observed in NIKS and NIKS16 cells with siRNA depletion of hDlg. Similar results 
were observed in HaCaT cells with stable depletion of hDlg. These data suggest 
the role of hDlg in maintaining the level of Cx43 and trafficking of Cx43 in non-
tumour cells.  
In cervical cancer cells, Cx43 was not located at the plasma membrane but was 
found in a perinuclear location. This was consistent with the loss of GJIC in these 
cells (Macdonald et al., 2012b). hDlg was found to colocalise with Cx43 in the 
cytoplasm in these HPVE6-positive cells. siRNA depletion of HPVE6 in W12GPXY, 
and in C33a cells of a mutated HPV18E6 that could no longer bind hDlg, led to 
the restoration of membrane Cx43 (Sun et al., 2015). Data here further confirm 
that HPVE6 controls the trafficking of Cx43 via its targeting of hDlg in cervical 
cancer cells. The re-establishment of GJIC between neighbour cells in the 
presence of inhibitors of protein synthesis, suggests the existence of a 
cytoplasmic pool of Cx43 allowing the re-building of the gap junction 
communication.  siRNA depletion of hDlg in W12GPXY cells led to a reduced level 
of Cx43, suggesting the role of hDlg in maintaining a cytoplasmic pool of Cx43 in 
cervical tumour cells (Macdonald et al., 2012b). Combined with results here, this 
indicates the general role of hDlg in maintaining a cytoplasmic pool of Cx43. A 
recycling of Cx43 from this type of cytoplasmic pool to re-establish gap junctions 
in daughter cells, rather than newly synthesized Cx43, during mitosis has been 
observed. This recycling of Cx43 might play an essential role in cytokinesis 
(Boassa et al., 2010). Therefore, it could be interesting to examine the role of 
hDlg in Cx43 membrane insertion during mitosis.  
MAGUK proteins such as hDlg might function in the localisation and recruitment 
of other proteins to the membrane or as molecular scaffolds allowing 
interactions of proteins/signals (Dimitratos et al., 1999). hDlg, as a member of 
the MAGUK protein family, might localise and recruit Cx43 onto the membrane 
and thus be involved in the control of Cx43 trafficking. The upper stronger bands 




compared to mock-treated cells (Figure 3.7 A and B). These might represent 
Cx43 undergoing post-translation modifications such as phosphorylation or 
ubiquitination. Phosphorylation plays an important role in GJIC. For example, 
phosphorylation of Cx43 at site S368 results in a reduction of the hemichannel 
opening (Bao et al., 2004). Phosphorylation might cause a conformational change 
that alters the interaction between Cx43 and other proteins. For example, 
phosphorylation of Cx43 at the site Y265 disrupts the binding between Cx43 and 
ZO-1 (Toyofuku et al., 2001). hDlg and ZO-1 both belong to the MAGUK protein 
family, but each has a different interaction region with Cx43 (Macdonald et al., 
2012b). It is still interesting to investigate whether phosphorylation affects the 
interaction between Cx43 and hDlg (this will be discussed in Chapter 5). Cx43 
can be a substrate for ubiquitin and mono-ubiquitination as a trigger for 
internalisation and further degradation via the lysosome.  
Previous data have indicated that most intracellular Cx43 and hDlg are targeted 
to the lysosomal degradation pathway in W12GPXY and C33aE6 cells (Peng Sun, 
PhD thesis, 2005). Lysosome inhibitor NH4Cl increases the level of Cx43 and hDlg 
in W12GPXY cells (Macdonald et al., 2012b), and in the presence of lysosome 
inhibitor, a notable increase of cellular Cx43 is observed in breast tumour cells 
(Qin et al., 2003). Both lysosome inhibitor NH4Cl and chloroquine increase the 
level and cytoplasmic accumulation of Cx43 in HaCaT and HEK293 cells 
compared to mock-treated cells. Lysosome inhibitors seem to have no effect on 
the alteration of both protein levels and the location of hDlg. This might suggest 
the degradation of Cx43 is mainly through the lysosome degradation pathway 
while hDlg might utilize another degradation pathway.  
20kDa Cx43 is a predominant truncated Ct isoform of Cx43 produced by 
translation reinitiation (Leithe et al., 2017b). It is only observed in NH4Cl-
treated but not chloroquine-treated HEK293 and HaCaT (Figure 3.10 A and 
Figure 3.11 A). The majority of Cx43 was located in the cytoplasm and almost no 
membrane Cx43 was observed in HaCaT cells treated with NH4Cl, while some 
membrane Cx43 was observed in chloroquine-treated HaCaT cells (Figure 3.10 C 
and D).  20kDa Cx43 can interact with full-length Cx43 as a protein-chaperone, 
which helps the trafficking of Cx43 to the border of cells (Epifantseva and Shaw, 
2017). It might also be involved in Cx43 trafficking to the cytoplasm, which 




but not in chloroquine treated cells. NH4Cl and chloroquine work as weak bases 
that neutralize the pH in the lysosomes (lysosomes require a highly acidic 
environment for proper function). Chloroquine prevents acidification of 
endosomes and lysosomes and prevents endosome-lysosome fusion. NH4Cl can 
inhibit lysosome movements and phagosome-lysosome fusion. Similar to Cx43, 
20kDa Cx43 is degraded via the lysosome and results here suggested that might 
be through phagosome-lysosome fusion but not endosome-lysosome fusion. 
20kDa Cx43 isoform was observed in HaCaT shDlg cells and HaCaT with 8h more 
growth after siDlg treatment (Figure 3.9 A and Figure 3.12). The 20kDa Cx43 
could help full-length Cx43 traffic to the membrane (Smyth and Shaw, 2013). 
Therefore, the expression of 20kDa Cx43 in HaCaT shDlg and HaCaT with 8h 
more growth after siDlg treatment might be triggered by Cx43 waiting to be 
trafficked to the plasma membrane.  
In conclusion, in this chapter, it is now shown that Cx43-hDlg interaction is 
neither HPVE6-dependent nor tumour cell-specific. Cx43 and hDlg colocalised on 
the plasma membrane in non-tumour cells, HEK293, HaCaT, NIKS, and NIKS16 
cells. Interaction between Cx43 and hDlg was also proved with co-
immunoprecipitation in these cell extractions. siRNA depletion of hDlg led to a 
reduction in levels of Cx43 in all these four cells, and cytoplasmic relocation in 
HaCaT and HEK293 cells. Further, a reduced level and cytoplasmic location of 
Cx43 was also observed in HaCaT cells with stable depletion of hDlg. Lysosome 
inhibitor-treated HaCaT and HEK293 cells showed increased levels of Cx43 and 
accumulation of cytoplasmic Cx43. Furthermore, treatment with lysosome 
inhibitor led to an increasing level of Cx43 in HaCaT cells with siRNA depletion of 
hDlg compared to mock cells. These results suggested widespread interaction 
between Cx43 and hDlg in cells and also indicates the role of hDlg in regulating 
the trafficking of Cx43 and maintaining the stability of Cx43 from degradation 





4 Chapter 4  
Cx43 and the wound healing process  
Skin is the first protection for humans against any infections. Any wound to the 
skin will lead to the wound healing process, which includes four stages: 
haemostasis, inflammation, proliferation, and migration, followed by scar tissue 
remodelling. This, as a result, closes the wound and restores the protective 
function of the skin (Gantwerker and Hom, 2011). Previously, data from several 
laboratories showed that protein levels of Cx43 changed during wound healing 
(Kretz, 2003, Coutinho, 2003). In human cutaneous wound healing, the first 
alterations were observed at 6h post-wounding when Cx43 was downregulated at 
the wound edge and the protein level was continually reduced until Cx43 was 
virtually undetectable within the first 1-2 days after wounding (Brandner et al., 
2004). These events are regulated through a ―kinase program‖, where specific 
Cx43 CT-phosphorylation events occur in a time-dependent manner during 
wound closure (Solan and Lampe, 2016). Although Cx43 is dramatically reduced 
in actively migrating leading edge keratinocytes, it has been found at relatively 
high levels a few cell rows back from the wound edge where there are actively 
proliferating cells. Interestingly, at the wound edge in keratinocytes Cx43 is 
reduced as early as 5h post-wound and nearly undetectable by 24h while Cx26 
and Cx30 which are normally expressed at low levels are found to be greatly 
increased in cells at the edge of wounds (Brandner et al., 2004). Cx26 and Cx30 
can form gap junctions with each other but not with Cx43 and they have very 
different coupling and dye transfer properties (Brandner et al., 2004). Therefore, 
cell migration requires gap junctional communication and is associated with less 
membranous Cx43 since a dramatic reduction in levels of Cx43 is observed in 





4.1 Cx43 is internalised during keratinocyte scrape 
wound closure 
The previous chapter has indicated that the interaction between Cx43 and hDlg 
occurs in non-tumour keratinocytes. siRNA depletion of hDlg led to the 
cytoplasmic location of Cx43 in normal keratinocytes. Sun and co-workers (Sun 
et al., 2015) demonstrated that deletion of the last four amino acids of E6, 
which are the site for Dlg binding, resulted in Cx43 membrane location in 
W12GPXY cells. This suggests that HPVE6 controlled the trafficking of Cx43 via 
its interaction with hDlg. However, HPVE6 together with HPVE7, the second viral 
oncoprotein, can alter several signalling pathways in infected cells leading to 
tumour progression (Gupta and Mania-Pramanik, 2019). Tumour progression is a 
complex process that includes alterations in many signalling pathways so E6 
could affect Cx43 location through the changes it induces in intracellular 
signalling equally as much as through its physical interaction with hDlg. The 
wound healing process and the process of cancer progression shares some 
signalling pathway changes: Sustaining proliferative signalling is one of the 
cancer hallmarks, while proliferation is one of the phases in wound healing 
process (Gantwerker and Hom, 2011, Hanahan and Weinberg, 2011). 
Understanding the role of Cx43 in wound healing process can provide an 
inspiration on how Cx43 in cancer progression.  
It has been reported previously that in keratinocytes Cx43 relocated from the 
plasma membrane into the cytoplasm during the early stages of the wound 
healing process (Wright et al., 2009), and this relocation is similar to what has 
been observed in HPVE6-positive tumour cells. To investigate whether hDlg is 
involved in controlling the trafficking of Cx43 during the wound healing process, 
we used a wound healing model in which a 20 µl yellow tip was utilized to create 
the wounds on a monolayer fully confluent cells, and the cells were harvested at 
certain time points after wounds at 0h, 4h, 8h, 16h, and 24h. 
First, immunofluorescence confocal microscopy was used to investigate the 
subcellular location of Cx43 and hDlg in HaCaT cells undergoing wound healing as 
a model for normal keratinocytes. As expected, Cx43 was located on the plasma 
membrane at 0h, which cells were fixed immediately after the wound created so 




stayed on the plasma membrane just as in an un-wounded state (Figure 4.1 A, 
white arrow). At 4h, Cx43 at the wound edge was moved into the cytoplasm, 
while the membrane Cx43 was still observed in cells away from the wound edges 
(Figure 4.1 B, white arrows). At 8h, Cx43 was observed in the cytoplasm and 
perinuclear areas in the cells along the wound edges. Cx43 was located in the 
cytoplasm in the cells away from the wound margin, while some membrane Cx43 
was observed in the cells behind the wound edge (Figure 4.1 C, white arrows). 
At 16h, Cx43 was still observed in the cytoplasm in the cells even behind the 
wound edge. No membrane Cx43 was observed (Figure 4.1 D, white arrows). The 
wound was closed at 24h and membrane Cx43 was observed again. Some 
cytoplasmic Cx43 was also observed (Figure 4.1 E, white arrows). This indicates 
that the movement of Cx43 during the wound healing process is from the 
membrane to the cytoplasm and back to the membrane. 
Then, the subcellular location of hDlg, as a potential controller of Cx43, was also 
investigated during the wound healing process. As can be seen in Figure 4.1 A, 
hDlg was located on the cell membrane that co-localised with Cx43 at 0h. At 4h, 
hDlg was not on the plasma membrane and might co-localised with Cx43 in the 
cells along the wound edge but remained and co-localised with Cx43 on the 
plasma membrane in the cells behind the wound (Figure 4.1 B, white arrows). 
hDlg was lost from the plasma membrane and co-localised with Cx43 in the 
cytoplasm and perinuclear area in the cells along the wound edge at 8h. Some 
hDlg was still observed co-localised on the plasma membrane and in the 
cytoplasm in the cells behind the wound margin (Figure 4.1 C, white arrows). At 
16h, hDlg was mainly located in the cytoplasm in the cells along and behind the 
wound edge where some co-localisation with Cx43 was observed. Still some 
membranous hDlg was observed in the cells behind the wound edge (Figure 4.1 
D). The wound was closed at 24h, hDlg was mainly located on the plasma 
membrane where it co-localised with Cx43 (Figure 4.1 E, white arrows). This 
indicates that at least some hDlg share a similar movement pattern and co-
localised with Cx43 during the wound healing process. 
It has been reported that the cellular level of Cx43 is reduced at the early stage 
of wound healing and then it recovers to a normal level after wound closure  
(Brandner et al., 2004). Therefore, western blotting, using a rabbit polyclonal 




the alteration in levels of Cx43 and hDlg during the wound healing process. 
Samples were harvested from the entire cell population (therefore most of the 
cells are not at the wound edges) according to the time points as previously 
stated. Mitomycin C was not employed to stop proliferation therefore the 
phenomenon is due to cell migration and proliferation.  Figure 4.2 B shows a 
drop in Cx43 levels at 4h post wound and a peak of Cx43 protein levels at 16h. 
The trend for Cx43 levels during the wound healing process was a reduction in 
levels from 0h to 4h then an increase in Cx43 levels from 4h to 16h followed by a 
slight reduction at 24h. A hyperphosphorylated band of Cx43 was observed in the 
protein samples harvested at 4h and 8h compared to mock, 16h and 24h (Figure 
4.2 A, arrows). For hDlg, a similar trend to that with Cx43 was observed (Figure 
4.2 C). The protein level of hDlg reduced from 0h to 4h, and then increased until 
a peak at 16h followed by a slight decrease at 24h.  
In order to investigate the wound repair process at a cellular level, photographs 
were taken at each time point at the same wound area during the time course 
experiment of wound closure in HaCaT keratinocytes. Figure 4.3 shows that 
between 0h to 8h, the area of the wound seemed not to change. The scrape 
wound gap started to close between 8h and 16h and then the gap closed much 
more rapidly between 16h and 24h. The gap closure was almost complete at 24h. 
This indicates that the reduced levels of Cx43 and hDlg observed in Figure 4.2 
were before the start of cell migration/wound closure (0h -4h), and the 
increased level of these two proteins correlated with rapid wound closure (8-
16h). When the closure was nearly finished, the protein levels dropped towards 
the unwounded state. These data indicated that hDlg might regulate Cx43 during 








Figure 4.1: Cx43 cycled from the plasma membrane to the cytoplasm during the wound healing process in HaCaT cells.  
Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in HaCaT (human keratinocyte cells) according to the wound healing time points: (A) 
0h, (B) 4h, (C) 8h, (D) 16h, and (E) 24h. Cx43 (red) and hDlg (green) were co-localised on the plasma membrane at 0h post-wound. White dotted lines indicate the 






Figure 4.2: The levels of Cx43 and hDlg in HaCaT cells are altered during the wound healing 
process.  
(A) Western blot showing the expression of Cx43 and hDlg in cell extracts from HaCaT cells 
according to the wound healing time points. Red arrows indicate the hyperphosphorylated forms of 
Cx43.  Images of hDlg and GAPDH were obtained from Licor imaging and image of Cx43 were 
exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the wound healing 
process. The intensity of Cx43 and hDlg bands was measure by ImageJ and normalised to un-







Figure 4.3: The wound closure process in HaCaT cells.  
(A) Photos were taken according to the wound healing time points (0h, 4h, 8h, 16h, and 24h). The 
red dotted lines indicate the wound edges. (B) Quantification of the wound area was normalized to 






These experiments were repeated in NIKS (normal immortalized keratinocyte 
cells) and NIKS16 cells (NIKS cells stably transfected with the HPV16 genome) in 
order to investigate whether HPV16 genome or low level of HPVE6 will affect 
cell behaviour in response to wound healing. Here, keratinocyte growth in KGM 
was used to avoid any influence of the 3T3 feeder layer that was normally used 
to support NIKS cell growth.  Similar to what was observed in HaCaT cells, Cx43 
in NIKS cells was located on the plasma membrane at 0h (Figure 4.4 A) and 
moved to the cytoplasm/peri-nuclear area at 4h (Figure 4.4 B), and stayed in the 
cytoplasm at 8h (Figure 4.4 C). At 16h, Cx43 was partially back on the plasma 
membrane and was located mainly on the membrane at 24h (Figure 4.4 D and E). 
These alterations were not only occurring in the cells along the wound edges but 
in the cells behind the wound edges as well, which might indicate a rapid spread 
of cell signalling in NIKS cells compared with HaCaT cells. hDlg co-stained with 
Cx43 on the plasma membrane at 0h (Figure 4.4 A), while co-staining was 
observed in the cytoplasm at 4h (Figure 4.4 B) and 8h (Figure 4.4 C) while some 
membrane hDlg was observed in the cells behind the wound at 4h (Figure 4.4 B). 
However, due to slow growth in KGM without feeder layers, NIKS cells were not 
fully confluent before the wound healing assay (Figure 4.4). There were some 
gaps between cells at 8h, 16h, and 24h (Figure 4.4 C, D, and E). This might 
explain the relative lack of gap junction plaques observed in Figure 4.4 
compared to those of the NIKS cells in the previous chapter. 
Regarding the protein levels, Cx43 levels in NIKS cells seemed not to change 
between 4h and 8h, they increased at 16h (peak) followed by a slight decrease 
at 24h (Figure 4.5 B). There were only low levels of Cx43 observed at 0h (Figure 
4.5 A), this might be due to low cell density at this time point compared to the 
mock-treated control (the GAPDH band at 0h is less intense than the others at 
later time points). There are increasing levels of hDlg between 0h to 16h and 
followed by a decrease at 24h (Figure 4.5 B). The trend of changes in Cx43 and 
hDlg levels in NIKS cells was similar to what is observed in HaCaT cells except for 
the decrease of Cx43 level at 4h that was observed in HaCaT cells (Figure 4.2 B 




In NIKS16 cells, Cx43 levels were very similar for the first 8 hours following 
scrape wounding. There was a clear peak of protein levels at 16h followed by a 
slight decrease at 24h (Figure 4.6 B). The levels of hDlg followed a similar 
pattern but there was no decrease at 24h (Figure 4.6 C). The protein level 
alteration between NIKS and NIKS16 cells during the wound healing process was 
quite different (Figure 4.5 and 4.6).  
Then the wound closure speed of NIKS and NIKS16 cells was checked using 
photographs of phase contract images according to the time points. For NIKS 
cells, the scrape wound area seemed not to change between 0h to 4h and 
started to close between 4h to 8h. There was a rapid closure phase between 8h 
and 16h, but the scrape wounds were not fully closed at 24h (Figure 4. 7 A). 
However, for NIKS16 cells, the process was much speedier. The wound closure 
seemed to start between 0h and 4h, rapid closure was observed between 4h and 
8h, and the wound was fully closed at 16h (Figure 4.7B). This indicates that the 







Figure 4.4: Cx43 cycled from the plasma membrane to the cytoplasm during the wound healing process in NIKS cells.  
Confocal immunofluorescence microscopy shows the location of Cx43 and hDlg in NIKS cells according to the wound healing time points: (A) 0h, (B) 4h, (C) 8h, (D) 
16h and (E) 24h. Cx43 (red) and hDlg (green) were co-localised on the plasma membrane at 0h post-wound. White dotted lines indicate the wound edges. The white 







Figure 4.5: The levels of Cx43 and hDlg in NIKS cells are altered during the wound healing 
process.  
(A) Western blot showing the expression of Cx43 and hDlg in NIKS cell extracts according to 
wound healing time points. Images of hDlg and GAPDH were obtained from Licor imaging and the 
image of Cx43 was exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the 
wound healing process. The intensity of Cx43 and hDlg bands was measure by ImageJ and 






Figure 4.6: The levels of Cx43 and hDlg in NISK16 cells are altered during the wound healing 
process. 
(A) Western blot showing the expression of Cx43 and hDlg in NIKS16 cell extracts according to 
wound healing time points. Images of hDlg and GAPDH were obtained from Licor imaging and the 
image of Cx43 was exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the 
wound healing process. The intensity of Cx43 and hDlg bands was measure by ImageJ and 












Figure 4.7: The wound closure process in NIKS and NIKS16 cells. 
Photos of wound area in (A) NIKS and (B) NIKS16 cells were taken according to wound healing 
time points (0h, 4h, 8h, 16h, and 24h). The red dotted lines indicate the wound edges. (C) 
Quantification of the wound area changes (normalized to 0h) according to wound healing time 




4.2 hDlg plays an important role in scrape wound healing  
hDlg has been thought to play roles in cell migration and cell proliferation 
(Stephens et al., 2018), both processes are included in the wound healing 
process. Together with the evidence that hDlg is a controller of Cx43 in 
keratinocytes, it would be worthwhile to investigate the location of hDlg with 
respect to Cx43 during the wound closure process. Some hDlg co-stained with 
Cx43 as it changed its location from the plasma membrane to the cytoplasm 
during scrape wound healing in HaCaT and NIKS cells (Figure 4.1 and 4.4). 
Reduced levels of Cx43 are required at the early stage of wound healing. 
Decreased Cx43 caused by Cx43-antisence resulted in increased ability of 
proliferation and migration of keratinocyte and fibroblast at wound sites (Mori et 
al., 2006). Since siRNA depletion of hDlg led to a reduction in the level of Cx43 
(Chapter 3), it would be interesting to investigate whether siRNA depletion of 
hDlg altered the closure of scrape wounds due to reduced Cx43 levels. To 
investigate this, mock or siDlg-treated HaCaT cells prior to scraping wounding 
were used and analysis of wound closure was carried out. Figure 4.8 shows 
phase-contrast images of HaCaT cells over a time course of wound closure for 
the same wound area. In mock-treated HaCaT cells, the wound closure process 
was very similar to that as previous described, and the wound was nearly closed 
at 24h (Figure 4.8 A). However, in HaCaT cells with siRNA depletion of hDlg, the 
area of the wound did not change between 0h to 8h. The wound started to close 
between 8h to 16h followed by a slight reduction in closure rate at 24h (Figure 
4.8 B). This data indicated that siRNA depletion of hDlg in HaCaT cells significant 
delayed the wound healing process. 
This experiment was repeated in NIKS16 cells to investigate the delayed wound 
healing by siRNA depletion since NIKS16 cells close the wound fast (complete 
closure at 16h in Figure 4.7). The results are shown in Figure 4.8. Significant 
delay of wound closure was observed in NIKS16 cells with siRNA depletion of hDlg. 
The wound only closed to around 50% after 24h while in mock-treated NIKS16 
cells the wound was fully close at 16h (Figure 4.9). This further supports the role 
of hDlg in the wound healing process. 
From these images, more dead cells were observed in the HaCaT and NIKS16 cell 




culture medium was changed after creating the wound. Therefore, the cell 
death during wound closure was not caused by siRNA transfection. Moreover, no 
significant cell death was observed in unwounded HaCaT and NIKS16 cells with 
siRNA depletion of hDlg compared to mock-treated cells in the previous chapter. 
Therefore, cell death must be due to the wounding process. To investigate this 
further, at the end of the 24h time course, supernatant in each well from the 
scrape wound assay was used to count live versus dead cells and the results are 
shown in Figure 4.10. More floating cells/dead cells were counted in HaCaT and 
NIKS16 cells with siRNA depletion of hDlg compared to mock-treated and 
negative control HaCaT cells. This indicated that during wound closure, cells 
with reduced hDlg levels led to a higher ratio of cell death than cells with 
normal hDlg levels. However, the cell death caused by siRNA depletion of hDlg in 
response to wounding should be further investigated maybe through the use of 
cell apoptosis markers.   
To understand more regarding hDlg in the wound healing process, HaCaT cells 
with a stable knockdown of hDlg (named HaCaT shDlg cells) were used to repeat 
the experiments. This cell line was used to avoid the possible effects of siRNA 
depletion of hDlg that might kill the cells in response to wound (Figure 4.10). For 
unwounded cells, HaCaT shDlg cells showed results consistent with HaCaT cells 
upon siRNA depletion of hDlg. There was a reduced level of Cx43 and the 
observation of the cytoplasmic location of Cx43 (as in the previous chapter). 
Whether the reaction to wounding in HaCaT shDlg is the same as that in HaCaT 
cells upon siRNA depletion of hDlg is worth checking. The reaction to wounding 
in both HaCaT cell lines was investigated as above. In HaCaT cells, the wound 
closure process was very similar to that previously described, and the scrape 
wound was nearly closed at 24h (Figure 4.11 A).  However, in HaCaT shDlg cells, 
surprisingly the wound was found to be fully closed at 16h, which was very 
different from the observation in HaCaT cells with siRNA depletion of hDlg that 
seemed to start to close at 24h (Figure 4.11 B). No significant cell death was 
observed in these experiments between HaCaT and HaCaT shDlg cells. This 
indicated that siRNA depletion of hDlg might weaken the cell‘s adaptability in 
response to wound healing. Comparing the repair speed of these HaCaT cells in 
response to the wound, it is easy to see that there is still a relative gap in HaCaT 




HaCaT cells after 24h (Figure 4.8). However, the HaCaT shDlg cells repaired the 











Figure 4.8: The wound closure process in mock-treated HaCaT and HaCaT cells with siRNA 
depletion of hDlg. 
Photos of wound area in (A) mock-treated HaCaT and (B) siDlg-treated HaCaT cells were taken 
according to wound healing time points (0h, 4h, 8h, 16h, and 24h). The red dotted lines indicate the 
wound edges. (C) Quantification of the wound area (normalized to 0h) changes according to wound 
healing time points (* indicates p<0.05; ** indicates p<0.005; *** indicates p<0.0005). This 












Figure 4.9: The wound closure process in mock-treated NIKS16 and NIKS16 cells with 
siRNA depletion of hDlg. 
Photos of wound area in (A) mock-treated NIKS16 and (B) siDlg-treated NIKS16 cells were taken 
according to wound healing time points (0h, 4h, 8h, 16h, and 24h). The red dotted lines indicate the 
wound edges. (C) Quantification of the wound area changes (normalized to 0h) according to wound 
healing time points (* indicates p<0.05; ** indicates p<0.005; *** indicates p<0.0005). This 






Figure 4.10: siRNA depletion of hDlg led to more floating cells in response to wound healing.  
Quantification of the cells counted from the supernatant in (A) HaCaT cells and (B) NIKS16 cells 
after 24h post wound with different treatment: mock-treated (mock), non-target siRNA control-












Figure 4.11: The wound closure process in HaCaT cells and HaCaT shDlg cells.  
Photos of wound area in (A) mock-treated HaCaT and (B) shDlg-treated HaCaT cells were taken 
according to wound healing time points (0h, 4h, 8h, 16h, and 24h). The red dotted lines indicate the 
wound edges. (C) Quantification of the wound area changes (normalized to 0h) according to wound 
healing time points (* indicates p<0.05; ** indicates p<0.005; *** indicates p<0.0005). This 





4.3 Behaviour of tumour cells during the wound healing 
process 
HPVE6 targets and leads to degradation of p53 resulting in uncontrolled cell 
proliferation (Martinez-Zapien et al., 2016). Recently HPV16 E6 was observed to 
increase the migration of cervical cancer cells by the down-regulation of PDZ-
domain-containing protein Na+/H+ exchanger regulatory factor (NHERF1) (Wang 
et al., 2018). HPV16 might increase wound healing speed in infected cells as 
NIKS16 cells close the wound much faster than NIKS cells (Figure 4.7), while 
stable loss of hDlg could lead to some cell alterations such as cell shape and 
motility which might speed up the wound healing process (Figure 4.11). HPVE6 
targets hDlg for degradation. Because of this known effect of E6, whether the 
wound healing process is enhanced in cervical cancer cells that express HPVE6 
was tested. Therefore, the wound healing process was repeated in C33a (HPV-
negative cervical tumour cells), C33aE6 (C33a cells stably transfected with an 
expression construct for HPV16E6), and HeLa43 cells (HPV18-positive cervical 
tumour cells transfected with an expression construct for Cx43). C33a cells, 
which express mainly membrane Cx43 and hDlg, showed no significant amount of 
wound closure during the scrape wound healing process (closed 17% of the gap at 
24h) (Figure 4.12 A). For C33aE6 cells, which contained mainly cytoplasmic Cx43 
and hDlg, the wound area seemed unchanged between 0h and 8h (similar to the 
observation in C33a cells) but the gap began to close between 8h to 24h and 
finally, the gap was closed to 33% at 24h (Figure 4.12 B). This experiment 
indicates that the expression of HPVE6, or the presence of less membranous 
Cx43, was associated with better wound healing.   
Next, how the levels of Cx43 and hDlg were changed during wound healing was 
investigated in C33a and C33aE6 cells. Figure 4.13 shows that in C33a cells, Cx43 
levels reached their lowest level at 4h, then reached a peak at 8h followed by a 
slight drop at 16h and 24h. Following a similar pattern to Cx43 levels, hDlg levels 
also dipped at 4h, but the peak of expression appeared at 16h followed by a 
reduction at 24h. However, in C33aE6 cells (Figure 4.14), the time of reduction 
in Cx43 levels was shifted from 0h to 4h after which it showed a slight increase 
at 8h followed by a significant increase at 16h and 24h. For hDlg, the level 
slightly dropped from 0h to 4h and then kept increasing from 4h to 24h. The 




partial degradation of hDlg, an unstable protein, which was observed at all the 
time points during wound healing, but the upper band, which is likely the 
phosphorylated form of hDlg was observed only at 16h and 24h. This suggests 
that hDlg can undergo post-translational modification in response to wound 
closure.  
To investigate whether HPVE6 or less membranous Cx43 or both is associated 
with faster wound healing, these experiments were repeated in HeLa43 cells 
(HPV-positive cervical cancer cells with ectopic expression of Cx43). Since 
HeLa43 containing membranous Cx43 and expression of HPVE6, the wound 
closure rate of HeLa43 should be between that of C33a and C33aE6. As expected, 
HeLa43 did not close the wound after 24h and the closure rate (30% closure at 
24h) is between that measured for C33a and C33aE6 (17% and 33% respectively) 
(Figure 4.15). 
At the protein level, in HeLa43 cells, Cx43 levels kept increasing between 0h to 
8h followed by a slight decrease at 16h and another increase at 24h (Figure 4.16 
B). For hDlg, the trend of alteration in protein levels was similar to what has 
been observed for Cx43: increased between 0h to 8h followed by a slight 
decrease at 16h. However, instead of increasing, the level of hDlg decreased at 
24h (Figure 4.16 B). More time-points were chosen to further investigate this 
alteration of Cx43 and hDlg levels in HeLa43 together with changes in HPV18E6 
protein levels (Figure 4.16 A). It seems there a little reduction between 0h to 2h 
for Cx43 levels. The HPV18E6 level seemed to increase between 0h to 8h and 
decreased to un-wound levels at 24h (Figure 4.16 A). This might be associated 
with the increasing levels of hDlg between 0h to 8h, then decreasing levels 
between 8h to 24h (Figure 4.16 B). The increase in hDlg might suggest that 
wound healing triggered a pathway that counteracted the ability of HPV18E6 in 











Figure 4.12: The wound closure process in C33a and C33aE6 cells.   
Photos of wound area in (A) C33a and (B) C33aE6 cells were taken according to wound healing 
time points (0h, 4h, 8h, 16h, and 24h). The red dotted lines indicate the wound edges. (C) 
Quantification of the wound area changes (normalized to 0h) according to wound healing time 






Figure 4.13: The levels of Cx43 and hDlg in C33a cells are altered during the wound healing 
process.  
(A) Western blot showing the expression of Cx43 and hDlg in C33a cell extracts according to 
wound healing time points. Images of hDlg and GAPDH were obtained from Licor imaging and the 
image of Cx43 was exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the 
wound healing process. The intensity of Cx43 and hDlg bands was measure by ImageJ and 






Figure 4.14: The levels of Cx43 and hDlg in C33aE6 cells are altered during the wound 
healing process. 
(A) Western blot showing the expression of Cx43 and hDlg in C33aE6 cell extracts according to 
wound healing time points. Images of hDlg and GAPDH were obtained from Licor imaging and the 
image of Cx43 was exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the 
wound healing process. The intensity of Cx43 and hDlg bands was measure by ImageJ and 









Figure 4.15: The wound closure process in HeLa43 cells.  
(A) Photos were taken according to the wound healing time points (0h, 4h, 8h, 16h, and 24h). The 
red dotted lines indicate the wound edges. (B) Quantification of the wound area (normalized to oh) 






Figure 4.16: The levels of Cx43 and hDlg in HeLa43 cells altered during the wound healing 
process.  
(A) Western blot showing the expression of Cx43 and hDlg in HeLa43 cell extracts according to 
wound healing time points. Images of hDlg and GAPDH were obtained from Licor imaging and the 
image of Cx43 was exposed with X-ray film. (B) Quantification of Cx43 and hDlg levels during the 
wound healing process. The intensity of Cx43 and hDlg bands was measure by ImageJ and 





4.4 Discussion  
Previously it is reported that the gap junction protein Cx43 and its binding 
partner, hDlg were presented on the plasma membrane in W12G cells while in 
tumour cells derived from them (W12GPXY cells (Aasen et al., 2003b) both 
proteins co-located in the cytoplasm. A  significantly increased level of HPVE6 
was observed in W12GPXY cells, where E6 was located in the nucleus and the 
cytoplasm compared to W12G cells, where E6 was mainly in the nucleus 
(Macdonald et al., 2012b, Sun et al., 2015). E6 siRNA depletion in W12GPXY cells 
resulted in Cx43 relocation from the cytoplasm back to the plasma membrane, 
which indicates that the increasing levels (or high levels) of HPVE6 in the 
cytoplasm can control Cx43 trafficking (Sun et al., 2015). A similar pattern of 
Cx43 trafficking to and from the membrane is known to occur during the wound 
healing process. In the early stages of the wound healing process, Cx43 was 
found to relocate from the plasma membrane into the cytoplasm in primary 
human keratinocytes at the leading edge of a wound (Wright et al., 2009).  
Therefore, the alteration of hDlg in subcellular location and expression was 
investigated in response to wound repair and whether it is related to the 
alteration of Cx43 during the wound healing process. Table 4.1 summarizes the 
subcellular location of Cx43 and hDlg in HaCaT cells and NIKS cells during the 
wound healing process in Figure 4.1 and Figure 4.4. Cx43 was observed to traffic 
from plasma membrane (0h) to the cytoplasm (4h, 8h in NIKS; 4h, 8h, 16h in 
HaCaT) and back to the membrane (16h in NIKS; 24h in HaCaT) in HaCaT and 
NIKS cells during the wound healing process (Figure 4.1 & 4.4). Membrane hDlg 
was observed in the entire wound repairing time points in both cells. Some hDlg 
co-localised with Cx43 in the cytoplasm during the wound healing process (4h, 
8h in NIKS; 4h, 8h, 16h in HaCaT) (Table 4.1). These data indicate the role of 
hDlg involved in the wound healing process.  
hDlg, involved in maintaining cell polarity, is also essential for cell migration 
especially directed migration (Etienne-Manneville, 2008). Briefly, hDlg is 
targeted to the plasma membrane of the leading edges of wounding cells and 
regulates microtubule interaction for the plus-end of microtubules at the plasma 




siRNA depletion of hDlg also led to the relocation of Cx43 from the plasma 
membrane into the cytoplasm in HaCaT cells similar to the trafficking of Cx43 at 
the early stages of wound healing. However, HaCaT cells with siRNA depletion of 
hDlg led to slow wound repair and lots of cell death during the wound healing 
process (Figure 4.8 & 4.10 A). This indicates the role of hDlg in maintaining cell 
survival in response to wounds and the expression of hDlg is required in the 
proper wound healing process.  
However, results shown in HaCaT cells with stable depletion of hDlg (HaCaT 
shDlg, growth medium containing puromycin) is not consistent with the 
observation in HaCaT cells with siRNA depletion of hDlg, instead, faster wound 
closure was observed (full closure at 16h) (Figure 4.11). This might be because 
HaCaT shDlg cells had adjusted their growth properties to exist without hDlg (no 
significant cell death was observed during wound healing or culturing under the 
normal conditions with these cells). In this case, some other proteins might 
function effectively to compensate for the loss of hDlg to maintain normal cell 
growth and hScrib came into consideration. hScrib and hDlg both are involved in 
the regulation of cellular polarity and acts as tumour suppressor proteins 
(Thomas et al., 1997, Dow et al., 2003). Both hScrib and hDlg are targeted by 
High-risk HPV E6 for proteasome degradation (Nakagawa and Huibregtse, 2000, 
Gardiol et al., 1999). Most importantly, Bank‘s group, where the HaCaT shDlg 
came from, found that hScrib and hDlg showed complementary roles, and the 
higher level of hScrib was observed in HaCaT shDlg cells. Loss of hDlg in HaCaT 
cells did not affect the cell-cell contacts (Massimi et al., 2012). Therefore, the 
possible explanation of faster wound repair in HaCaT shDlg cells could be that 
HaCaT shDlg has adapted into the loss of hDlg by expressing more hScrib to 
compensate for the loss of hDlg and maintains the cell polarity. This might 
increase cells' ability in response to cell stress (e.g. wound healing). Stable 
depletion of hDlg in endometrial cancer cell line KLE enhanced the cell 
migration in wound healing assay (Sugihara et al., 2016). In contrast, in HaCaT 
with siRNA depletion of hDlg, a complementary system to cover the loss of hDlg 
may not be activated leading to cell stress and then cell death during wound 
closure. This increasing rate of closure of HaCaT shDlg cell layers might also be 
due to increasing levels of beta-catenin in these cells (Massimi et al., 2012). The 




prevent beta-catenin from moving into the nucleus to activate transcription of 
genes encoding proteins involved in cell migration.  
Beta-catenin, involved in the Wnt pathway (normally activated in response to 
wounding), is known to be increased in response to injury, as are the levels of 
expression of its target genes during the proliferative phase (Houschyar et al., 
2015). In the absence of Wnt signalling, beta-catenin is maintained at a low level 
in the cells by continuous degradation by the so-called destruction complex 
which includes adenomatous polyposis coli (APC) (Stamos and Weis, 2013). Wnt 
signalling prevents degradation of beta-catenin and stabilized beta-catenin is 
translocated into the nucleus to activate transcription of genes in response to 
cellular stresses such as wound healing (Houschyar et al., 2019). Expressing 
stabilized beta-catenin in NBT-II epithelial cells increased cell migration (Müller 
et al., 2002). Knockdown of beta-catenin in renal cell carcinoma cells (A498) 
significantly decreased cell migration while its overexpression in renal cell 
carcinoma cells (786-O and ACHN) increased cell migration (Yang et al., 2017). 
Therefore, increasing levels of activated beta-catenin and its nuclear location is 
important in wound healing. hDlg might also be involved in the regulation of 
beta-catenin since hDlg activates beta-catenin signals in vascular endothelial 
cells (EC) (Cho et al., 2019). Transfection with Dlg1 increased the signalling of 
beta-catenin in HEK293 cells with a knockout of hDlg (Cho et al., 2019). 
Interestingly, NIKS16 cells closed the wound faster than NIKS cells (Figure 4.7). 
Comparing the expression of Cx43 and hDlg in NIKS and NIKS16 cells during the 
wound healing process, the significant difference that could be observed is that 
in NIKS16 cells the level of hDlg was increased between 0h and 4h followed by a 
reduction at 8h while in NIKS cells it was other way around. The gap area of NIKS 
cells at 8h was similar to that in NIKS16 cells at 4h (Figure 4.7). This indicates 
that the presence of the HPV16 genome increased cell proliferation and 
migration, perhaps due to the expression of HPV16 E6, which can induce cervical 
cancer cell migration (Wang et al., 2018). This is possibly due to HPVE6 induced 
accumulation of nuclear beta-catenin via its PDZ-binding domain (Bonilla-
Delgado et al., 2012) since the nuclear accumulation of beta-catenin was only 
observed in transgenic mice expressing wild-type HPVE6 but not with truncated 




Table 4.1: Summary of the location of Cx43 and hDlg in cells during the wound healing 
process in HaCaT and NIKS cells. 
(Cx43 is indicated in red and hDlg is indicated in black) 
 0h 4h 8h 16h 24h 
HaCaT M/M C,M/C,M C,Pn/C,M C/C,M C,M/M 
NIKS C,M/M C,Pn/C,M C,Pn/M M/M M/M 
M: membrane; C: cytoplasm; Pn: peri-nuclear area. 
 
Table 4.2: Summary of expression of Cx43 and hDlg during the wound healing process in 
different cell types. 
(Cx43 is indicated in red and hDlg is indicated in black) 
 0h 4h 8h 16h 24h 
HaCaT -   /     /  -   /     /   
NIKS -   /   -  /   -  /     /   
NIKS16 -   /     /     /     /  - 
C33a -   /     /     /     /  - 






In cervical cancer cells with membrane Cx43 (C33a and HeLa43 cells), without 
membrane Cx43 (C33aE6 cells), or with HPVE6 (C33aE6 and HeLa43 cells) or 
without HPVE6 (C33a cells), the scrape wounds did not close (Figure 4.12 & 4.15). 
These data indicate that less membranous Cx43 led to better wound healing, 
which might be associated with nuclear beta-catenin. Cx43 is thought to interact 
with beta-catenin at the membrane and prevent its translocation to the nucleus. 
shRNA knockdown of Cx43 in PC3 human prostate cancer cells led to no 
significant changes in total protein levels of beta-catenin but accumulated 
nuclear beta-catenin was observed (Hou et al., 2019). Overexpression of Cx43 in 
human mammary adenocarcinoma cells (MCF-7 and MDA-MB-231) did not change 
the total levels of beta-catenin but increased its membrane location (Talhouk et 
al., 2013). Also, nuclear beta-catenin could reduce the mRNA expression of GJA1 
(Cx43) in HaCaT cells with infections of adenovirus (Calhoun et al., 2020). 
Together with the observation that HPVE6 increased the nuclear beta-catenin 
(Bonilla-Delgado et al., 2012), the non-closure of the wound in cervical cancer 
cells could be explained: for C33a cells, membranous Cx43 prevents nuclear 
location of beta-catenin, which leads to reduced wound closure. For C33aE6 
cells, HPVE6 targets and degrades hDlg which decreases protein levels and 
membranous location of Cx43, resulting increasing nuclear beta-catenin and 
better wound closure. For HeLa43 cells, overexpression of Cx43 leads to 
accumulated membranous Cx43 preventing nuclear transition of beta-catenin, 
but HPVE6 in HeLa43 promotes nuclear beta-catenin. Thus, wound closure rate is 
slowest in C33a cells, and similar in C33aE6 and HeLa43 cells (Figure 4.11 and 
4.15).     
In conclusion, Cx43 in the cells at the wound edge traffic from the plasma 
membrane into the cytoplasm and back to the membrane during the wound 
healing process. hDlg partially trafficked together with Cx43 in this process. The 
role of hDlg in the wound healing process might be as a regulator of Cx43, 
together with regulating cell polarity involved in direct cell migration. The 
nuclear location of beta-catenin is important for the wound healing process and 





5 Chapter 5  
Mapping the interaction of Cx43 C-terminal tail 
with hDlg  
Cx43 has a 150 amino acids long C-terminal tail (residues 232-382) (Leithe et al., 
2017b). NMR (nuclear magnetic resonance) analysis of Cx43 CT residues 255-382 
suggested that most of the structure of the Cx43 CT is disordered but with two 
regions of helical structure observed (Sorgen et al., 2004).  High conservation of 
the amino acid sequences of Cx43 CT is observed in vertebrate species including 
zebrafish (Bai, 2016, Chatterjee et al., 2005). This suggests a fundamental 
function of Cx43 CT within these species. Cx43 CT has been thought to be 
involved in many biological processes, especially in the regulation of gap 
junction channel functions.  This is mainly done by the interaction between Cx43 
CT with other proteins or post-translation modification on the Cx43 CT. For 
example, integral membrane proteins caveolins interact with Cx43 CT in the 
Golgi apparatus and are then trafficked together to the plasma membrane in 
lipid raft in keratinocytes. A reduced level of caveolins may reduce Cx43 
trafficking to the plasma membrane, which is associated with a reduced gap 
junction intercellular channel (GJIC) (Langlois et al., 2008). In the case of post-
translational modifications, the reduced opening of hemichannels (made of six 
Cxs) was observed under the PKC-induced phosphorylation of Cx43 at S368 (Bao 
et al., 2004). Cx43 CT enhanced HeLa cell migration via the p38 MAP kinase 
pathway (Behrens et al., 2010) and in human glioma cells, migration was 
increased by Cx43 CT through inducing regeneration of the actin cytoskeleton 
(Crespin et al., 2010). 
Cx43 can interact with a large number of proteins mainly through its C-terminal 
tail. These interactions serve in the regulation of Cx43, gap junction assembly, 
or even cell cycle control. The Cx43 CT sequences which interact with some 
binding partners have been listed in Figure 5.1. Cx43 CT binds to 14-3-3 theta at 
the 14-3-3-binding motif (370-376), which requires Akt-induced phosphorylation 
of Cx43 CT-S373 (Park et al., 2006, Park et al., 2009). Caveolin-1directly binds 
to Cx43 CT via its caveolin-scaffolding domain (residues 82-101) and the C-
terminal domain (135-178) (Schubert et al., 2002). The specific binding region of 
caveolin-1 on Cx43 CT remains unclear. CIP75 (Cx43-interacting protein of 75kDa) 




Cx43-CIP75 interaction region was between 264 and 302 within Cx43 CT (Li et al., 
2008). NEDD4 (neural precursor cell-expressed developmentally downregulated 
gene 4) binds to the PY motif (XPPXY, where P is proline, X is any amino acid, 
and Y is tyrosine) on the Cx43 CT specifically at 283-286 (Spagnol et al., 2016). 
Membrane-associated guanylate kinase protein ZO-1 is found to directly bind to 
the last five amino acids of Cx43 CT via its middle PDZ domain (Toyofuku et al., 
1998, Giepmans and Moolenaar, 1998).  
In this chapter, the binding of hDlg to the Cx43 CT was investigated, and 
attempted to map for the first time the Cx43 CT-hDlg interaction, and 






Figure 5.1: Sequence information of Cx43 CT with some interaction partners. 
(A) Topological presentation of Cx43 CT with some protein-protein interaction domains. (B) A table 
listing the binding partners of Cx43 CT and potential binding sequences. The figure is taken from 




5.1 The region of Cx43 which binds hDlg is located in the 
last 33 amino acids of the Cx43 C-terminus 
Like ZO-1, hDlg is a MAGUK (membrane-associated guanylate kinase) protein. It 
shares a similar structure with ZO-1, which includes a GUK domain, an SH3 
domain, a HOOK domain, and three PDZ domains (Matsumine et al., 1996b). hDlg, 
with its SH3/HOOK domain, has been shown to bind to the C-terminal of another 
gap junction protein Cx32 (aa 209-283) (Duffy et al., 2007) and MS/MS analysis 
showed its potential binding affinity to the Cx43 C-terminal tail (Singh and 
Lampe, 2003). Previously Macdonald and co-workers utilized the HPV-positive 
cervical tumour cell W12 model to investigate Cx43 behaviour in the presence of 
oncoprotein HPVE6 during tumour progression. HPVE6 has been known to target 
hDlg for proteasome degradation. Therefore, a Cx43-hDlg-E6 interaction is under 
consideration. Co-IP experiments showed the interaction between Cx43 and hDlg 
in both non-transformed W12G and fully transformed W12GPXY cells, although 
the interaction was greatest in W12GPXY cells. The GST-pulldown assay showed 
that the Cx43 CT binds not to the PDZ domains (like ZO-1) but to both N-
terminal and C-termini of hDlg. GST-Cx43 CT with deletion of the last five amino 
acids (the binding site for ZO-1) could still interact with hDlg, indicating the 
binding sites of Cx43 to hDlg are different from ZO-1 (Macdonald et al., 2012b).  
In vitro direct protein-protein pull-downs showed that Cx43 and hDlg could bind 
directly (Macdonald et al., 2012b) (Figure 5.2). Three years later, Proximity 
Ligation Assays (PLA) confirmed the Cx43-hDlg interaction in cervical tumour 
tissues in vivo (Sun et al., 2015). Chapter 3 in this thesis showed that Cx43-hDlg 
interaction is neither HPV-dependent nor cancer cell-specific. siRNA depletion of 
hDlg in non-tumour cells led to a reduction in levels of Cx43 and this reduction 
could be rescued in the presence of lysosomal inhibitor NH4Cl, which is 
consistent with MacDonald et al. observations in W12GPXY cells (Macdonald et 
al., 2012b). The Cx43 C-terminal corresponds to amino acids 263 – 382, while the 
N-terminal of hDlg corresponds to amino acids 1-122, and the C-terminal of hDlg 






Figure 5.2: A scheme of Cx43 interaction with hDlg.  
Specifically, the Cx43 CT correspond to amino acids 263 – 382 and the last 5 amino acids 
responsible for Cx43-ZO-1 interaction is not involved in Cx43-hDlg binding. The Cx43-hDlg binding 
regions in hDlg correspond to N-terminal (aa 1-122) and C-terminal (aa 560 -911) including SH3, 





To investigate the specific region responsible for Cx43-hDlg interaction, 
preparing the deletion mutants of the Cx43 C-terminus is the first step. The 
human Cx43-containing plasmid pcDNA3-Cx43, kindly provided by Dr Dale Laird, 
was used as the template for PCR-mediated mutagenesis. Primers were used to 
generate Cx43 CT (wild-type) corresponding to amino acids 263-382 (Macdonald 
et al., 2012b). The plasmids of Cx43 CT deletions were generated through 
mutagenesis. D1 contains region 1 which correlates to amino acid 232-282. D2 
contains region 1 and region 2, which correlates to amino acid 232-348. D3 
contains region 2 and region 3, which correlates to amino acid 282-382. D4 
contains region 3, which correlates to amino acids 349 – 382. All Cx43 deletions 
were fused with a 3X Flag tag so that they can be identified by anti-Flag 
antibody (Figure 5.3A). HEK293 cells are good cells for transfection with high 
expression of proteins expressed from transfected plasmids. All plasmids of Cx43 
CT deletions together with wild-type Cx43 CT were transfected into HEK293 cells 
for 48h before harvesting cells and preparing protein extracts with NP-40 lysis 
buffer. Cell extracts were checked by western blot to ensure the expression of 
all these Cx43 deletions (Figure 5.3 B). It is clear that Cx43 CT wild-type and two 
deletion forms (D2 and D3) were successfully expressed. However, only very low 
levels of D1 were detected by western blot and no clear bands of D4 were 
observed (Figure 5.3B). The possible explanation for this is that D1 and D4 
contain small regions of the Cx43 CT (150bp and 100bp) resulting in the 
expression of proteins with low molecular weight (about 8.55kDa and 6.7 kDa), 
which are difficult to blot successfully. Also, these small protein fragments could 
have been unstable. Therefore, Cx43 CT deletions (D2 and D3) were used for 
further experiments.  
GST-fused hDlg protein preparations were carried out as described in (Macdonald 
et al., 2012b). Fused GST proteins were prepared for full-length hDlg (GST-hDlg) 
and for N-terminus of hDlg plus the first PDZ domain (GST-hDlg NT+1), both of 
which are known to bind Cx43 CT. Coomassie stain showed the successful 
induction of these GST-fused proteins upon the treatment with 1mM IPTG (Figure 
5.4A, arrows). Bacterial lysates were incubated with Protein-G beads that can 
bind to the GST tag. Coomassie stain showed the successful binding of beads to 




GST and supported the successful induction of GST-fused proteins under the 
IPTG treatment.  
The next step was to incubate these beads with GST-fused protein and lysates of 
cells expressing the Cx43 CT deletions. Under incubation with Cx43 CT wt, a 
faint band was observed in the control GST-EV lane, but a much stronger band 
was observed in the lane for GST-hDlg, which indicated that Cx43 CT wt could 
interact with GST-hDlg (Figure 5.5A). This is in accordance with what Macdonal 
et. al have observed (Macdonald et al., 2012b). However, no clear bands were 
observed in lanes for GST-hDlg and GST-EV when incubation with Cx43 CT D2 was 
performed (Figure 5.5B). This indicated that Cx43 CT deletion form 2 did not 
bind to GST-hDlg, which further suggested the region 1 and region 2 at the Cx43 
CT did not contain the regions responsible for Cx43-hDlg interaction. For Cx43 
CT D3, a clear band was observed in the lane for GST-hDlg but not in the lane for 
control GST-EV (Figure 5.5C). That is the binding domain of Cx43-hDlg is 
contained in region 2 and region 3. Taken together, the binding region of Cx43-
hDlg was located in region 3, which is at the last 100bp of the Cx43 CT (which 
containing amino acid 348 – 382). The last five amino acids on Cx43 CT, which 
are responsible for Cx43-ZO-1 interaction, are not involved in Cx43-hDlg 
interaction (Macdonald et al., 2012b). Therefore, the binding region of Cx43-






Figure 5.3: Generating the flag tagged Cx43 CT deletions.  
(A) The diagram shows the region of Cx43 CT deletions. Region 1 is 150bp long. Region 2 is 
200bp long and region 3 is 100bp long. D1 – D4 were referred to different regions. The amino acids 
sequence region of the Cx43 CT contained are also listed. (B) Western blot shows the successful 






Figure 5.4: GST-hDlg is successful induced by IPTG.  
(A) Coomassie stain shows the successful induction of GST-fused proteins. Lanes 1 and 2 are 
GST-hDlg without or with IPTG induction. Lanes 3 and 4 are GST-hDlg NT +1 (N-terminal and first 
PDZ domain) without or with IPTG induction. Lanes 5 and 6 are GST-EV (empty vector) without or 
with IPTG induction. The arrows indicate the location of GST-fused protein. (B) Coomassie stain of 
the purified GST-fused proteins. Lane 1 is GST-hDlg, lane 2 is GST-hDlg NT+1 and lane 3 is GST-





Figure 5.5: The binding region of hDlg is located at the last 100bp of Cx43 CT.  
(A) Co-IP shows that Cx43 CT wt can bind to GST-Dlg. (B) Co-IP shows that Cx43 CT D2 cannot 
bind to GST-hDlg. D2 contains region 1 and region 2 of Cx43 CT. (C) Co-IP shows that Cx43 CT 
D3 can bind to GST-hDlg. D3 contains region 2 and region 3 of Cx43 CT. Input is one-tenth of the 




5.2 Phosphorylation mutation does not affect the 
interaction between Cx43 and hDlg 
Data from previously, and in this chapter, showed that while Cx43 binds to the 
central PDZ domain of  ZO-1 through the very end of its C-terminus (last 5 amino 
acids), Cx43 bound to both the N and C-termini of hDlg through the last 33 amino 
acids of the C-terminal tail, and the ZO-1 binding domain was not involved 
(Macdonald et al., 2012b). Phosphorylation is an important bioprocess that 
controls the interactions between proteins, and also can control the opening and 
closing of gap junctions. Previous data suggested that the phosphorylated status 
of Cx43 is decreased in cervical tumour cells (Sun et al., 2015). These cells 
expressed HPV16E6, which is known to regulate cellular signalling pathways 
(Ganti et al., 2015). Therefore, six individual phosphorylation site mutations of 
the Cx43 CT domains were made to exam the effects of phosphorylation on 
interactions between Cx43 and hDlg (Table 5.1). These six phosphorylation sites 
are each phosphorylated by one of three pathways (MAPK, Akt, and PKC). These 
three pathways are regulated by HPV16 E6 (Chen, 2015). Site-directed 
mutagenesis in GST tagged plasmid pGEX2TGSTCx43 changed serine residues to 
alanine, which mimics the un-phosphorylated form of serine. Phosphorylation of 
S255, S279, and S282 is known to inhibit GJ opening. Phosphorylation of S262 
and S368 can reduce the cell to cell communication of gap junctions (Johnstone 
et al., 2012). Batra and co-workers (Batra et al., 2014) discovered that AKT 
phosphorylation of Cx43-S373 is critical for the closure of Cx43 hemi-channels 
and for interaction with integrin 5. Cx43 CT with an S373A de-phosphorylated 
mimic mutant was no longer able to interact with integrin 5 and was unable to 
inhibit the opening of hemichannels. This involved the disengagement of Cx43 
from ZO-1. The phosphorylation mutantion at S373 of Cx43 CT blocked its 
interaction with ZO-1. Other phosphorylation/dephosphorylated form mutants at 
S365, S368 and a phosphorylated form mutant at S373 of the Cx43 CT affected 
the subcellular location of the Cx43-ZO-1 complex throughout the GJ plaques, 
while wild-type Cx43 bound to ZO-1 at the periphery of GJ plaques (Thévenin et 
al., 2017). Therefore, these six phosphorylation sites at the Cx43 CT were 
chosen for site-directed mutagenesis.   
Mutations 368 and 373 belong to region 3, which is located in the potential 




279 belong to Cx43 CT deletion 3, which is shown to interact with GST-hDlg in 
the Co-IP experiments. Mutations 255 and 262 are outside this region. However, 
sometimes the conformational change caused by a phosphorylation event outside 
the interaction region will affect the binding affinity of two proteins. Therefore, 
plasmids expressing each of these phosphorylation site-mutations of Cx43 CT 
were transfected into HEK293 cells. After 48h incubation, cells were harvest and 
protein lysates were prepared in NP-40 lysis buffer. Successful expression of 
these phosphorylation site mutations was confirmed by western blot (Figure 5.6).   
Co-IP utilized the GST fusion proteins from Figure 5.4 to investigate the effect of 
phosphorylation site-mutations in the interaction of Cx43-hDlg. GST pull-down 
with Cx43 CT wt gave a stronger band on the western blot corresponding to GST-
hDlg compared to that under GST-EV (control). This indicates Cx43 CT can bind 
to GST-hDlg as expected.  A band in the lane of GST-Dlg NT+1 was observed but 
is lighter than that in the lane of GST-EV, which is unable to indicate the 
interaction between GST-Dlg NT+1 and Cx43 CT (Figure 5.7 A) that was reported 
previously (Macdonald et al., 2012b). An unexpected band was observed in the 
lane of GST-EV, which should be a negative control (Figure 5.7 A). This might be 
due to the use of glutathione sepharose beads that trapped Cx43 as non-specific 
binding or it could be due to contamination of the protein preparation with 
nucleic acid (Nguyen and Goodrich, 2006). For the mutation S255A, a stronger 
band was observed in the lane of GST-Dlg. No bands were observed in the lane of 
GST-Dlg NT+1. There was a weak band in the lane of GST-EV lighter than that in 
the lane of GST-Dlg (Figure 5.7 B). For mutation S262A, a band was observed in 
the lane of GST-Dlg with a lighter band observed in the lane of GST-EV and the 
lane of GST-Dlg NT+1 (Figure 5.7 C). For mutation S279A, A band was observed in 
the lane of GST-Dlg, while no clear bands were observed in the lane of GST-Dlg 
NT+1 and GST-EV (Figure 5.7 D). A strong band was observed in the lane of GST-
Dlg in Cx43 CT with mutated S282A. No obvious bands were observed in the lane 
of GST-Dlg NT+1 and GST-EV (Figure 5.7 E). All these four mutations belonging to 
the MAPK pathway shared similar patterns that a band was observed in the lane 
of GST-Dlg and no clear band was observed in the lane of GST-Dlg NT+1 and GST-
EV (Figure 5.7 B – E). For mutation S368A, there was a strong band in the lane of 
GST-Dlg. A weak band was observed in the lane of GST-Dlg NT+1 and GST-EV 




was observed in the lane of GST-Dlg with a weak band observed in the lane of 
GST-EV and a weaker band in the lane of GST-Dlg NT+1 (Figure 5.7 G).  
In order to investigate the effect of these un-phosphorylated mimic mutations at 
different Cx43 CT sites on Cx43-hDlg interaction, the band intensities were 
measured by ImageJ. The band intensity was obtained utilizing the intensity 
measured in the lane of GST-Dlg minus the intensity measured in the lane of 
GST-EV in each Cx43 CT mutations and all related to the results in wild-type 
Cx43 CT. The results were shown in Figure 5.6 H. It was clear that apart from 
mutation S282A higher than wt, the band intensity of the rest mutations was 
lower than wt (Figure 5.7 H). This indicates that un-phosphorylated at the site 
S282 increases the Cx43-hDlg interaction and the rest decreases the binding of 
Cx43 CT to hDlg, in which mutation S255A showing the lowest binding affinity 
(about 23% of wt), S262A and S279A showing higher binding affinity (about 40% of 
wt) and S368A and S373A showing even higher binding affinity (about 60% of wt) 
(Figure 5.7 H). This indicates that compared with PKC and Akt pathway, 





Table 5.1: List of phosphorylation mimic site-mutation at Cx43 CT and the kinase involved in 







Figure 5.6: Successful expression of all these un-phosphorylation mimic site mutations of 
the Cx43 CT.  
Plasmids expressing Cx43 CT with these mutations were transfected into HEK293 cells. After 48h 
post-transfection, cells were harvested, and western blot was carried out on protein lysates to 









Figure 5.7: Non-phosphorylation mimic site mutations at Cx43 CT did not affect/block the 
Cx43-hDlg interactions.  
(A) Co-IP shows that Cx43 CT wild-type (O'Neill et al.) can bind to GST-hDlg. Co-IP shows the 
Cx43 CT with the mutations at sites (B) S255A, (C) S262A, (D) S279A, (E) S282A, (F) S268A, and 
(G) S373A can bind to GST-Dlg. GST-Dlg indicates the full length of hDlg. GST-Dlg NT+1 indicates 
the N-terminal and first PDZ domain of hDlg. GST-EV indicates the empty vector, which is a 
negative control. (H) Related band intensity of GST-Dlg in each mutation compared with the band 
intensity in wt Cx43 CT. related band intensity of GST-Dlg in each mutation was achieved by the 





5.3 Discussion  
Cx43, as the most widespread Cx, has a long C-terminal tail that contains many 
protein-protein interaction regions. This allows Cx43 to interact with many other 
proteins such as binding to other Cxs (Cx26, Cx33, and Cx40), actins, and PDZ 
domain proteins zonula occludens -1 (ZO-1) and hDlg (Giepmans and Moolenaar, 
1998, Macdonald et al., 2012b, Fiorini, 2004, He et al., 1999, Squecco et al., 
2006). With interaction with other proteins, Cx43 gets involved in cell signalling 
pathways leading to regulation of gap junction channel abilities. Previously 
Macdonald and co-workers (Macdonald et al., 2012b) have shown that Cx43 binds 
to both the N-terminal (amino acids 1- 122) and C-terminal (amino acids 560 - 
911) of hDlg via its C-terminal tail (amino acids 263 – 382). In terms of Cx43, in 
that experiment, the Cx43 CT was defined from amino acid 263 to 382. Studies 
here limited the interaction region of Cx43-hDlg to a location at the last 100bp 
of the Cx43 CT coding region, which is from amino acids 348 to 382. The binding 
region of Cx43 to hDlg is different from the binding sites of Cx43 to ZO-1, and 
loss of Cx43 the binding region to ZO-1 did not affect the interaction between 
Cx43 and hDlg (Macdonald et al., 2012b). The last 5 amino acids at the Cx43 CT 
are responsible for binding to ZO-1 (Giepmans and Moolenaar, 1998). Therefore, 
the binding region of Cx43 to hDlg is located at amino acids 348 to 377. Only the 
14-3-3-theta-binding site was found previously in this region (Leithe et al., 
2017b). 14-3-3 theta was identified as one of the binding partners to Cx43 
utilizing a yeast two-hybrid screen of a mouse embryonic cDNA of Cx43 CT 
(amino acids 222 – 382) (Jin et al., 2000).  
In terms of hDlg, the regions of hDlg utilized in Macdonald‘s experiment includes 
the L27 (lin-2 lin-7) binding domain at its N-terminal (amino acids 2 – 62; NCBI, 
https://www.ncbi.nlm.nih.gov/protein/NP_001277912.1) and the C-terminal 
including the SH3, HOOK, and GUK domains (Macdonald et al., 2012b). hDlg with 
its L27 binding domain can bind to CASK, another protein that belongs to the 
MAGUK family (Lee et al., 2002). Co-immunoprecipitation indicated the direct 
interaction between CASK and Cx43 and PDZ binding domain in Cx43 CT (lack the 
last three amino acids) was not involved in CASK-Cx43 interaction (Marquez-
Rosado et al., 2012). This indicates that Cx43 might have an L27 domain or MASK 
could be involved in Cx43-hDlg interaction. hDlg with its SH3/HOOK/GUK domain 




et al., 2007, Stauch et al., 2012). There is an SH3 binding domain located in the 
C-terminal of Cx43 (amino acids 253 – 256) (Solan and Lampe, 2009). However, 
this region is not included in the identified region (amino acids 348 – 377). It is 
located in region 1, which is included in Cx43 CT deletion 1 and deletion 2 
(Figure 5.3). The band shown in Cx43 CT deletion 3 was weaker than that in wt 
(Figure 5.5) and the Cx43 CT bound to C-terminal of hDlg weakly compared to its 
binding to N-terminal of hDlg (Macdonald et al., 2012b). In this case, the binding 
between Cx43 CT SH3 binding domain and SH3 domain in hDlg might be too weak 
to be observed in Co-IP experiments. Another sensitive method is required. To 
identify the regions of Cx43-hDlg interaction more specifically, truncated 
experiments could be carried out. For example, the L27 region of hDlg could be 
truncated and pull-down with Cx43 CT.  
Phosphorylation plays an important role in Gap Junction Intracellular Channels 
(GJIC). For example, phosphorylation at S364 increases the assembly and 
stability of gap junctions. There are in total 66 S/T/Y sites in Cx43 that could be 
phosphorylated with many kinases such as MAPK and Akt, and nearly half of 
them are in the CT domain (Chen et al., 2013b). Phosphorylation might cause a 
conformational change that alters the interaction between Cx43 and other 
proteins. For example, phosphorylation of Cx43 at the site of Y265 disrupts the 
binding between Cx43 and ZO-1 (Toyofuku et al., 2001). Interaction between 
Cx43 and 14-3-3 theta requires phosphorylation at S373 (Park et al., 2009).  Our 
studies demonstrated that un-phosphorylation mimic mutations at S255, S262A, 
S279A, S282A, S368A, and S373A of Cx43 CT did affect the interaction between 
Cx43 and hDlg to some extend. Within these un-phosphorylation site-mutations, 
S282A increased the binding affinity of Cx43 CT to GST-hDlg reached over 1.8-
fold to wt Cx43 CT (Figure 5.7 H). The mutation S255A decreased the binding 
affinity to about 20% of Cx43 CT wt, while mutation S262A and S279A decreased 
to about 40%, and S368A and S373A decrease to about 60% of Cx43 CT wt (Figure 
5.7 H). Phosphorylation at these chosen sites was driven by different kinases: 
MAPK phosphorylated S255, S262, S279, and S282; S368 was phosphorylated by 
PKC, and S373 was phosphorylated by Akt. Therefore, MAPK seems to affect the 
Cx43-hDlg interaction stronger than PKC and Akt kinases.     
However, the phosphorylation site mutation in this experiment was used as a 




phosphorylation of these chosen sites on Cx43-hDlg interaction, phosphor mimic 
mutations at the same phosphorylation sites should be investigated in their 
interaction with hDlg by Co-IP. Comparison of both phosphor-null and phosphor-
mimic data of the same phosphorylation site in interaction with hDlg could 
provide better evidence of the binding affinity of Cx43-hDlg interaction affected 
by the phosphorylated site at Cx43 CT. Also, mimetic peptides of Cx43 CT with 
phosphor-null or phosphor-mimic site mutations could be generated to 
investigate whether phosphorylated Cx43 affect the Cx43-hDlg interactions.  
PDZ domain protein hDlg normally works as a scaffold protein that provides a 
hub for more proteins to interact.  It could also be considered that other 
proteins might work as hub or help in the Cx43-hDlg interactions. 14-3-3 theta 
might be one of the candidates, due to its ability to interact with both Cx43 and 
hDlg (Park et al., 2006, Nakajima et al., 2019).  The interaction between Cx43 
and 14-3-3 theta was associated with internalization of gap junctions, which led 
to subsequent phosphorylation at Ser368 in the Cx43 CT and followed by 
ubiquitination, which results in gap junction internalisation (Smyth et al., 2014). 
14-3-3 zeta and epsilon could bind to Dlg in Drosophila and through these 
interactions, the Scrib/Dlg complex may control the orientation of the planar 
spindle (Nakajima et al., 2019).  
Calcium/calmodulin-dependent serine kinase (CASK, also known as Lin2) is also 
considered since it can interact with both Cx43 and hDlg (Lee et al., 2002, 
Marquez-Rosado et al., 2012). CASK is expressed mainly in the cytoplasm and has 
limited co-localisation with Cx43. Cx43 appears on the plasma membrane in 
unwounded human foreskins explant tissue and extensive colocalization between 
Cx43 and CASK were observed on the plasma membrane after one hour in the 
skin experiment wound model (Márquez-Rosado et al., 2012). Co-expression of 
Cx43 and CASK increased the migration of Madin-Darby canine kidney (MDCK) 
cells (Márquez-Rosado et al., 2012). Both CASK and hDlg belong to the MAGUK 
family of proteins and their colocalization was observed on the epithelial cell 
membranes in the intestine and in neuromuscular junctions of skeletal muscles 
(Nix et al., 2000, Sanford et al., 2004). They might be involved in the same 
developmental pathway since mutations disrupting the function of hDlg or CASK 





From the STRING website, where protein-protein interaction networks are 
deposited (https://string-db.org/), Cx43 and hDlg share one common interaction 
candidate, CTNNB1, which is beta-catenin. Beta-catenin is a critical protein 
involving in the Wnt signalling pathway. Beta-catenin interacts with Cx43 CT at 
residues 259-275, 282-295, and 302-319 by Nuclear Magnetic Resonance (NMR) 
and this interaction was negatively regulated by Src phosphorylation at the 
residues Y265 and Y313 at Cx43 CT (Spagnol et al., 2018). Beta-catenin, as part 
of adheren junctions, colocalized with Cx43 in cardiac myocytes in response to 
Wnt signalling (Ai et al., 2000).  Interaction with and leading to the proteasomal 
degradation of hDlg might be one mechanism through which beta-catenin 
contributes to tumour progression (Subbaiah et al., 2012). 
In conclusion, in this chapter, it is now shown that the potential binding region 
of hDlg is located at the last 100bp of Cx43 CT (amino acids 348 to 377). The un-
phosphorylation mimic mutation at Cx43 CT that can be phosphorylated by 
kinase MAPK, PKC and Akt did show the ability to affect the Cx43-hDlg 
interactions.  Cx43 binding domain to 14-3-3 theta is located in this area (amino 
acids 370 – 376) and Cx43 CT with a mutation at the site of 282 showed the 
strongest bands within all these mutations. Therefore 14-3-3 theta, CASK, and 





6 Discussion, conclusion and future work 
Gap junction intracellular channels (GJIC) act as a bridge between two 
neighbouring cells, allowing the exchange of small molecules (< 1kDa) between 
cells and their surrounding environment to maintain proper cellular physiological 
activities (Alexander and Goldberg, 2003a). It has been reported that GJIC is 
normally disrupted during the cancer progression pathway in many cancers. For 
example, the loss of GJIC is observed in HPV-related cervical cancer cells (Aasen 
et al., 2003b). Therefore, the role of connexins, the building block of gap 
junctions, involved in cancer progression is important to investigate. Both anti- 
and pro-tumorigenic activities of connexins are indicated depending on different 
types and stages of cancers (Aasen et al., 2019).  Since connexins only have a 
short half-life of 1 – 5 h, the regulation of the connexin life cycle is important, 
especially in response to tumourigenesis and cellular stress such as wound 
healing. However, the full story of the connexin life cycle in detail still remains 
to be elucidated. Previously, utilizing the W12 cervical cancer cell line model, 
our lab found that the high-risk HPV E6 oncoprotein controls the trafficking of 
Cx43 to the membrane, the most spread connexin, via the interaction with hDlg, 
a PDZ-domain MAGUK protein (Macdonald et al., 2012b, Sun et al., 2015). This 
indicates the role of hDlg in controlling the trafficking of Cx43, at least in HPV-
positive cervical cancer cells.  
The first aim of this project was to investigate the Cx43-hDlg interaction in non-
tumour epithelial cells. To test this, HEK293, HaCaT, NIKS, and HPV-positive 
non-tumour NIKS16 cells were used. The interaction of Cx43 and hDlg was 
confirmed by colocalisation on the plasma membrane in these non-tumour cells 
by immunofluorescence confocal microscopy and by Co-IP of the protein in 
lysates from these cells (Figure 3.4, 3.5, and 3.6). The Cx43-hDlg interaction was 
also observed on the membrane of C33a cells that are HPV-negative cervical 
cancer cells (Figure 3.1 A, Figure 3.2 A) and in these cells ectopically expressing 
HPV E6 oncoprotein (C33aE6 cells). Although in this case, the interaction was no 
longer at the cell membrane in C33aE6 cells but in the cytoplasm. This indicates 
the Cx43-hDlg interaction is neither HPVE6-dependent nor cancer cell-specific, 
which further indicates the role of hDlg in regulating Cx43 could be a general 




There is a cytoplasmic pool of Cx43 that can be used to re-build gap junctional 
communication (Boassa et al., 2010), and previous data together with the data 
reported here show that hDlg plays a role in maintaining a cytoplasmic pool of 
Cx43. siRNA depletion of hDlg in non-tumour cells led to a reduction in levels of 
Cx43 (Figure 3.7) and relocation of Cx43 from the plasma membrane into the 
cytoplasm in HaCaT and HEK293 cells (Figure 3.8). This reduction in levels and 
cytoplasmic location of Cx43 were also observed in HaCaT cells with stable 
depletion of hDlg (Figure 3.9). This reduction in levels of Cx43 by siRNA 
depletion of hDlg in HaCaT cells was reversed by endo-lysosome inhibitors NH4Cl 
and Chloroquine (Figure 3.12), which is consistent with the observation of 
MacDonald et al. in W12GPXY cervical tumour cells (Macdonald et al., 2012b).  
Based on data in this thesis, it can be hypothesised that the involvement of hDlg 
in regulating the life cycle of Cx43 can be separated into two parts: the 
transport of Cx43 to the membrane and the transport of Cx43 from the 
membrane (Figure 6.1). For the aspect of transport to the membrane, the 
cytoplasmic pool of Cx43 that can be used to rebuild gap junctions must rely on 
hDlg as discussed above. Connexins traffic to the plasma membrane in the form 
of connexons. Connexons leaving the Golgi in vesicles can traffic to the 
membrane along the microtubules (Shaw et al., 2007). hDlg has been found to 
be involved in controlling the trafficking of vesicles, which requires the motor 
protein KIF13B (Walch, 2013). hDlg controls cell polarity and mutation of 
Drosophila Dlg resulted in disorganisation of epithelial structure and loss of cell 
polarity (Bilder, 2004, Roberts et al., 2012a). hDlg is also required for the proper 
organisation of the actin cytoskeleton (Laprise et al., 2004). Loss of Dlg protein 
led to disruption of proper location of actin and tubulin (Woods et al., 1996a). 
hDlg, as a scaffold protein, can tether many other proteins through its binding 
domains. For example, cytoskeletal protein protein 4.1R is reported to bind to 
the HOOK domain of hDlg (Hanada et al., 2003). It can also bind to tumour 
suppress protein APC and tumour suppressor phosphatase PTEN with its PDZ 
domain (Goode and Perrimon, 1997, Matsumine et al., 1996a, Valiente et al., 
2005). Therefore, hDlg could bind Cx43 and allow interaction with vesicular 
trafficking and/or the actin cytoskeleton for transport to the membrane. 
Phosphorylation at S373 in the Cx43 CT allows its binding with 14-3-3 theta 




trafficking of Cx43 to the plasma membrane (Majoul et al., 2009, Batra et al., 
2013, Park et al., 2006, Park et al., 2009). Phosphorylation at S365 is required to 
prevent phosphorylation at S368 induced by interaction with 14-3-3 theta and 
led to ubiquitination and lysosome degradation. However, de-phosphorylation at 
S373 is required for Cx43 at the cell membrane to allow its interaction with ZO-1, 
which targets connexons to gap junction plaques. This de-phosphorylation at 
S373 prevents the interaction between Cx43 and 14-3-3 theta. hDlg can interact 
with 14-3-3 as well (Nakajima et al., 2019) and the Cx43-14-3-3 region is 
involved in the potential Cx43-hDlg interaction region (aa 348 – 382). Therefore, 
hDlg could replace 14-3-3 binding with Cx43 and deliver Cx43 to the plasma 
membrane (possibly de-phosphorylation at S373), or together with 14-3-3 theta 
deliver Cx43 to the plasma membrane. After reaching the plasma membrane, 14-
3-3 is released from Cx43 due to de-phosphorylation at S373, which allows the 
Cx43-ZO-1 interaction that targets connexons to gap junction plaques. hDlg may 
or may not be involved in the building of gap junctions. Co-localisation of Cx43 
and hDlg were observed on the plasma membrane in gap junction plaques 
(Figure 3.4 and 3.6) and the Cx43-hDlg interaction region is different from Cx43-
ZO-1 (Macdonald et al., 2012b). Further work is required to address this question. 
For the aspect of transport from the membrane, hDlg could accompany Cx43 into 
endosomes (Figure 6.1). hDlg was observed co-stained with Cx43 in the early-
endosomes and late-endosomes in W12GPXY and C33aHPV18E6 cervical cancer 
cells. However, no co-staining was observed for Cx43 and early endosome 
marker (EEA1) in C33a (HPV-negative cervical cancer cells) and C33aHPV18mutE6 
(C33a cells transfected with mutated HPV18E6 that lack PDZ binding domain) 
(Peng Sun, PhD thesis, 2005). After internalisation, Cx43 can be fused with the 
early-endosomes and sorted to the recycle-endosomes (without ubiquitination) 
and then back to the plasma membrane or to the late-endosomes (with 
ubiquitination) and further to the lysosomes for degradation. Cx43 can be mono-
ubiquitinated, which is a signal for lysosome degradation. This ubiquitination 
process is regulated by E3 ubiquitin ligase NEDD4. Overexpression of NEDD4 in 
HeLa43 cells led to increased ubiquitination of Cx43 and reduced level of Cx43 
(Totland et al., 2017). De-phosphorylation at S365 of Cx43 CT leads to a 
conformational change and is required for phosphorylation at S368, which is 




that we have identified as the hDlg binding site. Therefore, if Cx43 is bound to 
hDlg, the complex could block Cx43 lysosomal degradation.  
Phosphorylation at S373 of Cx43 CT, as a docking sign for Cx43 on the plasma 
membrane, led to disruption of the interaction between Cx43 and ZO-1, thus 
making Cx43 available to trafficking from the plasma membrane. The 
phosphorylation and ubiquitination sites involved in internalisation are within 
the region of Cx43-hDlg interaction (aa 348 – 382). Therefore, hDlg might 
maintain a cytoplasmic pool of Cx43 by preventing its ubiquitination. Cx43 
molecules would then be available to be recycled to the plasma membrane 
instead of being degraded in the lysosomes. Phosphorylation at S373 also allows 
14-3-3 binding to Cx43 CT (aa 370 -376) (Park et al., 2006, Park et al., 2009). 
This interaction is important in the internalization of Cx43. The un-
phosphorylated mimic mutation S373A at Cx43 CT disrupts Cx43-14-3-3 
interaction and stabilizes Cx43 on the plasma membrane (Smyth et al., 2014).  
hDlg can also interact with 14-3-3 (Nakajima et al., 2019). High-risk HPV E6 
interacts with 14-3-3 through its PDZ-binding motif (Boon and Banks, 2013). This 
suggests that 14-3-3 could be an essential molecule that is involved in the 
hDlg/E6 regulation of Cx43. It will be important in future studies to determine if 
14-3-3 is part of the Cx43/hDlg complex in the cytoplasm of non-tumour and 
tumour cells.  
The second aim of this project was to investigate the Cx43/hDlg interaction 
during the wound healing process. The wound healing process shares many 
similarities with tumour progression. Some scientists have concluded that the 
hallmarks of cancer are also the hallmarks for wound healing; cancer is a result 
of over-healing of a wound (MacCarthy-Morrogh and Martin, 2020, Sundaram et 
al., 2018). The key cellular behaviour for wound healing is proliferation and 
migration. Many growth factors, such as epidermal growth factor (EGF), are 
involved in the wound healing process as well as in cancer metastasis  (Sundaram 
et al., 2018, MacCarthy-Morrogh and Martin, 2020). Results in Chapter 4 show 
that Cx43 relocated from the plasma membrane into the cytoplasm in the cells 
at the leading edge of a scrape wound in HaCaT cell monolayers during the early 
stage of wound healing (4h post-wound), and was relocated back to the 




also observed in NIKS cell monolayers (Figure 4.4). This is consistent with key 
observations in human epidermal keratinocytes (Wright et al., 2009). Similar 
movement was observed for hDlg during wound healing, where it specifically co-
localised with Cx43 (Figure 4.1 and 4.4). This again suggests the role of hDlg in 
the regulation of Cx43 trafficking. Observations of protein levels during wound 
healing in HaCaT cells (Figure 4.2), where Cx43 decreased at the early stage of 
wound healing, followed by increasing levels of the protein (peak at 16h) then 
recovery to un-wounded level after wound closure, are consistent with the 
previous observations (Wright et al., 2009). The pattern of alteration in levels of 
hDlg is similar to what has been observed for Cx43 levels (Figure 4.2). An upper 
band of Cx43, possibly ubiquitination, was observed clearly at 4h and 8h post-
wounding, when the total levels of Cx43 and hDlg were decreased. If hDlg 
protects Cx43 from lysosomal degradation then in its absence, as discussed 
above, Cx43 ubiquitination could lead to lysosomal degradation of Cx43. This 
suggests that hDlg could inhibit Cx43 post-translational modification, possibly 
prevent its mono-ubiquitination which as tag delivery to lysosome for 
degradation and through binding with Cx43, hDlg might recycle it back to the 
membrane (Figure 6.1). Poly-ubiquitination leads to proteasome degradation of 
Cx43, which normally occurs through ERAD (endoplasmic-reticulum-associated 
protein degradation). Mono-ubiquitination triggers the internalisation of Cx43 
from the plasma membrane.  This could be tested with ubiquitination antibodies 
and markers for recycle-endosomes.  
siRNA depletion of hDlg led to cell death during the wound healing process and 
loss of wound closure (Figure 4.8 and 4.9). This indicates the importance of hDlg 
for cells that are dividing and/or migrating to close the wound. One key 
inconsistency in the results is that while hDlg depletion by siRNA leads to 
inhibition of wound closure, in cells where hDlg expression is stably knocked 
down wound closure occurred faster than that in mock-treated cells (Figure 
4.10). hScrib and hDlg show complementary roles and higher levels of hScrib 
were observed in HaCaT cells with stable depletion of hDlg by the Bank‘s group 
who supplied the HaCaT shDlg cells (Massimi et al., 2012). Endometrial cancer 
cells KLE with stable knockdown of hDlg increased cell migration in a wound-
healing assay (Sugihara et al., 2016). Upon the stable loss of hDlg (an opposed to 




compensate by increased activity and lead to a faster response to cellular stress 
such as wound healing.   
It is interesting to notice that none of the cervical cancer cell lines investigated 
in this report was able to close scrape wounds properly either in the absence or 
presence of HPV E6. These data might suggest that loss of membranous Cx43 
leads to better wound healing and might do so through regulation of nuclear 
beta-catenin. C33aE6 and HeLa43 cells containing HPVE6 that could lead to 
accumulated beta-catenin in the nucleus, which would allow faster wound 
healing than in C33a cells, which expressing just membranous Cx43 that prevents 
beta-catenin from transitioning to the nucleus (Figure 4.12 and 4.15).  
Cx43 and hDlg roles in wound healing might be through regulating nuclear beta-
catenin. In response to wounding, Wnt signalling is activated and leads to 
stabilization of beta-catenin, which led to the cytoplasmic location of Cx43 (Hou 
et al., 2019). This activation of beta-catenin also leads to the proteasomal 
degradation of hDlg (Subbaiah et al., 2012), which could lead to a decrease in 
levels of Cx43 and hDlg at early stages of wound healing (Figure 4.2 and 4.5). 
Also, the lower level of hDlg might lead to less membranous Cx43, which 
enhances nuclear beta-catenin. Thus, nuclear beta-catenin activates the 
expression of proteins involved in the wound healing process. After the activity 
of these healing-wound proteins is complete, nuclear levels of beta-catenin 
become reduced perhaps due to the increasing levels of Cx43 and hDlg as 
observed in Figures 4.2 and 4.5. When wound closure is complete, membranous 
Cx43 is observed, part of which might be recycled from a cytoplasmic pool 
maintained by hDlg.  
The final aim of this project was to investigate the possible region of Cx43-hDlg 
interaction at the Cx43 CT and whether some phosphorylation sites at the Cx43 
CT are involved in this interaction. We limited the Cx43-hDlg interaction region 
to within amino acid 348 – 382 at the Cx43 CT. Un-phosphorylated mimic 
mutation at S282 shows almost double the affinity for Cx43 binding to hDlg while 
other un-phosphorylated mimic mutations at Cx43 CT showed reduced Cx43-hDlg 
interaction (Figure 5.7). This indicates the phosphorylation site of S282 at Cx43 




However, there are limitations to the study. Some of the data in this thesis are 
still preliminary and require further investigation. For example, Golgi tracker 
could be used to test whether the accumulation of Cx43 occurs in the Golgi upon 
the siRNA depletion of hDlg in HaCaT cells. Markers could be used to 
identify/measure apoptosis, as well as using trypan blue to count live or dead 
cells together with counting floating cells in the wound closure experiments. 
Data in this thesis indicate the Cx43-hDlg interaction occurs widely in epithelial 
cells. However, the experiments were carried out in vitro in cell lines. It would 
be important to test their interaction in vivo. For example, immunofluorescence 
staining of Cx43 and hDlg could be used in healthy epithelial tissues, and 
proximity ligation assay (PLA) could be done on healthy epithelial tissue samples 
as previously described using epithelial tissue from patients with cervical cancer 
(Sun et al., 2015). 
For the subcellular location alteration of Cx43 and hDlg during wound healing, it 
would be worth investigating this using live-cell imaging with fluorescently-
tagged Cx43 and hDlg. This would give a clearer picture of the timed movement 
of Cx43 and hDlg during wound repair. The movement of Cx43 and hDlg during 
wound healing could also be done in 3D organotypic raft cultures, which are a 
model to mimic the multi-layers of epithelial tissue. This time-lapse trafficking 
model should also be carried out in primary epithelial cells.   
Data in this thesis indicate the siRNA depletion of hDlg led to a reduction in 
levels and the cytoplasmic location of Cx43. It would be worth repeating these 
experiments using NIKS and NIKS16 cells to compare the subcellular location 
changes on Cx43 upon siDlg treatment and investigate whether the presence and 
expression HPV16 genome affects this process.  
The effects of some un-phosphorylated mimic mutations of some of the 
phosphorylation sites at the Cx43 CT on Cx43-hDlg interaction have been 
investigated. It would be worth to also test the effects of the phosphorylated 





In conclusion, this thesis expanded the Cx43-hDlg interaction in a wider range of 
cells and showed that the interaction is not limited to cancer cells nor is 
dependent on the involvement of HPVE6. This study limited the Cx43-hDlg 
interaction region at the Cx43 CT to amino acids 348 – 382. The study also 
indicated the role of hDlg in the trafficking of Cx43 to the plasma membrane and 
maintaining the cytoplasmic pool of Cx43, which might involve 14-3-3 theta. 
Given that abnormal regulation of Cx43 trafficking is observed in many diseases 
and cancers, these findings help to picture the full story of the Cx43 life cycle 
and may have considerable future clinical implications. For example, designing a 
blocker or antisense RNA that blocks the Cx43-hDlg interaction so that 
membranous Cx43 is maintained in cervical cancer cells or to prevent Cx43 





Figure 6.1: A schematic diagram of the Cx43 life cycle and the possible stages that hDlg and 
ZO-1 were involved.  
From the trans-Golgi network, connexons are transported to the plasma membrane in vesicles. 
hDlg may be involved in this transport process. ZO-1 then interacts with Cx43 and targets it to gap 
junction plaques. For internalisation, connexons are released from ZO-1 and are transported to 
early endosomes where they are further sorted to 1) recycling endosomes (without ubiquitination) 
and back to the plasma membrane or to 2) late-endosomes (with ubiquitination) and further 
degraded in the lysosomes. hDlg may maintain a cytoplasmic pool of Cx43 and recycle it to the 
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